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General overview Systemic Sclerosis (SSc)
Diagnosis	and	classification
Systemic sclerosis (SSc; scleroderma) is a generalized disorder of the connective tissue 
with unknown etiology and highly variable expression. It is characterized by Raynaud’s 
phenomenon, small vessel vasculopathy, inflammatory manifestations and fibrosis. 
Skin tautness is the most apparent manifestation (1). The variability in disease course is 
illustrated by different patterns of skin tautness as well as differences in organ system 
involvement. Based on clinical characteristics, SSc can be divided roughly into a) limited 
cutaneous SSc (LcSSc) with skin tautness of distal extremities and usually moderately 
and slowly evolving organ fibrosis; b) diffuse cutaneous SSc (DcSSc) with rapidly 
progressive fibrosis including proximal extremities and/or trunk and more severe organ 
damage. In order to document and quantify skin changes over time, several scoring 
systems have been proposed, of which the modified Rodnan Skin Score (mRSS) has 
been best studied and validated (2). The mRSS assesses skin thickness in 17 body 
surface areas using a 0 to 3 scale (figure 1). 




Microangiopathy is a predictor of the development of SSc and may precede other 
symptoms by many years (3). Nailfold videocapillaroscopy (NVC) is a non-invasive and 
safe diagnostic tool that illustrates microvascular damage. Moreover, in SSc different 
nailfold patterns can be defined; early pattern (few giant capillaries and hemorrhages 
without evident loss of capillary density); active pattern (frequent giant capillaries and 
hemorrhages and moderate loss of capillary density); and late pattern (ramified/bushy 
capillaries, few giant capillaries and hemorrhages, severe loss of capillary density) 
(4). A dynamic transition of microvascular damage through different NVC patterns of 
microangiopathy was demonstrated with clinical symptoms progressing in accordance 
with the nailfold morphologic changes in 60% of the SSc patients (5). Moreover, the 
different patterns correlate with auto-antibodies and clinical disease manifestations 
(6). 
Preliminary criteria for the classification of definite Systemic Sclerosis of the American 
College of Rheumatology were established in 1980 (7). In daily practice however, these 
criteria demonstrated low sensitivity in early and limited SSc (8). Revised classification 
criteria were proposed by leRoy (9) including three subtypes; a) limited cutaneous 
SSc (lcSSc), b) diffuse cutaneous SSc (dcSSc) and c) limited non cutaneous SSc (lSSc) 
without skin involvement. People with either objective Raynaud’s phenomenon, SSc-
type nailfold capillary pattern or SSc selective autoantibodies, or subjective Raynaud’s 
phenomenon, SSc-type nailfold capillary pattern and SSc selective autoantibodies are 
classified as having limited non cutaneous SSc. Other classification propositions based 
on prospective studies include diffuse (truncal), intermediate (extremities but not the 
trunk) and limited (fingers only) subtypes (10). 
Recently, ACR/EULAR criteria for the classification of SSc were published (Table 1); 
according to this classification patients with a total score of ≥9 can be classified as 
having definite SSc (11). In a validation sample of 405 patients, these criteria resulted 
in a sensitivity of 0.91 (0.87–0.94) and specificity of 0.92 (0.86–0.96). 
Auto-antibodies
SSc specific auto-antibodies may help to establish a diagnosis, but the absence does 
not exclude systemic sclerosis. Up to 11% of patients with SSc can test negative 
for antinuclear antibodies. An overview is listed in table 2 (12). The performance 
characteristics of anti-body testing in SSc depend on the clinical context in which they 
are used; for anti-Scl70 in SSc patients versus healthy controls an overall sensitivity of 
0.20 and specificity of 1.0 was found and in SSc patients versus persons with primary 
Raynaud’s phenomenon a sensitivity of 0.28 and specificity 0.98 was established (13). 
Anti-centromere antibodies demonstrated an overall sensitivity of 0.33 and specificity 
of 0.99 in SSc patients versus healthy controls. 
Table	1.	The	American	College	of	Rheumatology/European	League	Against	Rheumatism	criteria	
for Systemic Sclerosis (11)
Item Sub item Weight
Skin thickening of the fingers of both hands 
extending proximal to the metacarpophalangeal 
joints (sufficient criterion)
9
Skin thickening of the fingers (only count the 
higher score)
Puffy fingers
Sclerodactyly (proximal to PIP’s)
2
4





Abnormal nailfold capillaries 2
Pulmonary arterial hypertension and/or interstitial 
lung disease (maximum score is 2)
2
Raynaud’s phenomenon 3
SSc-related autoantibodies (anticentromere, 
anti–topoisomerase I [anti–Scl-70], anti–RNA 
polymerase III)
3
The criteria are not applicable to patients with skin thickening sparing the fingers or to patients 
who have a scleroderma-like disorder that better explains their manifestations (e.g., nephrogenic 
sclerosing fibrosis, generalized morphea, eosinophilic fasciitis, scleredema diabeticorum, 
scleromyxedema, erythromyalgia, porphyria, lichen sclerosis, graft-versus-host disease, diabetic 
cheiroarthropathy)
Table	2.	Auto-antibodies	in	scleroderma	(12)
Anti-body ANA staining 
pattern
% in all 
patients
Clinical	characteristics Organ involvement
Anti-Scl70* speckled 10-40 dcSSc lung fibrosis
Anti-Centromere 15-40 lcSSc PH, esophageal disease
Anti-U1 RNP speckled 5-35







4-25 dcSSc renal, skin, PH




Anti-PM-Scl nucleolar 3-6 overlap, mixed muscle
Anti-Th/To nucleolar 1-7 lcSSc
PH, lung fibrosis, small 
bowel
Anti-U11/U12 nucleolar 1-5 lcSSc and dcSSc lung fibrosis
Anti-Ku 1-3 Overlap muscle, joint, 





SSc is a relatively rare disease. The prevalence of SSc in the Netherlands, using the 
ACR preliminary classification criteria and leRoy’s criteria, was estimated to be 8.9 
per 100.000 inhabitants (14). This rate was based on the number of included patients 
in the POEMAS registry (Pulmonale hypertensie Opsporing Een multidisciplinaire 
Aanpak bij Sclerodermie), combined with a questionnaire sent to both academic and 
non-academic rheumatologists not participating in the POEMAS registry. Using the 
estimated prevalence rate of 8.9 per 100.000, the total number of patients living with 
SSc in the Netherlands is about 1500. The estimated prevalence is comparable with 
other North European countries, including Norway (9.9/100.000) (15) and 8.8/100 000 
in northwest England (16). In southern European countries the estimated prevalence 
range from 15.8/100.000 in France (17) to 27.7/ 100.000 population in Spain (18), 
supporting a north-south SSc prevalence gradient. In the United States of America a 
prevalence of up to 24.2/100.000 was reported (19) in the Detroit area. Differences in 
prevalence among countries may also be explained by differences in ethnic background 
(20), the methodology used to identify patients with SSc (21), or inclusion criteria.
Prognosis
Mortality in SSc is high; in a systematic review and a meta-analysis of the literature (22) 
including 2691 SSc patients in 9 cohort studies, the pooled Standardized Mortality Ratio 
was (SMR) was 3.53. Among 732 deaths, heart involvement was the most frequent 
cause of death (29%), followed by lung involvement (22). In the EULAR Scleroderma 
Trials and Research group (Eustar) database (23), 55% of deaths were due to SSc, 
whereas 45% of deaths were thought to be unrelated to SSc. Of the SSc-related deaths, 
26% were cardiac (predominantly heart failure and arrhythmias), whereas 29% of non-
SSc related deaths were due to cardiac causes. 
In the above mentioned systematic review (22) adjusted meta-regression analysis 
did not show significant change in SMR over time when comparing a 3 time cohorts 
(< 1980, 1980-90 and > 1990). In contrast, in a British cohort (24), five-year survival 
among diffuse cutaneous SSc (dcSSc) patients improved from 69% in a historical cohort 
(1990-1993) to 84% in a contemporary cohort (2000-2003), with dramatically more 
diagnoses of clinically significant Interstitial Lung Disease (ILD) and Pulmonary Arterial 
Hypertension (PAH). The 5-year survival among the limited cutaneous SSc (lcSSc) 
patients remained unchanged. 
In a Canadian single centre study (25) including 158 patients seen between 1994 and 
2004, the 5-year survival was 90% (95% for limited and 81% for diffuse) and the 10-year 
survival was 82% (92% for limited and 65% for diffuse). Deceased persons were more 




Cardiac involvement can be primary or secondary to Pulmonary Arterial Hypertension 
(PAH), Interstitial Lung Disease (ILD), or kidney disease. Cardiac abnormalities 
may include pericarditis, microvascular coronary artery disease (with resultant 
myocardial ischemia), conduction abnormalities (including bradyarrhythmias and 
tachyarrhythmias) and impaired myocardial contractility or relaxation with our without 
clinically overt heart failure (31). 
Myocardial dysfunction seems mainly due to myocardial fibrosis, which might be the 
result of recurrent ischemia reperfusion injury due to microangiopathy, vasospasm 
and poor vasodilator reserve, and of inflammation (when present). Several studies 
demonstrated that diffuse cutaneous SSc, rapid progression of skin thickening, and 
older age at SSc onset are all risk factors for cardiac involvement in SSc (27-29). In a 
7 year prospective study, severe cardiac Raynaud was found to be a strong long-term 
predictor of systolic LV dysfunction in SSc patients (30).
Myocardial fibrosis was seen in a post mortem study in 70% of patients with systemic 
sclerosis as compared to 37% in controls (31). More recently, myocardial fibrosis was 
demonstrated by delayed enhancement in 24/36 scleroderma patients undergoing 
MRI investigation (32). Conventional echocardiography assessment of left ventricular 
(LV) systolic function (based on measurement of the LV ejection fraction) has shown 
low sensitivity in demonstrating myocardial abnormalities, being able to identify only 
5% of patients with cardiac involvement (27). The discrepancy between findings of 
myocardial fibrosis by histological investigation on the one side and clinical studies 
using conventional echocardiography methods on the other has led to a search for 
more sophisticated techniques for the assessment of LV function. One of these 
techniques, Tissue Doppler Imaging (TDI), assesses myocardial tissue velocities and is 
able to provide information on longitudinal function at the mitral valve annular level, 
which is often earlier impaired by myocardial fibrosis and might therefore represent 
a more sensitive parameter in identifying subtle cardiac dysfunction. Main measures 
by TDI are S’, systolic myocardial velocity, E’, early diastolic myocardial relaxation, and 
Aa, myocardial velocity associated with atrial contraction at the end of ventricular 
filling. In particular, S’ at the lateral mitral annulus is a measure of longitudinal systolic 
function and is correlated with measurements of LV ejection fraction, while E’ and A’ 
are measure of myocardial relaxation. An example of the role of TDI in patients with 
SSc was demonstrated in 100 SSc patients with both limited and diffuse subtype 
disease. A trend towards a significant difference in LVEF was seen as compared to 
age- and sex-matched healthy controls; 64.9 (SD 0.6) versus 67.2 (SD 0.7) (p= 0.069) 




patients, as compared with none of the controls (P = 0.040), suggesting a relatively 
high prevalence of reduced LV contractility. However, myocardial analysis by TDI is 
significantly limited by angle dependency (the measure changes with the insonation 
angle) and does not allow the evaluation of all LV segments and of different directions 
of myocardial deformation. Recently, two-dimensional (2D) speckle tracking analysis 
has been proposed as a sensitive and accurate method for the evaluation of subclinical 
myocardial dysfunction, providing measures of LV regional and global strain in three 
orthogonal directions (longitudinal, circumferential and radial), overcoming the 
limitations of TDI (34).
Pulmonary disease
The major pulmonary complications of SSc are Interstitial Lung Disease (ILD) and 
Pulmonary Hypertension (PH) (35). ILD may lead to a restrictive lung function pattern and 
is difficult to reverse since curative therapies are not yet available. Early identification 
and appropriate monitoring of patients with SSc complicated by PAH and/or ILD is 
challenging but mandatory, so that active pulmonary disease may be controlled and 
tissue damage prevented or delayed. The most common pathological finding in lung 
biopsies of ILD in 80 patients with SSc was Non-Specific Interstitial Pneumonia (NSIP), 
although Usual Interstitial Pneumonitis (UIP) was also occasionally found (36). In this 
study including only patients of whom surgical lung biopsies was obtained, disease 
outcome was found to be linked more strongly to disease severity at presentation and 
serial DLCO trends than to histopathologic findings.
The prevalence of interstitial lung disease depends on the diagnostic tool that is 
studied. High Resolution Computed Tomography (HRCT) and pulmonary function 
testing, particularly Forced Vital Capacity (FVC) and Lung Diffusing Capacity for Carbon 
Monoxide (DLCO), are currently used to define and monitor lung fibrosis, respectively. 
There is a wide range in normal pulmonary function testing (FVC 80-120% predicted), 
depending on the lower limit of normal (LLN) (37), so in the disease course it is the 
degree of reduction from a premorbid level that may indicate development of lung 
disease. In Idiopathic Lung Fibrosis patients a DLCO threshold at baseline of 40% 
predicted and a decline during follow up of the Forced Vital Capacity > 10% and DLCO 
> 15% has been associated with increased mortality (38). Steen at all showed that a 
major decline in FVC occurs within the first 4–6 years of onset of systemic sclerosis, 
resulting into a moderate to severe restrictive lung disease in 40% of SSc patients (39). 
HRCT proves to be very sensitive for the detection of SSc-ILD. In a study quantifying 
the prognostic value of baseline pulmonary function testing and HRCT, 277/330 (84%) 
SSc patients had evidence of ILD (40). In another smaller series of 23 SSc patients, 91% 
showed ILD on HRCT, whereas only 31% of the same patients showed abnormalities 
on chest X-ray (41). Recently, based on predictors of mortality, Wells et all presented a 
simple algorithm with SSc-ILD staged as limited disease (minimal disease on HRCT or, 
in indeterminate cases, FVC ≥70%) or extensive disease (severe disease on HRCT or, in 
indeterminate cases, FVC <70%) (40). 
Estimates of the prevalence of pulmonary hypertension (PH) in patients with SSc range 
from 4.9% (17 of 344 patients) (42) to 38% (16 of 47 patients) (43), with an average rate 
in multiple studies of 16% (300 of 1.837 patients) (44). The widely ranging prevalence is 
due to the use of various definitions and diagnostic criteria and various measurement 
methods (with or without right hart catheterization (RHC). Pulmonary arterial 
(precapillary) hypertension is defined as a mean pulmonary artery pressure measured 
by RHC of >25 mmHg at rest and a pulmonary capillary wedge pressure (PCWP) < 15 
mmHg. Raised N-terminal probrain natriuretic peptide (NTproBNP) levels are directly 
related to the severity of PAH and baseline and serial changes in NTproBNP levels are 
highly predictive of survival in SSc-PAH (45). PAH is a serious disease complication; in 
131 SSc patients with incident PAH who were followed for a mean of 2.0±1.4 years. 1-, 
2-, and 3-year cumulative survival was 93%, 88%, and 75% (46). 
An average delay between symptom onset and the actual diagnosis of PAH of ≥ 2 year 
was demonstrated, which may be explained by initially non-specific symptoms such as 
fatigue or breathlessness and lack of fitness, as well as concurrent diagnoses such as 
heart failure or ILD (47). 
In a retrospective study including 815 SSc patients who had a lung function performed, 
19% had an isolated reduction in DLCO (48). This group of patients was younger, 
and, as can be expected, included more past or present smokers. Subsequently, a 
subset of 11% developed isolated pulmonary hypertension. In this group, pulmonary 
hypertension was strongly associated with an initial DLco of < 55% of predicted normal 
and a FVC (%predicted)/DLco (% predicted) ratio of >1.4. Patients with a poor outcome 
demonstrated an initial DLCO < 50% predicted. Isolated PAH is less common in diffuse 
scleroderma, and when present it is often seen with patients with the nucleolar 
antibody anti-U3-RNP (49).
Annual systematic screening resulted in more complete ascertainment of lung 
complications and substantial improved survival for the diffuse cutaneous subset of SSc 
patients (24). SSc PAH detection programs were able to identify patients with milder 
forms of the disease, as compared with patients in routine clinical practice, allowing 
earlier management (50). However, although early intervention by PAH-targeted 
treatment demonstrated benefits in mildly symptomatic (majority idiopathic) PAH 
patients (51), a clear benefit for early treatment in SSc-PAH has not yet been established. 
Current guidelines recommend annual echocardiography screening for symptomatic 
PAH patients, and state that annual screening may be considered in asymptomatic 
patients (52). For patients with SSc and SSc spectrum disorders expert opinion 
recommend echocardiography screening and a pulmonary function test annually and 
in case of new symptoms (including NT-ProBNP) (53). A detection algorithm “DETECT” 




% predicted, current/past telangiectasias, serum anti-Centromere antibody, serum 
NTproBNP, serum urate and right axis deviation on ECG), and defines a need for referral 
to echocardiography in case of a total risk points > 300 (Step 1). Two echocardiographic 
variables (Right Atrial area and tricuspid regurgitant jet (TR) velocity) and the total risk 
points from Step 1 were included in Step 2 in order to determine the need for referral 
for RHC. Of 466 SSc patients (with an increased risk of PAH) included in this study, 87 
(19%) had RHC-confirmed PAH. The DETECT algorithm recommended RHC in 62% of 
patients (referral rate) and missed 4% of PAH patients (false negatives). 
Renal disease
Renal involvement in SSc includes scleroderma renal crisis (SRC), normotensive 
renal crisis, antineutrophil cytoplasmic antibodies-associated glomerulonephritis, 
penicillamin-associated renal disease, and reduced renal functional reserves 
manifested by proteinuria, microalbuminuria, or isolated reduction in glomerular 
filtration rate (55). SSc renal crisis (SRC) is most often seen in patients with a disease 
duration less than 4 years, early or rapidly progressive diffuse skin involvement and 
presence of friction rubs. In European patients, a prevalence of 4.2% in patients with 
dcSSc and 1.1% in lcSSc was seen (35). Anti-RNA polymerase III antibodies are identified 
as the most important risk factor, with a 25% risk of developing SRC (independent of 
corticosteroid exposure), compared with a 2% risk in the absence of this antibody (56). 
Use of glucosteroids > 15 mg/day are another risk factor that was identified (57;58). 
The dramatically reduced mortality due to SRC in the past decades (59) may well be 
the result of prompt and adequate therapy. Administration of Angiotensin Converting 
Enzym (ACE) inhibitors as first line treatment with careful titration of blood pressure 
is recommended, with Angiotensin II receptor blockers (ARBs), calcium channel or a 
antagonists added if necessary (60). The preventive rol of ACE inhibitors in SRC is a 
subject of discussion. In a retrospective study 23/91 (25.3%) SRC patients used ACE 
inhibition at SRC onset versus 82/427 (19.2%) SSc controls (57). 
Gastro	intestinal	disease
The prevalence of gastrointestinal involvement depends on the diagnostic tool that 
is used for evaluation. In an autopsy study, GI muscle atrophy and/or fibrosis was 
found in the esophagus, small intestine, and large intestine in 74%, 48%, and 39% 
of patients, respectively (61). Myopathic changes in the intestine are thought to be 
preceded by a neuropathic phase (62).  SSc involvement of the GI tract affects motility, 
digestion, absorption and excretion. Symptoms in both limited as diffuse SSc patients 
include pain, dysphagia, reflux, early satiety, bloating, emesis, diarrhoea, constipation, 
faecal incontinence and substantial weight loss. Bleeding from telangiectasias and 
gastric antral vascular ectasia (GAVE, or watermelon stomach) is more often seen in 
elderly patients with limited SSc (63). Malabsorption may also be due to pancreatic 
insufficiency or bacterial overgrowth.
Muscular,	osteo-articular,	skin	and	soft	tissue	involvement
In the early disease course the skin may be swollen with a shiny appearance (64). The 
fingers may have a ‘puffy’ aspect and patients may complain of pain or itch. A loss of 
strength of the hands, sometimes combined with a feeling of numbness in the fingers, 
is often interpreted as a carpal tunnel syndrome. In active disease, fibrinous deposits 
in tendon sheats may result in a rubbing sound when a joint is moved, so called 
tendon friction rubs. As fibrosis advances, microstomia may develop as well as flexion 
contractures in hands and in diffuse SSc more proximal sites. Joints may be stiff and 
painful due to arthritis and/or tendinitis , myositis can be present with often moderately 
elevated creatine phosphokinase (CPK) (65). Musculoskeletal manifestations were 
almost twice as common in dcSSc as in lcSSc in 3656 patients included in the EUSTAR 
database (35).
Sicca syndrome is common in SSc, almost always due to salivary fibrosis (66). Patients 
with SSc and associated Sjögren’s syndrome are more likely to have other auto-immune 
disorder or other autoantibodies and demonstrate a lower frequency of lung fibrosis 
then SSc alone. Soft tissue and vascular involvement of the urogenital system may 
result in physical and psychological complaints in both female and male SSc patients 
(67;68).
Psychological	functioning
Patients with SSc have to cope with an uncertain disease course, variable impact on 
physical functioning and limited therapeutic options. Moreover, patients are often 
confronted with altered appearance due to scleroderma facial features, skin sclerosis, 
contractures, teleangiectasias, pigment changes and digital ulcers. In recent years, 
growing awareness is seen for the psychological distress that is associated with the 
disease. A systematic review of the literature found that apart from reduced physical 
quality of life, mental quality of life was significantly impaired in SSc patients (69). 
In a review by Thombs (70), a prevalence of mild-to-moderate symptoms of depression 
was found in 51%-65% of SSc patients fulfilling ACR criteria. Evaluation with a more 
conservative cut-off score identified 46% and 56% of patients. In a cross-sectional 
study, 18 % of 376 SSc patients demonstrated scores indicating probable depression, 
with sociodemographic and individual disease severity indicators (tender joint count, 
number of gastrointestinal symptoms, and breathing difficulties) significantly related 
to symptoms of depression (71). Matsuura et al found depressive symptoms were 
ranging from mild to severe state in 46% of 50 patients, with measures of depression 
being significantly correlated with low working ability, low social activity, low Sense 
of Coherence (SOC), pain, and helplessness, and not associated with disease severity 
variables including skin score and internal organ involvement (72). Moreover, multiple 
regression analysis showed that a high level of helplessness and a low level of sense of 




conclude that patients with a high level of helplessness or a low level of sense of 
coherence may be vulnerable to depression, and psychological interventions including 
counseling with special psychotherapists or antidepressant medication may prevent 
the development of depression. 
In particular women with SSc were found to have lower self-esteem, than for example 
burns patients (73). Patients who were objectively rated as having more severe 
visible signs, had higher distress and felt more isolated (74). Van Lankveld et al found 
decreased appearance self esteem (ASE) in 123 SSc with low values in both diffuse and 
limited SSc (75). Female patients had lower ASE than male patients and higher levels of 
limitations were related to lower levels of ASE; the Health Assessment Questionnaire 
Disability Index (HAQ-DI) and subscales together explained 28% of the appearance self 
esteem questionnaire variance. Moreover, lower ASE was correlated with self-assessed 
disease severity as well as disease symtoms such as pain, Raynaud and tiredness. In 
contrast, physician assessed disease variables such as the Modified Rodnan Skin Score 
(2) were unrelated to ASE. 
Outcome measurements 
In the clinical assessment of patient, both self reported measures as well as physical 
examination and organ specific tests are useful in monitoring disease course and 
treatment effect. Moreover, properly validated measures are essential in observational 
studies and clinical trials. Many disease measures in Systemic Sclerosis have been 
described, the essentials are summarized below and references if possible are added. 
General:
Inflammatory markers, anemia, auto-antibodies, 
Aerobic capacity
Exercise testing (ergometry), exercise oxygen saturation, oxygen uptake (VO2), 
production of carbon dioxide (VCO2), ventilation (VE), six minute walk distance 
(6MWD), functional class (New York Heart Association) 
Cardiac	function: 
Electrocardiogram, echocardiography, heart catheterization, CT (angiography), 
MRI,  cardiac scintigraphy (ejection fraction), 
Pulmonary	function
VAS dyspnoe, blood gas analyses, pulmonary function tests particularly forced 
vital  capacity (FVC) (measured by spirometry) and diffusion lung capacity of 
carbon monoxide (DLCO single-breath), bodybox (Total Lung Capacity), imaging 
(High Resolution CT scan), ventilation/perfusion (V/Q) lung scan. Saint George’s 
Respiratory Questionnaire (76), 
Gastro-intestinal	function
upper GI endoscopy, pH studies, oesophageal manometry, electrogastrographic 
recording, gastric scintigraphic evaluation, faeces sampling/cultures, hydrogen 
breath test, endosonography. University of California, Los Angeles Scleroderma 
clinical trials consortium gastrointestinal scale (UCLA SCTC GIT) 2.0 (77)
Renal	function:	
Urinalysis, creatinin and glomerular filtration rate (GFR), proteinuria, renal 
biopsy, renal vascular resistive index (78).
Muscular,	osteo-articular,	skin	and	soft	tissue	involvement
modified Rodnan Skin score (2), skin durometer, maximal mouth opening, 
Mouth Handicap In Systemic Sclerosis questionnaire (79), Cochin Hand 
Function Scale (80), Hand Mobility In Systemic Sclerosis (HAMIS), Michigan 
hand questionnaire, Hand Anatomic Index, Kapandji hand index, Fingertip Palm 
Distance, grip strength, pinch grip, digital ulcer burden, 
Sexual	function
Sexual Relationships subscale of the PAIS-SR, Female Sexual Function Index, 
Female Sexual Distress Scale
Raynaud’s phenomenon (RP) (81)
Raynaud Condition score, RP attack frequency (no. per day), RP attack duration 
(minutes), HAQ VAS for RP, Physician’s assessment of RP (by VAS), Patient’s 
assessment of RP (by VAS) 
Digital ulcer (81)
SHAQ VAS for digital ulcers, Physician’s assessment of digital ulcers (by VAS), 
patient’s assessment of digital ulcers (by VAS)
Daily	activities	and	Body	functions:	
HAQ DI and SHAQ (82), UK Scleroderma Functional Score (UKFS) (83), 
Scleroderma Assessment Questionnaire
Mental	/	psychological	functions:
Beck depression inventory, Center for Epidemiological Studies Depression 
Scale (CES-D), Hospital Anxiety and Depression Scale (HADS-D), Delusions 
Symptoms States Inventory/states of Anxiety and Depression scale (DSSI/sAD), 
Montgomery-Asberg Depression Rating Scale (MADRS), Fear of Progression 




Illness Cognition Questionnaire, Illness Perception Questionnaire, Psychosocial 
Adjustment to Illness Scale (PAIS-SR) (86)
Adapted Satisfaction with Appearance (SWAP) scale (85)
Quality of life
Short Form SF-36, EuroQol 5 D, Symptom burden index (87), Cambridge 
Pulmonary Hypertension Outcome Review (McKenna 2006)
Environmental factors
Evaluation of Daily Activity Questionnaire (EDAQ) (88)
Pharmacological treatment of Scleroderma
Treatment options in SSc consist of supportive medication on one hand and therapy 
that aims to reduce inflammation, fibrosis and vasculopathy on the other. Examples of 
supportive measures are antibiotic therapy, indicated for infectious complications (digital 
ulcers, interstitial lung disease with bronchial hyper reactivity or bronchiectasias), local 
therapy, wound dressing and consultation by plastic surgeon in case of complicated 
calcinosis cutis or digital ischemia and dietary measures needed in case of malnutrition. 
So far a cure is not available. The vascular, inflammatory and fibrotic processes in SSc 
have a variable expression and often unpredictable disease course. In the past years, 
treatment targeting involved organs has been the hallmark of SSc management. Early 
recognition of complications is therefore crucial. Therapy must be tailored to the 
individual patient depending on the extent and severity of organ involvement and 
the patho-physiologic stage of the disease; active or inactive. A number of targeted 
treatments are listed in table 3. Most of them have been assessed in a randomized 
controlled trial (RCT) or have been recommended by expert opinion (89). 
A few novel immune modulatory therapies demonstrated promising results in recent 
years; Mycophenolate Mofetil (MMF) (90), Rituximab (91;92), and autologous 
haematopoietic stem cell transplantation (93). Anti-fibrotic treatment by Imatinib was 
found to have variable effectiveness and poor tolerability in SSc trials (89).
Tabel 3. Pharmacological treatment overview
Clinical feature Treatment	options
Raynaud’s phenomenon
Calcium channel blockers, alpha-blockers, serotonin 
inhibitors, angiotensin II receptor inhibitors, local nitrates, 
iloprost
Digital ulcers healing Iloprost, phosphodiestherase inhibitors
New digital ulcers prevention Bosentan 
Calcinosis cutis Calcium channel blockers, colchicine, minocycline
Scleroderma Methotrexate
Interstitial Lung Disease
Cyclophosphamide (with/without corticosteroids), 
azathioprine
Pulmonary arterial hypertension
Endothelin receptors antagonists, phosphodiestherase 
inhibitors, prostanoids
Esophageal reflux Proton pump inhibitors, pro-kinetics
Intestinal bacterial overgrowth Broad spectrum antibiotics
Arthritis Corticosteroids, methotrexate
Myositis
Corticosteroids, azathioprine, methotrexate, 
immunoglobulins
Serositis (pericarditis, pleuritis) Corticosteroids, cyclophosphamide
Scleroderma renal crisis
Angiotensin converting enzymes inhibitors, angiotensin II 
receptors inhibitors, calcium channel blockers
Non-pharmacological treatment of Scleroderma 
The combination of impaired physical as well as mental quality of life and limited 
therapeutic options warrants appropriate guidance by health professionals and the 
provision of non-pharmacological treatment. This may focus on limitations in physical 
functioning or psychosocial functioning or both. 
Physical	rehabilitation	
Studies evaluating the effectiveness of non-pharmacological care in SSc have a 
large variety in interventions as well as outcome measures. Moreover, research on 
this subject is hampered by small sample sizes and a low methodological quality of 
studies. In a review on musculoskeletal rehabilitation in SSc, a number of studies were 
described evaluating modalities as paraffin waxing, range of motion exercises, splinting, 
massage and general exercise (94). These techniques were either applied alone or 
in combination, which makes comparisons complicated. An overview of the most 
relevant rehabilitation studies in SSc is presented in Appendix 1. With the limitation of 
the available literature taken into account, a few assumptions can be made:
• range of motion exercises and connective tissue massage with joint manipulation of 




• prior paraffin treatment may support stretch exercises
• range of motion and stretching exercises can be effective in increasing mouth 
opening
• splinting has not proven to be effective for flexion contractures
• there is limited evidence for increased muscle strength, improved quality of life and 
reduced disability after general exercise programs with partly sustained results. An 
increased peak oxygen uptake was seen in a selected group op SSc patients without 
interstitial lung disease, without information on post treatment sustainment.
Psychological support
The awareness for the need for psychological support is growing in recent years 
resulting in a number of publications. A few educational programs were described 
(95;96), including self-management programs. Only recently, two more specific psycho-
educational programs, including cognitive behavioural modules were published. 
Kwakkenbos et al demonstrated statistically significant, yet small improvements of 
helplessness and acceptance in patients who participated in a program consisting of 7 
psycho-educational sessions of three hours in 5 weeks. Other studies did not include 
measures of effectiveness. An overview of the literature is presented in Appendix 2.
Introduction	part	II:		
Health	 status	 in	 SSc	 according	 to	 the	 International	 Classification	 of	 Functioning,	
Disability and Health (ICF)
The International Classification of Functioning, Disability and Health (ICF) of the World 
Health Organisation WHO is a useful framework for describing and understanding 
the impact of SSc on the patient (97). From a medical point of view, the consequence 
or outcome of a disease is usually expressed as physical (dys)function or (dis)ability 
(morbidity). The WHO initiated the development of ICF classifications for established 
diseases, and placed the patient’s perspective in the center of this framework instead 
of his/her condition. Thus, functioning according to the ICF classification also includes 
patients’ activities and participation in society. Moreover, the influence of environmental 
factors, patients’ personal characteristics and interaction with the environment on 
(dys) function are taken into account in the ICF model (98). If a person with a given 
health condition lives in an environment characterized by barriers at every level their 
performance will be restricted; but if a person lives in a facilitating environment this 
will serve to increase their performance. 
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Figure	 2:	 Health status in SSc according to the International Classification of Functioning, 




The first part of the ICF classification describes the type and degree of various 
functioning impairments, limitations and restrictions related to or associated with a 
condition. There are 1454 classifications rubricated in a detailed structure, enabling 
comparisons between patients, diseases or nations in “ICF language”. In the clinical 
context, the ICF can be used for the assessment of needs, matching interventions to 
specific health states, rehabilitation and outcome evaluation. 
Body function (b) levels include: b1 mental functions, b2 sensory function and 
pain, b3 voice and speech functions, b4 functions of cardiovascular, hematological, 
immunological and respiratory system, b5 functions of the digestive, metabolic and 
endocrine system etc. These can be specified into a second and third level. In practice: 
b5 concerns the first-level of classification ‘Functions of the digestive, metabolic and 
endocrine systems’; b510 concerns the second-level classification ‘Ingestion functions’; 
b5105 concerns the third level Swallowing and b51052 pertains to the more detailed 
classification of ’Esophageal swallowing’ (100). Severe impairment of esophageal 
swallowing can be described as b51052.4, where ‘4’ refers to a scale of 0-4 from 0 (no 
impairment) to 4 (complete impairment). If a code is not applicable, the code will be 
followed by ‘.9’. 
Body functions (b), body structures (s), and activities and participation (d) belong to the 
part ‘functioning and disability’. Environmental factors and personal factors belong to 
the part ‘contextual factors’. Personal factors (p) (race, gender, age, educational level, 
coping styles, etc. ) have not been classified because of the wide variability among 
cultures. The chapters for body structure (s) and body function (b) are parallel to each 
other for ease of use. 
For clinical use or research a so called ICF core set can be developed, pertaining to a 
selection of ICF domains or categories from the whole classification which can serve 
as minimal standards for the reporting of functioning and health in patients with a 
certain illness. For rheumatoid arthritis a Delphi exercise resulted in a brief core set 
compromising 39 second-level categories (8 on body functions, 7 on body structures, 
14 on activities and participation, and 10 on environmental factors) (99). For SSc, a core 
set is currently being generated (100). A core set is not intended to replace validated 
instruments, but may be helpful in clarifying to what extent these instruments describe 
disease experience. 
Aspects of functioning and disability addressed in this thesis are body structures, body 
functions (physiological and psychological functions) and activities and participation. 
A. Disease consequences in terms of body structures and functions 
The inflammation, fibrosis and vasculopathy in the skin and internal organs leads to a 
variable degree of morbidity. The disease manifestation due to involved organ systems 
have been discussed in part I with body structures and function discussed together.
B. Disease consequences in terms of daily activities and societal participation 
Daily	activities 
Limitation in daily functioning is common in SSc patients and may be due to skin fibrosis, 
sicca syndrome, musculoskeletal pain or impairment, vascular injury, gastro-intestinal 
symptoms, decrease in aerobic capacity and tiredness (101). Impaired aerobic capacity 
may be due to cardiac as well as pulmonary involvement and may lead to a decreased 
(submaximal) exercise performance (102), which is often used as a parameter to 
disease severity. 
Significant disability in activities of daily living as expressed by the HAQ was 
demonstrated in patients with both the diffuse and limited subtypes of SSc (103), with 
the highest disability in the components activity and grip, and lowest in walking. Among 
the physical factors that were evaluated, extensive skin thickening and severe joint and 
muscle involvement had the highest correlation with global disability.  Other studies 
confirmed that hand functional disability is the major component of global disability 
in patients with SSc (80). Limitations in daily activities were also evaluated using the 
Evaluation of Daily Activity Questionnaire (EDAQ) in thirty patients with SSc (88). This 
questionnaire includes 102 daily activities in 11 dimensions: eating/drinking, transfer, 
toileting, dressing, bathing, cooking, mobility indoors, cleaning, washing/clothes care, 
mobility outdoors/ shopping, and communication. Most limitations were seen in the 
dimensions Eating/Drinking and Washing/Clothes, and the fewest in Mobility indoors 
and Transfers.
Societal	participation	
The majority of patients with both diffuse as limited SSc perceive major consequences 
for their lives due to their illness (104). Disease symptoms of SSc may not only influence 
everyday self care and household occupations but also professional activity and hobbies 
(105;106). Work disability is usually defined as work cessation due to the disease prior 
to the age of retirement (107). Other definitions and endpoints that are employed 
in studies on the impact of SSc on work ability include absenteeism or sick leave, 
reduction in productivity while present at work (presenteeism) and productivity loss. 
The influence of SSc on work status is best determined by comparing clearly defined 
endpoints between SSc patients and matched controls living in the same area, taking 




account. This methodology was employed by Mau et al in Germany, who demonstrated 
reduced participation in labor force as expressed by standardized employment ratios 
in individuals with SSc (108). A number of recent studies found that lower educational 
level, less social support, poor functional ability and longer disease duration were 
associated with work disability (109;110).
C. Personal and external factors; health care usage and needs 
Given the complexity of the disease, SSc patients usually require multidisciplinary 
treatment, involving the general practitioner, a rheumatologist, other medical 
specialists and non-medical health professionals such as physical therapists, 
occupational therapists, dieticians, nurses or psychologists. In a few available studies 
on health care utilization, the number of visits to the rheumatologist varied from 
2.4 to 4.0 visits per year (111-113) and to the general practitioner from 3.5 to 10.3 
visits per year. Only one of these studies focused on factors associated with health 
care utilization; higher skin scores, more co morbidity and worse physical functioning 
were associated with higher health care utilization (111). In a survey including 1437 
members of 12 provincial chapters of the Scleroderma Society of Canada, 43 percent 
of SSc patients were diagnosed by a rheumatologist (114). Among patients with diffuse 
disease, 90% were followed by a rheumatologist; however just over half of patients 
had seen a gastroenterologist (54%), cardiologist (51%), pulmonologist (67%), and less 
than half had seen a dermatologist (42%), nephrologist (13%), physiotherapist (46%), 
or occupational therapist (34%). 
A number of studies have investigated the unmet needs and preferences regarding 
health care delivery among patients with SSc, concluding that unmet health care and 
information needs are common (115;116). Rubenzik found health care needs in the 
psychological/spiritual/existential domain in a group of 25 patients with SSc (115). In 
addition, in a Dutch study in 123 patients with SSc, the need for practical information 
on disease background, medication usage and dealing with pain was identified (116). 
Introduction	part	III:	
Aims of this thesis
Due to the complexity of the disease, health care providers involved with Systemic 
Sclerosis patients experience challenges in diagnosis as well as monitoring of disease 
course and complications. As was demonstrated in the introduction, patients may have 
a large variability in symptoms, but in most patients substantial morbidity is present. 
For good clinical practice minimal standards for the reporting of functioning and health 
in patients with Systemic Sclerosis are essential. For this purpose, a framework as the 
International Classification of Functioning, Disability and Health (ICF) may be helpful.
For this thesis, a general aim was to gain more insight into the impact of SSc on a 
number of aspects of patients’ health , related to the ICF chapters Body functions and 
structures, Activities and participation and Contextual factors such as rehabilitation. 
The studies also examined the clinical and scientific value of a number of relevant 
disease outcome measures. 
In Chapter 2 two-dimensional (2D) speckle tracking analysis was used to evaluated 
subclinical myocardial dysfunction, providing measures of LV regional and global 
strain in three orthogonal directions (longitudinal, circumferential and radial) and thus 
overcoming the limitations of TDI (34). Also the relationship of this technique with 
functional capacity and ventricular arrhythmias was investigated.
In Chapter 3 sexual functioning and distress of women with SSc was compared 
with healthy controls, and the association between sexual function and disease 
characteristics was evaluated.
In Chapter 4 French-generic Mouth Handicap in Systemic Sclerosis (MHISS) was 
translated, field-tested, adapted into Dutch language and its validity was tested. 
Complaints of mouth-opening restriction, dryness and esthetic concerns of patients 
with SSc can be monitored by this questionnaire. 
In Chapter 5 the validity and responsiveness of the Michigan Hand Questionnaire 
(MHQ) in patients with SSc was assessed, a self-reported questionnaire with scores 
for overall hand function as well as ability to complete activities of daily living, pain, 
work performance, aesthetics and patient satisfaction. The MHISS addresses domains 




Since work is an important part of patient’ participation, a systematic review was 
performed in Chapter 6 to evaluated work status and factors associated with work 
disability (WD) in patients with SSc.
In Chapter 7 a survey was done to establish how available health care services relate to 
healthcare needs of patients with SSc. Also, the association between needs and patient 
characteristics was studied and patients preferences regarding the provision of care 
was recorded.
 
Finally in Chapter 8 a randomized controlled trial evaluated safety and effectiveness 
of a multidisciplinary team care program provided by the Rheumatology Ambulatory 
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Background:	Systemic sclerosis is a connective tissue disease characterized by vascular 
inflammation and fibrosis. Visceral involvement, including cardiac manifestations can 
lead to severe clinical complications, such as congestive heart failure, arrhythmias and 
sudden death. Conventional echocardiography parameters have limited sensitivity to 
detect subtle myocardial dysfunction in patients with systemic sclerosis (SSc). The aim 
of the study was to assess, using novel speckle tracking strain analysis, the presence of 
myocardial dysfunction in SSc patients and to investigate its relationship with functional 
capacity and ventricular arrhythmias. 
Methods:	A total of 104 SSc patients (age 54 ± 12 yrs, 77% female) were included 
and underwent cardiopulmonary exercise testing, 24-hour electrocardiography Holter, 
and transthoracic echocardiography. For comparison purposes, 37 matched healthy 
controls were included. 
Results:	The total population consisted of 51 patients with limited SSc and 53 patients 
with diffuse SSc. Peak VO2% predicted was 91 ± 20% and 28 patients had abnormal 
Holter findings (ventricular tachycardia or ventricular ectopics >100/day). Patients with 
SSc, as compared with controls, had impaired global longitudinal and circumferential 
strains (-18.2 ± 1.8% versus -21.3 ± 1.7% and -18.2 ± 2.3% versus -21.3 ± 2.1% 
respectively; each p < 0.01), but there was no difference in the left ventricular ejection 
fraction between patients and controls (63.5 ± 7.2% vs 64.6 ± 4.4%, p=0.20). In patients 
with SSc, global longitudinal (r=-0.46, p<0.01) and circumferential strains (r=-0.41, 
p<0.01) correlated with peak VO2% predicted. Multivariate analysis showed that global 
longitudinal and circumferential strains were independently associated with peak VO2% 
predicted. Compared to SSc patients with normal results on EKG Holter monitoring, SSc 
patients with abnormal results showed impaired global longitudinal strains (-18.5 ± 
1.5% versus -17.1 ± 2.1%; p <0.01) and circumferential strains (-18.7 ± 2.0% versus -17.3 
± 2.5%; p=0.01), and each strain measure was independently associated with abnormal 
Holter findings 
Conclusion:	Speckle tracking strain analysis detected subtle myocardial dysfunction in 
SSc patients. Importantly, decreased global longitudinal and circumferential strains are 
associated with lower functional capacity and rhythm disturbances. 
Introduction
Systemic sclerosis (SSc) is an autoimmune disease characterized by deposition of 
collagen in multiple organs and associated with significant disability and reduced life 
expectancy.1 Cardiovascular involvement has been shown to be one of the leading 
causes of mortality in SSc2 and to occur in up to 70% of patients as autoptic finding.3 
Early diagnosis and accurate staging of myocardial involvement are therefore crucial 
for the management of these patients and for therapeutic strategies. 
Conventional echocardiographic assessment of left ventricular (LV) systolic function 
is based on the measure of LV ejection fraction (EF). This approach however showed 
limited sensitivity for the assessment of myocardial abnormalities in SSc patients, being 
able to identify only 5% of patients with cardiac involvement.4 More sophisticated and 
sensitive techniques for the assessment of LV function are therefore needed to improve 
the detection of subclinical myocardial dysfunction in SSc patients. Initial studies using 
tissue Doppler imaging suggested that myocardial velocity and deformation (strain) 
might be more sensitive than conventional measures in identifying subtle cardiac 
dysfunction in asymptomatic SSc patients.5-7 However, the clinical implications of this 
alternative approach for LV function assessment have not been evaluated.
Recently, two-dimensional (2D) speckle tracking analysis has been proposed as a 
sensitive and accurate method for the evaluation of subclinical myocardial dysfunction, 
providing measures of LV regional and global strain in three orthogonal directions 
(longitudinal, circumferential and radial).8 The aim of this study was therefore to apply 
this novel technique to assess the presence of LV systolic dysfunction in a large cohort 
of SSc patients. Furthermore, the clinical value of the measurement of LV global strain 
by 2D speckle tracking analysis was evaluated in relation with functional capacity and 
ventricular arrhythmias in these patients.
Methods 
Patient	population	and	protocol
The current study included 113 consecutive patients with SSc referred to the 
department of Rheumatology, Leiden University Medical Center. The patients were 
recruited from two studies; a randomized controlled trial evaluating the effectiveness 
of a multidisciplinary team care program9 and a study evaluating the outcomes of a 
two-days diagnostic multidisciplinary daycare program10. All patients underwent an 
extensive screening, including detailed physical examination, a Modified Rodnan Skin 
Score assessment,11 laboratory testing (including erythrocyte sedimentation rate, anti-
nuclear, anti-topoisomerase I, anti-RNP and anti-centromere antibodies assessments), 
chest X-ray and lung function test. Interstitial lung disease was diagnosed by chest 
X-ray and by lung function test, and with computed tomography scan when indicated. 
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Patients were classified as limited systemic sclerosis (lSSc) or diffuse systemic sclerosis 
(dSSc), according to the classification system described by LeRoy et al.12 In addition, 
cardiopulmonary exercise (CPET) and 24-hour electrocardiography (ECG) Holter 
monitoring were performed to assess patient functional capacity and potential 
ventricular arrhythmias, respectively. None of the patients had angina pectoris or 
symptoms attributable to cardiovascular disease and therefore specific tests for 
microvascular and macrovascular ischemia were not performed. Transthoracic 
echocardiography was performed to evaluate conventional parameters of cardiac 
function and to assess subclinical LV systolic dysfunction using novel speckle tracking 
analysis. The relationship of LV function with functional capacity and ventricular 
arrhythmias was evaluated.
Seven patients were not able to perform CPET (because of severe pulmonary 
hypertension in 4 patients, severe aortic valve stenosis in 1 patient and severe SSc 
disease status in 2 patients) and therefore excluded from the analysis. In addition, 2 
patients were excluded because of an incomplete clinical assessment. The final study 
population consisted of 104 patients. 
For comparison purposes, 37 normal individuals (1:3 ratio with SSc patients) matched 
for age and gender were included as a control group. These subjects were referred 
for atypical chest pain, palpitations, or syncope without murmur and showed normal 
structural heart on echocardiography. 
The study protocol was approved by the Ethics Committee of the Leiden University 
Medical Center. All participants provided written informed consent for the studies in 
which they participated
Lung	function	test
Lung function test was performed in all SSc patients and included spirometry and single 
breath diffusion lung capacity for carbon monoxide (DLCO). Spirometry measurements 
included forced vital capacity (FVC) and total lung capacity (TLC) measured according 
to the American Thoracic Society/European Respiratory Society recommendations13-15 
and expressed as percentage predicted.
Conventional	echocardiography
All SSc patients and controls were imaged in the left lateral decubitus position using a 
commercially available system (Vingmed Vivid 7, General Electric Vingmed Ultrasound, 
Milwaukee, USA). Images were obtained using a 3.5-MHz transducer and digitally 
stored in cine-loop format; offline analysis was performed using EchoPAC version 
108.1.5 (General Electric - Vingmed, Horten, Norway). LV dimensions, volumes and 
EF were measured according to the current recommendations.16 Evaluation of LV 
diastolic function was based on the pulsed-wave Doppler of mitral valve inflow as 




diastolic velocity (E), peak late (A) diastolic velocity, their ratio (E/A) and the E wave 
deceleration. Pulmonary venous flow velocities during systole (S) and diastole (D) were 
also recorded. Using tissue Doppler imaging, the early diastolic velocity (E`) and systolic 
velocity (S`) was measured at the level of the LV basal lateral segment. In addition, E/
E` ratio was calculated as an estimation of LV filling pressure.18 LV diastolic dysfunction 
was therefore categorized as previously described: normal; mild, defined as LV 
impaired relaxation without evidence of increased filling pressure; moderate, defined 
as LV impaired relaxation associated with moderate elevation of filling pressures or 
pseudo-normal filling; and severe, defined as restrictive LV filling.17 Pulmonary arterial 
systolic pressure (PASP) was estimated by right ventricular systolic pressure, which was 
calculated from the tricuspid regurgitation peak gradient using Bernoulli equation, and 
adding right atrial pressure estimated by the dimension and the degree of inferior vena 
cava respiratory collapse.19 
Two-dimensional speckle tracking strain analysis
Two-dimensional speckle tracking analysis is a novel imaging technique which allows 
the assessment of LV myocardial deformation by tracking natural acoustic markers 
(speckles) in a frame-to-frame basis within the cardiac cycle. The speckles are visible in 
the standard gray-scale 2D images and are equally distributed within the myocardium. 
As represented in Figure 1, LV deformation can be assessed in three orthogonal 
directions as longitudinal, circumferential and radial strain.20 
Figure	1:	Schematic representations of the three orthogonal directions of strain measured with 
two-dimensional speckle tracking analysis. Global longitudinal strain evaluates the shortening/
lengthening of the myocardial wall. Radial strain evaluates the thickening and thinning of the 
myocardial wall and circumferential strain asses the shortening/lengthening along the curvature 














Figure 1:  Schematic representations of the three orthogonal directions of strain measured with two-
dimensional speckle tracking analysis. Global longitudinal strain evaluates the shortening/lengthening 
of the myocardial wall. Radial strain evaluates the thickening and thinning of the myocardial wall and 
circumferential strain asses the shortening/lengthening along the curvature of the LV.  
 
Longitudinal strain, evaluating the shortening/lengthening of the myocardial wall, was  
measured from the 3 apical views: 2-chamber view (including anterior and inferior walls), 4- 
chamber view (posteroseptal and lateral walls) and long axis view (anteroseptal and posterior 
walls). Each wall was divided into 3 levels (basal, mid and apical) and subsequently 18 segmental 
strain curves were obtained. Global longitudinal strain was calculated as the average of peak 
systolic strain values of the 18 segments (Figure 2a).  
From LV mid-ventricular short-axis view, circumferential strain (evaluating myocardial 
shortening/lengthening along LV curvature) and radial strain (evaluating myocardial 
thickening/thinning) were measured. The global values of circumferential and radial strains 
were derived from the average of peak systolic strain values of 6 segments, as illustrated in 




L = Longitudinal 
C = Circumferential 
R = Radial 
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Figure	2:	Left ventricular strain assessment in 3 orthogonal directions by two-dimensional speckle 
tracking analysis. Figure 2a illustrates the calculation of global longitudinal strain from the apical 
4-chamber, 2-chamber and the long-axis views. Each color line denotes regional segmental strain 
(6 segments per views, for a total of 18 segments) and the white dotted line represents the 
average strain value of each view. The global longitudinal strain is calculated by the average of 
peak strain in the three apical views. From the mid-ventricular short-axis view of the LV, global 
circumferential (Figure 2b) and radial (Figure 2c) strains are calculated by averaging the peak 






Figure 2: Left ventricular strain assessment in 3 orthogonal directions by two-dimensional speckle 
tracking analysis. Figure 2a illustrates the calculation of global longitudinal strain from the apical 4-
chamber, 2-chamber and the long-axis views. Each color line denotes regional segmental strain (6 
segments per views, for a total of 18 segments) and the white dotted line represents the average strain 
value of each view. The global longitudinal strain is calculated by the average of peak strain in the three 
apical views. From the mid-ventricular short-axis view of the LV, global circumferential (Figure 2b) and 
radial (Figure 2c) strains are calculated by averaging the peak strain of six LV segments.  
 
Figure 2a  
2a2a 
Longitudinal strain, evaluating the shortening/lengthening of the myocardial wall, was 
measured from the 3 apical views: 2-chamber view (including anterior and inferior 
walls), 4- chamber view (posteroseptal and lateral walls) and long axis view (anteroseptal 
and posterior walls). Each wall was divided into 3 levels (basal, mid and apical) and 
subsequently 18 segmental strain curves were obtained. Global longitudinal strain was 
calculated as the average of peak systolic strain values of the 18 segments (Figure 2a). 
From LV mid-ventricular short-axis view, circumferential strain (evaluating myocardial 
shortening/lengthening along LV curvature) and radial strain (evaluating myocardial 
thickening/thinning) were measured. The global values of circumferential and radial 
strains were derived from the average of peak systolic strain values of 6 segments, 
as illustrated in Figure 2b and 2c, respectively. Global longitudinal and circumferential 
strains are expressed as negative values, and a lower strain is represented by less 
negative values. Global radial strain is expressed as positive values, and lower values 
indicate lower strain.
The intra- and inter-observer agreement for the measurements of longitudinal, 
circumferential and radial strains have been reported previously.20 
Cardiopulmonary	exercise	testing	
All SSc patients performed a maximal exercise stress test on an electrically braked 
stationary cycle ergometer using a ramp protocol according to the American Thoracic 
Society/American College of Chest Physician statement on cardiopulmonary testing.21 
Briefly, a tight fitting facemask was worn by the patients and allowed ventilation 
and metabolic gas exchange measurements (Oxycon Pro, Jaeger-Viasys Healthcare, 
Hoechberg, Germany). The initial work load was 30W, with further increment of 5W 
every 30 seconds. Patients were encouraged to exercise until exhaustion or until 
supervising physician stopped the test because of significant symptoms, such as chest 
pain, dizziness, ST-segment deviations, or marked systolic hypotension or hypertension. 
Peak VO2 was defined as the highest oxygen consumption during any stage of maximal 
exercise. Furthermore, peak VO2 was adjusted to age, gender and weight and expressed 
as percentage predicted. 
24-hour electrocardiography Holter monitoring
A 24-hour ECG Holter monitoring was performed in 100 out of 104 patients to 
detect potential ventricular arrhythmias. Abnormal Holter results were defined as 
the presence of intermittent bundle branch block, ventricular arrhythmias including 
frequent monomorphic and/or polymorphic premature ventricular contractions >100 
per day, or non-sustained or sustained ventricular tachycardia.22 





SSc (n=104) lSSc (n=51) dSSc (n=53) p value
Age (yrs) 54±12 58±12 50±12 <0.01
Female gender, n (%) 80(77) 43(84) 37(70) 0.08
Time since diagnosis, yrs 5.1±2.3 7.1±3.5 4.1±2.5 <0.01
Time since onset of Raynaud’s, yrs 8.6±6.3 15.0±5.8 5.8±4.2 <0.01
Time since onset of skin manifestation, yrs 5.6 ±3.5 7.1 ±6.2 4.7 ±2.8 0.02
Modified Rodnan Skin Score 5.6±6.1 2.8±2.2 8.3±7.4 <0.01
Systolic blood pressure, mmHg 122±18 125±18 119±18 0.08
Diastolic blood pressure, mmHg 71±9 70±8 72±11 0.23
Systemic hypertension 11(11) 2(18) 9(82) 0.03
ESR, mm/hr 20.5±17.6 20.7±19.8 20.3±15.4 0.91
Immune markers: 
Anti-nuclear, n (%)
Anti-topoisomerase, n (%)    


















Interstitial lung disease, n (%) 49(47) 15(28) 34(64) <0.01
Pulmonary hypertension 4(4) 1(2) 3(6) 0.62

































Current cardiovascular medications (%):
Calcium antagonists, n (%)









Abbreviations:	ACE = Angiotensin converting-enzyme; dSSc= Diffuse systemic sclerosis; DLCO = 
Diffusion lung capacity for carbon monoxide; ESR = Erythrocyte sedimentation rate; FVC = Forced 
vital capacity; TLC = Total lung capacity. *Chronic kidney disease was defined as an estimated 
glomerular filtration clearance rate < 60ml/min/1,73m2 for more than 3 months
Statistical	analysis
Continuous variables are presented as mean ± standard deviation. Categorical data 
are presented as frequencies and percentages. Continuous variables were tested for 
normal distribution with the Kolmogorov-Smirnov test. Statistical comparisons were 
performed by using Student’s t test for continuous variables, and chi square test for 
binary variables. Univariate linear regression analysis was used to identify potential 
determinants of peak VO2% predicted. Correlations were expressed in terms of 
Pearson’s correlation coefficient. Moreover, univariate binary logistic regression 
was used to determine the factors associated (using odd ratios (OR) and confidence 
intervals (CI)) with abnormal Holter results. The final multivariate models for peak 
VO2% predicted and abnormal Holter results were obtained using the enter method 
by including parameters that were statistically significant in univariate analysis. To 
avoid bias from multicollinearity, multi-directional global strains were entered to the 
step-wise model individually. Analysis of covariance tests with inclusion of covariates 
to correct for significant different variables of subpopulation characteristics were 
performed. All statistical analysis were performed using the statistical package SPSS 
for windows (Version 15.0, SPSS, Chicago, USA). A p value <0.05 was considered to be 
statistically significant.  
Results
Clinical	characteristics	of	the	patient	population
A total of 51 (49%) patients were classified as having lSSc and 53 (51%) patients as 
having dSSc. Clinical characteristics of the total population and of the 2 subtypes of SSc 
(limited and diffuse) are shown in Table 1. According to the matching criteria, age (54±10 
vs. 54±12, p=0.82) and gender (female 77% vs. 73%, p=0.66) were similar between SSc 
patients and controls. Most of SSc patients were positive for antinuclear antibodies 
and approximately 50% had underlying interstitial lung disease. In addition, 24 patients 
(20 dSSc patients and 4 lSSc patients) received a treatment with cyclophosphamide, 
and 13 patients (all dSSC) stem cell transplantation. A total of 4 patients had mild 
pulmonary hypertension (2 due to underlying interstitial lung disease and 2 due to 
pulmonary arterial hypertension), 1 patient had a previous myocardial infarction and 2 
patients were known for epicardial coronary artery disease successfully revascularised 
by coronary artery bypass grafting.
Patients with dSSc were associated with a younger age, shorter time since diagnosis and 
time since onset of Raynaud’s phenomenon and skin manifestation. Moreover, patients 
with dSSc were more likely to have systemic hypertension, underlying interstitial lung 
disease, lower TLC% predicted and to receive angiotensin-converting enzyme inhibitors 
(mainly to prevent renal crisis) as compared to patients with lSSc. Patients with lSSc had 
a significantly lower prevalence of anti-topoisomerase antibodies and a lower modified 
Rodnan skin score.
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LV end diastolic volume (ml) 70.6±20.6 76.0±25.4 0.21 72.9±22.4 78.9±23.0 0.24
LV end systolic volume (ml) 26.6±5.7 29.1±13.1 0.13 28.8±13.9 29.4±12.5 0.82
LV ejection fraction (%) 64.6±4.4 63.5±7.2 0.20 64.6±7.9 63.4±6.4 0.19
PASP (mmHg) 21.7±6.3 28.9±8.7 <0.01 29.5±8.3 28.3±9.1 0.48
LV diastolic function, n (%)
   Normal 21 (62) 35 (34) <0.01 18 (35) 17 (32) 0.62
   Mild 9 (24) 24 (23) 12 (24) 12 (23)
   Moderate 5 (14) 30 (29) 16 (31) 14 (26)
   Severe 0 (0) 15 (14) 5 (10) 10 (19)
E` velocity (cm/s) 9.8±2.0 8.5±2.8 0.03 8.8±2.7 8.1±3.0 0.22
E/E` ratio 7.7±1.9 10.1±3.8 <0.01 10.2±3.8 10.0±3.7 0.73
S` velocity (cm/s) 6.4±1.4 6.3±2.1 0.81 6.8±2.0 5.7±2.0 <0.01
Speckle tracking analysis
Global longitudinal strain (%) -21.3±1.7 -18.2±1.8 <0.01 -18.6±1.6 -17.9±1.9 0.02
Global circumferential strain (%) -21.3±2.1 -18.2±2.3 <0.01 -19.0±2.0 -17.5±2.3 <0.01
Global radial strain (%) 40.3±12.4 37.0±13.9 0.18 37.6±13.1 36.3±14.7 0.65
Abbreviations:	LV= Left ventricular; PASP= Pulmonary arterial systolic pressure; E = Early; A = 
Late; E`= Early diastolic velocity at basal mitral annulus; For other abbreviations, see Table 1.
Echocardiographic	characteristics	of	the	patient	population
Conventional echocardiographic parameters of LV systolic and diastolic function of SSc 
patients and controls are shown in Table 2. No significant differences were noted in 
LV volumes and EF between SSc patients and controls (Table 2). Moreover, S` velocity 
derived from tissue Doppler imaging was similar to controls. However, estimated PASP 
was significantly higher in SSc patients as compared to controls and E/E` ratio and LV 
diastolic dysfunction grade were significantly worse. When comparing the 2 different 
subtypes of SSc, both groups showed similar values of conventional echocardiographic 
parameters.
In order to detect subtle LV dysfunction, myocardial strain values in three orthogonal 
directions were measured by speckle tracking analysis (Table 2). Both global longitudinal 
and circumferential strains were significantly impaired in SSc patients as compared to 
controls. However, no difference was noted in global radial strain between SSc patients 
and normal subjects. Of note, dSSc patients showed worse values of global longitudinal 
and circumferential strain as compared to lSSc patients. 
Cardiopulmonary	exercise	testing
All SSc patients completed the CPET with at least 50W exercise level and reached 
anaerobic threshold; the heart rate recovery (HRR) was >12 beats/minute and the 
respiratory exchange ratio was >1.00, suggesting a satisfactory exercise capacity in the 
study population. The mean peak VO2% predicted was 90.6±20.4% and the maximum 
exercise time was 9.9±3.6 min suggesting a relatively preserved functional capacity 
in the population. Patients with dSSc had a significantly lower peak VO2% predicted 
compared to those with lSSc (83.2±21.1 vs. 99.7±24.7%, p<0.01). 
According to Pearson’s correlation analysis, peak VO2% predicted was not related to 
conventional echocardiographic parameters including LV dimensions, LVEF and LV 
diastolic function (p>0.05). However, peak VO2% predicted was significantly related 
to global longitudinal (r=-0.46, p<0.01), circumferential (r=-0.41, p<0.01) and radial 
(r=0.20, p=0.05) strains (Figure 3). 
Univariate analysis revealed that among all the clinical and echocardiographic 
characteristics, age (β=0.24, Confidence interval [CI] = 0.09-0.83, p=0.02), subtype 
dSSc (β=0.40, CI = 0.30-0.79, p<0.01), underlying interstitial lung disease (β=0.24, 
CI = 2.23-20.6, p=0.02), TLC% predicted (β=0.40, CI = 0.30-0.79, p<0.01) and DLCO% 
predicted (β=0.49, CI = 0.46-0.96, p<0.01) were significantly associated with peak VO2% 
predicted. Strain measurements were adjusted with the aforementioned parameters 
in a multivariate analysis, which demonstrated that global longitudinal (β=-0.36, CI = 
-0.21, -0.72, p<0.01) and circumferential (β=-0.34, CI = -0.19,-0.75, p<0.01) strains were 
independently associated with peak VO2% predicted, together with age and DLCO%. 
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Figure	 3:	 Correlation between peak VO2 % predicted and global longitudinal (Panel A), 
circumferential (Panel B) and radial (Panel C) strain measured by two-dimensional speckle 
tracking analysis. Dashed lines correspond to 95% confidence interval. 
24-hour ECG Holter monitoring
Among the 100 SSc patients who underwent 24-hour ECG Holter monitoring, 28 (28%) 
patients had abnormal results. In particular, 9 patients presented with non-sustained 
ventricular tachycardia and 19 patients had ventricular ectopic >100 per day. No atrial 
arrhythmias were recorded.
Clinical and echocardiographic parameters differences between patients with or 
without abnormal Holter results are shown in Table 3. Patients with abnormal Holter 
results were more likely to be male and with underlying interstitial lung disease. 
Conventional LV systolic function, LV diastolic dysfunction grade, and S` velocity were 
similar between patients with or without abnormal Holter results. However, E/E` ratio 
was significantly higher in patients with abnormal Holter results. Moreover, global 
longitudinal and circumferential strains, but not global radial strain, were significantly 
impaired in patients with abnormal Holter results.
Univariate analysis demonstrated that the presence of abnormal Holter results was 
associated with male gender (OR = 2.94, CI = 1.12, 7.69, p<0.01), interstitial lung 
disease (OR = 3.32, CI = 1.32, 8.36, p<0.01), higher E/E` ratio (OR = 1.15, CI = 1.02, 1.32, 
p=0.04), and lower values of global longitudinal (OR = 1.71, CI = 1.24, 2.38, p<0.01) and 
circumferential strains (OR = 1.55, CI = 1.18, 2.03, p<0.01). After multivariate adjustment, 
both global longitudinal (OR = 1.47, CI = 1.05, 2.07, p=0.03) and circumferential (OR 
= 1.35, CI = 1.01, 1.82, p=0.04) strains remained the only independent predictors of 
abnormal Holter results in SSc patients.
Discussion
The results of the current study demonstrated that patients with SSc present subtle LV 
systolic dysfunction, as assessed by 2D speckle tracking strain analysis, despite normal 
LVEF and dimensions. More importantly, LV global longitudinal and circumferential 
strains, but not conventional echocardiographic parameters, were independently 
associated with functional capacity assessed by CPET, and ventricular arrhythmias 
detected by 24-hour ECG Holter monitoring. 
Cardiac involvement in patients with SSc has been mainly described by the presence 
of elevated PASP and LV diastolic dysfunction.5,6 Recent studies5-7 using tissue Doppler 
imaging in relatively small groups of SSc patients, have also suggested an impairment 
in myocardial systolic deformation (strain), despite preserved LVEF and dimensions.4,23 
However, strain analysis by tissue Doppler imaging is significantly limited by angle 
dependency (the measure changes with the insonation angle) and does not allow for 
the evaluation of all LV segments and of different directions of myocardial deformation. 
The advent of 2D speckle tracking analysis overcomes these limitations and allows 
angle-independent, direct evaluation of LV global strain in all three orthogonal 
directions, providing more accurate assessment of LV function.8 











Age, yrs 54±13 56±12 0.45
Female gender, n (%) 59(81.9) 17(60.7) 0.04
Interstitial lung disease, n (%) 9(32.1) 19(67.9) 0.01
Diffuse systemic sclerosis, n (%) 35(48.6) 19(67.9) 0.12
Modified Rodnan Skin Score 5.1±5.8 7.2±7.1 0.16
Immune markers:
    Anti-nuclear, n (%) 65(90.3) 26(92.9) 1.00
    Anti-topoisomerase, n (%) 22(31.4) 13(46.4) 0.17
    Anti-centromere, n (%) 17(26.2) 7(25) 1.00
    Anti-RNP, n (%) 6(8.6) 1(3.6) 0.67
Lung function:
    FVC% predicted 89.0±17.8 83.2±18.5 0.17
    TLC% predicted 64.6±17.2 60.4±16.1 0.25
    DLCO% predicted 95.4±13.7 93.6±15.0 0.58
Conventional	echocardiographic	parameters
LV end diastolic volume, ml 73.5±22.4 79.4±28.7 0.34
LV end systolic volume, ml 27.5±9.9 32.1±18.8 0.23
LV ejection fraction, % 63.9±6.6 62.8±9.1 0.57
PASP, mmHg 28.0±7.5 30.1±10.2 0.36
LV diastolic function, n (%)
   Normal 26 (36) 8 (29) 0.36
   Mild 17 (24) 5 (18)
   Moderate 21 (29) 8 (29)
   Severe 8 (11) 7 (25)
E` velocity, cm/s 8.6±2.9 8.1±2.6 0.35
E/E` ratio 9.4±3.8 11.7±4.0 0.04
S` velocity, cm/s 6.3±2.0 6.2±2.2  0.79
Speckle tracking analysis
Global longitudinal strain, % -18.5±1.5 -17.1±2.1 <0.01
Global circumferential strain, % -18.7±2.0 -17.3±2.5 0.01
Global radial strain, % 37.8±14.0 33.7±13.1 0.17
Abbreviations:	see Table 1 and 2.
The current study applied this novel analysis in a large cohort of SSc patients and 
found that both LV global longitudinal and circumferential strains were modestly but 
significantly impaired in SSc patients as compared to controls. The relatively small 
difference of strain values noted between the 2 groups could be explained by the 
fact that SSc patients in the present cohort were asymptomatic and had a relatively 
preserved functional capacity, suggestive of mild and subclinical cardiovascular 
involvement. Furthermore, dSSc patients showed worse values of global longitudinal 
and circumferential strains as compared to lSSc patients, confirming a more common 
and severe cardiac involvement in the diffuse form of the disease.5, 24 
Therefore, the use of more sensitive echocardiographic parameters may enable the 
detection of subtle LV systolic dysfunction before clinical manifestation, not identified 
by conventional approaches. Of note, both the present result and the studies from 
Mele and Kepez et al5,6 failed to show a significant difference in myocardial function 
by using tissue Doppler imaging derived S` velocity between SSc patients and controls. 
These findings therefore suggest that 2D speckle tracking derived strain analysis, which 
allows angle-independent and global LV functional assessment, is superior to tissue 
Doppler imaging derived S` velocity to detect subtle myocardial dysfunction in SSc 
patients. 
Although the mechanism underlying LV systolic dysfunction is unknown, previous studies 
have demonstrated the presence of significant myocardial fibrosis in SSc patients, 
using delayed gadolinium enhanced magnetic resonance imaging.25,26 These structural 
alterations, mainly caused by repeated focal ischemia due to abnormal vasoreactivity, 
may be responsible for myocardial dysfunction. Interestingly in the current study, multi-
directional strain analysis demonstrated significant impairment of longitudinal and 
circumferential strains (shortening), but not of radial strain (thickening). This finding 
may suggest that myocardial involvement of the subendocardial layer (responsible 
for longitudinal and circumferential shortening) occurs earlier as compared to the 
subepicardial layer (responsible for radial deformation), since the subendocardium 
is more susceptible to ischemia and fibrosis phenomena. Nevertheless, the exact 
mechanism of myocardial dysfunction requires further studies. 
Patients with SSc were shown to have reduced cardiopulmonary exercise capacity 
measured by VO2% predicted, which could be caused by multiple factors.
27-30 Previous 
studies have suggested that lung pathology is one of the main determinants of impaired 
functional capacity in these patients.28, 31 Similarly, the present study also showed the 
important role of lung function assessed by DLCO% predicted, which was independently 
associated with VO2% predicted.
31 In addition, a recent study by Walkey and colleagues 
has also suggested that exercise induced LV diastolic dysfunction, undetected by resting 
echocardiography, was a cause of impaired exercise capacity.29 However, the potential 
role of LV systolic dysfunction as an important contributing factor to functional capacity, 
has not been demonstrated before. Importantly, the present study demonstrated that 
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LV global longitudinal and circumferential strains were significantly related with VO2% 
predicted, independently of age, SSc subtype and lung function. This observation 
thus provided direct evidence that LV systolic dysfunction significantly contributes to 
impaired functional capacity in patients with SSc. Therefore, novel 2D speckle tracking 
strain analysis may be used in conjunction with lung function testing in order to provide 
a global assessment and monitoring of the cardiopulmonary status in SSc patients. 
Ventricular arrhythmias commonly occur in patients with SSc32 and, are responsible for 
up to 6% of the deaths, as demonstrated by a recent study.2 In particular, the presence 
of non-sustained ventricular tachycardias has been reported in 6-10% of patients with 
SSc and showed to be significantly associated with total mortality and sudden death.31,32 
In the current study, 24-hour ECG Holter monitoring was systematically performed in a 
large group of SSc patients and identified non-sustained ventricular tachycardias in 9% 
of the cases. Importantly at the multivariate analysis, LV systolic dysfunction, assessed 
by LV global longitudinal and circumferential strains, was the only independent 
predictor of ventricular arrhythmias (ventricular ectopics and non-sustained ventricular 
tachycardia). These results suggest that subtle LV systolic dysfunction is per se an 
important factor associated with ventricular arrhythmias and may also reflect the 
extent of myocardial fibrosis, which is a well-known arrhythmogenic substrate.25 These 
novel echocardiographic parameters therefore represent a valuable tool to improve risk 
stratification of SSc patients. The current study underscores the need for implementing 
speckle tracking strain analysis in larger systemic sclerosis cohort studies, investigating 
risk stratification and potential protective effects of anti-arrhythmic strategies.
The current study was a cross-sectional analysis and therefore a causal relationship 
between impaired 2D speckle tracking derived strain and impaired functional capacity 
and ventricular arrhythmias in SSc patients could not be established. Moreover, the 
current population included SSc patients with preserved functional capacity and low 
prevalence of pulmonary hypertension and the results of the present study can not 
be extrapolated to SSc patients with severe cardiopulmonary involvement. Lastly, 
microvascular and macrovascular ischemia were not fully documented, since all 
patients had no clinical evidence of myocardial ischemia (neither during CPET) and 
invasive evaluations and/or vasoreactivity tests were therefore not performed. Future 
studies are required to evaluate the impact of both microvascular or macrovascular 
ischemia on 2D speckle tracking derived multi-directional strain in SSc patients.
In conclusion, patients with SSc are associated with LV systolic dysfunction measured 
by 2D speckle tracking strain analysis. Importantly, LV global longitudinal and 
circumferential strains independently predicted impaired functional capacity measured 
by CPET and ventricular arrhythmias detected by 24-hour ECG Holter monitoring. The 
use of this novel imaging technique may therefore improve risk stratification and 
monitoring of the cardiovascular involvement in patients with SSc.
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Objective:	To compare sexual function in female patients with systemic sclerosis (SSc) 
with healthy controls and to determine the association between disease characteristics 
and sexual function.
Methods:	We conducted a cross-sectional study of 69 women with SSc (ages 18 to 60 
years) and 58 age-matched controls. Assessment included the Female Sexual Function 
Index (FSFI), Female Sexual Distress Scale (FSDS), Hospital Anxiety and Depression 
Scale (HADS), Short Form 36 health survey, socio-demographic characteristics, and in 
patients only, the Health Assessment Questionnaire (HAQ). 
Results:	Of 69 eligible SSc patients 37 (54%) responded, in addition to 37 (64%) of 
58 controls. The FSFI total score and the subscale scores for lubrication, orgasm, 
arousal and pain were significantly lower and FSDS scores were significantly higher in 
patients with SSc. Longer disease duration and higher levels of marital dissatisfaction 
were significantly related with low sexual function in patients with SSc. Longer disease 
duration, more depressive symptoms and the use of anti-depressants were significantly 
associated with sexual distress. Multivariate analyses indicated that marital distress 
was the only variable significantly associated with low sexual function in patients with 
SSc (β = 0.40, P< 0.5), whereas depression was the only variable significantly associated 
with sexual distress (β = 0.32, P< 0.05). The same pattern of associations was found in 
the healthy control group.
Conclusions:	Women with SSc reported significantly impaired sexual functioning and 
more sexual distress then healthy controls. Impaired sexual functioning and sexual 
distress were associated with marital distress and depressive symptoms. These results 
indicate that in daily practice, inquiring after sexuality and screening for depression is 
indicated in every patient with SSc, irrespective of their clinical characteristics. 
Introduction
Systemic sclerosis (SSc; scleroderma) is an autoimmune disease characterized by 
fibrosis of multiple organs. SSc was found to have a major impact on various aspects 
of life, including sexuality (1). In men with SSc, the prevalence of erectile dysfunction 
appears to be substantial (2). So far, the literature on sexual dysfunction in women with 
SSc is scarce. 
Bhadauria et al. (3) compared sexual function between 60 patients with SSc and 23 
women with rheumatoid arthritis (RA) or systemic lupus erythematosus matched for 
age and disease duration. It was found that women with SSc had a significantly lower 
number and intensity of orgasms and significantly more women with SSc reported 
skin tightness and heartburn, reflux or vomiting as symptoms causing problems during 
intercourse compared with control subjects. Sampaio-Barros et al (1) found that 
dyspareunie was mentioned by 49 (37%) of the 131 sexually active patients with SSc. 
All of these 49 patients reported vaginal dryness before, and worsening of symptoms 
after the onset of SSc. In a survey by Guerriere (4) 40% of 101 SSc patients reported 
to be sexually inactive, with only 7% attributing their sexual inactivity to SSc. None of 
these 3 studies had a study design with healthy controls. Moreover 2 of these studies 
did not use validated questionnaires to evaluate sexual complaints .
In both healthy subjects as well as patients with a chronic illness, including fibromyalgia, 
psychosocial factors such as relationship dissatisfaction and depression have been 
identified as determinants of impaired sexual function (5-8) . Recent studies confirm 
that the prevalence of depressive symptoms is high among patients with SSc, and 
a relation between depressive symptoms, disease severity and specific medical 
symptoms has been demonstrated (9,10).
Given the scarcity of data on sexual function among women with SSc, this study was 
designed to examine the type and extent of sexual problems in female SSc patients 
as compared to healthy women, and to determine associated variables of sexual 
function in this patient group. The aforementioned observations stress the need to 




The study had a cross-sectional, multicenter design. Approval for this study was 
obtained from the Institutional Review Boards of two hospitals and a primary health 
care center. All participants gave written informed consent. They were compensated 
with 10 Euros ($12.71 US dollars) after returning the questionnaires.




Women with SSc were recruited at two academic rheumatology outpatient clinics 
between January 2007 and January 2008. Inclusion criteria were: diagnosis of 
SSc according to the American College of Rheumatology (formerly the American 
Rheumatism Association) criteria (11) and aged 18-60. The selection of patients was 
done by their treating rheumatologist.
Information leaflets, explaining the aim and the methods of the study, were either 
sent to all eligible patients by mail or handed over in person to all eligible patients. 
Patients were contacted by the principle investigator (AAS) two weeks later, unless the 
patient had already indicated to decline participation. All patients willing to participate 
were then sent a set of questionnaires. If the patient was invited by the rheumatologist 
during a visit at the outpatient clinic, and the patient was interested to participate, the 
set of questionnaires was provided immediately.
Healthy controls
Participating patients with SSc who were asked to invite a healthy female friend or 
family member of similar age (age range ± years) to participate in this study. Because 
the number of questionnaires returned by healthy relatives or friends was relatively 
low, a general practitioner (CWVV) invited another 25 women visiting a primary health 
care center, who had no SSc or other rheumatic disease and were ages 18-60,to 
participate in the study. 
Assessment methods. 
Sexual function and sexual distress
Sexual function was measured by the Female Sexual Function Index (FSFI), a 19-item 
self-report questionnaire that assesses sexual functioning in women in 6 separate 
subscales (desire, arousal, lubrication, orgasm, satisfaction, pain) (4,12,13). In addition, 
a total score (range 2-36) can be computed. A higher subscale or total score indicates 
better sexual function. A cut-off score of < 26.55 is proposed as a criterion for a sexual 
dysfunction (14). The Dutch version of the FSFI has good psychometric properties 
differentiates well between women with sexual dysfunctions and healthy controls (15). 
Sexual distress was measured with the Female Sexual Distress Scale (FSDS), which 
quantifies the personal distress that any sexual complaints cause (14). Consensus-
based characterizations of female sexual dysfunction (FSD) have emphasized personal 
distress as an essential component of the definition of FSD. The total score ranges 
from 0-44, with higher scores representing more sexuality related personal distress. 
A cut off score of > 15 is proposed as a criterion for impaired sexual function (14). The 
Dutch version FSDS has good psychometric properties and is able to differentiate well 
between women with sexual dysfunctions and non-dysfunctional controls (15). 
Quality of life 
Quality of life was measured with the Short Form-36, which includes eight domain 
scores: physical functioning, role limitation due to physical problems, bodily pain, 
general health perception, vitality, social functioning, role limitation due to emotional 
problems, and mental health. The scores of the SF-36 subscales range from 0-100, with 
higher scores indicating better quality of life. The subscales can be converted into two 
summary scales: the physical and mental component summary scale, standardized to 
a score with a mean ±SD of 50 ±10 in the general population. For that purpose, we 
used the scores from an age- and sex-matched, normative sample, drawn from a large, 
random, nationwide sample of adults (n=1742) from the general Dutch population (16) 
and factor score coefficients (17). The psychometric properties of this questionnaire 
have been found to be adequate (16;18).
Mental status
Anxiety and depression were measured by means of a Dutch version of the Hospital 
Anxiety and Depression Scale (HADS), a 14-item questionnaire (19,20). It was 
developed to indicate the possible presence of anxiety and depressive states in the 
setting of a medical outpatient clinic and is considered to be unbiased by coexisting 
general medical conditions (20,21). It contains two 7-items scales: one for anxiety and 
one for depression. Higher scores represent higher levels of anxiety and/or depression 
symptoms (range 0–21 per scale). The questionnaire is validated for the Dutch language 
and has good psychometric properties (20). 
Disease characteristics and function
In patients with SSc, disease duration (years) and disease subset (limited or diffuse), 
were derived from the medical record. In addition, patients were asked to complete 
the Scleroderma Health Assessment Questionnaire (SHAQ), a 20-item questionnaire 
comprising 8 domains of activities of daily living with the final score ranging from 0 
(no disability) to 3 (severe disability). It additionally contains scleroderma symptom 
visual analog scales (VAS) for Raynaud’s disease, digital ulcers, intestinal symptoms, 
pulmonary symptoms, overall symptoms, and pain. All VAS were 100-mm horizontal 
lines, with the anchors on the left being no symptoms and no pain, whereas the anchors 
on. the right were the worst imaginable symptoms and severe pain (22). The SHAQ has 
been found to be a reliable outcome measure for disease severity in SSc (23).
Sociodemographic variables, menstrual status, marital satisfaction, abuse history, and 
medication usage. Sociodemographic variables included age, ethnic origin, status
of living (living with a partner yes/no), paid employment (yes/no), and educational level 
(primary education [0–8 years], secondary education [9–16 years], or higher vocational
education/university [17 years]). Patients were asked if they were still menstruating, 
and if not, for what reason (menopause, uterus extirpation, or hormonal therapy). 
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Sexual function may be influenced by drugs, such as antidepressants. Therefore, the 
questionnaire asked for information on current medication, which was afterward 
categorized by the principal investigator (AAS) using the following categories: 
analgesics, anti-inflammatory drugs, antidepressants, anxiolytics, and mood stabilizers.
Marital dissatisfaction was measured by means of the subscale of general relationship 
dissatisfaction of the Maudsley Marital Questionnaire, a 20-item instrument measuring 
dissatisfaction with the subject’s general relationship, sexual relationship, and life in 
general (24,25). Higher scores represent larger dissatisfaction. The questionnaire is 
validated for the Dutch language and has good psychometric properties (25).
To assess the prevalence of sexual and physical abuse during childhood and later 
years, the 7-item Sexual and Physical Abuse Questionnaire was used (26). Sexual abuse 
was restricted to sexual abuse with actual physical contact, and physical abuse was 
restricted to intentional violence resulting in some kind of physical injury.
Need for counseling. At the end of the questionnaires, participants were asked if they 
felt the need to talk to someone about sexual issues, and if so, who they would confide 




The calculation of the number of patients needed for this study was based on the 
difference between the FSFI total scores of patients with SSc and those of healthy 
controls. Assuming a FSFI total score of 30.5 in the healthy population and a difference 
of 5 points on the FSFI score to be clinically relevant, with alpha = 0.05 and beta =0.80, 
the number of patients (N) needed in each group to detect such a difference would be 
(N= 7.85 x (5.3)² x 2 / (4.5)² x 1). All results were reported according to the Strengthening 
the Reporting of Observational Studies in Epidemiology guidelines for cohort, case–
control, and cross-sectional studies (27). Data entry was performed using Microsoft 
Office Access 2003 (Microsoft, Redmond, WA). Statistical analyses were executed using 
SPSS software, version 16.0 (SPSS, Chicago, IL). 
P values (2-sided) less than 0.05 were considered statistically significant. Descriptive 
statistics were calculated for all variables. If appropriate, data sets were transformed to 
get a normal distribution. Univariate statistics were conducted in order to investigate 
whether patients with SSc differed on biographic, somatic, and psychological 
characteristics, sexual functioning, and sexual distress compared with healthy control 
subjects. In patients with SSc, the univariate association between sexual functioning 
and sexual distress with somatic and psychological characteristics was assessed 
with Pearson’s, Spearman’s, or point-biserial correlation coefficients as appropriate. 
Variables that were significantly correlated with sexual functioning or sexual distress 
were subsequently stepwise entered in a hierarchical multiple regression model. 
Results
We invited 69 patients to participate in this study (Figure 1). Of these, 24 patients 
declined participation by returning the answering form or during the telephone 
contact with the principle investigator, because of embarrassment (n=5), no sexual 
relationship (n = 5), not being interested (n = 5), or for other/no reasons (n = 9). Of 
the 45 patients who were willing to participate, 37 returned the questionnaires, 
yielding a final response rate of 37 (54%) of 69. Of these, 33 patients volunteered to 
invite a relative or friend, resulting in 30 questionnaires returned by healthy controls. 
In addition, 7 of the 25 healthy women recruited at the primary health care center 
returned the questionnaire, yielding a final response rate of 37 (64%) of 58 healthy 
women. In 2 patients and 3 controls the SF-36 could not be calculated because of 
missing values (>10%). The general relation dissatisfaction subscale of the Maudsley 
Marital Questionnaire was not filled out by 6 of 37 patients and 1 of 37 control subjects 
because they were not involved in a long-term relationship. All other questionnaires 
had <5% missing values. 
Differences	in	biographic,	somatic	and	psychological	characteristics	between	women	
with SSc and Controls
All SSc patients and healthy controls were Caucasian. There were no significant 
differences in characteristics between the patients and the healthy controls with respect 
to age, living status, education level, sexual or physical abuse history and menstrual 
status (Table 1). The mean age of SSc patients was 46 years and controls 43 years. A 
significantly smaller proportion of patients as compared to healthy controls had a paid 
profession. Moreover, the amount of working hours per week was significantly lower in 
those SSc patients having a paid profession than in healthy working women. There was 
no difference in the prevalence of sexual or physical abuse between SSc patients and 
controls. SSc patients did not differ from the healthy controls with respect to marital 
dissatisfaction. As for prescribed medication, significantly more SSc patients used anti-
inflammatory drugs and antihypertensives as compared to healthy controls. There 
was no difference in proportions of patients and healthy controls using analgesics, 
anti-depressants, anxiolytics, oral anti-conceptives or hormonal replacement therapy. 
None of the patients or healthy control used antihistamines. There were no significant 
differences in any of the variables between patients with limited and patients with 
diffuse SSc (results not shown).
The results of the quality of life questionnaires and measures of mental and physical 
function are shown in Table 2. The mean SF-36 physical component summary subscale 
score was significantly lower in the patients with SSc than in the healthy controls. More 
specifically, the SF-36 subscales of role limitation due to physical problems (P< 0.01), 














































Age, years; M (SD) 45.6 (9.5) 43.3 (8.0) -1.142 0.257
Living status; N (%)
    Partner (yes) N (%)
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    low
    Medium













Paid employment; N (%)



















Menopause (%) 10 (27.0) 6 (16.2) 0.131 0.397
Medication ♦ N (%)


























Limited SSc; N (%)
Diffuse SSc; N (%)
18 (51.4)
19 (48.6)
Disease duration; M (SD) 6.5 (8.8)
SSc = Systemic sclerosis; N= Number; M = mean; SD= Standard Deviation; MMQ= Maudsley 
Marital Questionnaire; ¶ Low: primary education (0-8 years), Medium: secondary education (9-
16 years), High: higher vocational education/ university (17 years or more) ♦ NSAID; Non-Steroid 
Anti-Inflammatory Drug, OAC: oral anti-conceptives, HRT hormonal replacement therapy; # 
according to the t-test for independent sample or Chi-Square test 
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0.88 (0.55) n.a.
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SSc= Systemic Sclerosis, N= Number; M = mean; SD= Standard Deviation, SF = Shortform-36, 
HADS= Hospital Anxiety and Depression Scale, HAQ= Health Assessment Questionnaire FSFI= 
Female Sexual Function Score FSDS=Female Sexual Distress Score, n.a. not applicable; #=p-value 
of Mann-Whitney U test
general health perceptions (P < 0.01), and vitality (P< 0.01) denoted impairments in 
quality of life in the patients with SSc as compared with healthy controls (data not 
shown). Patients with SSc had significantly higher HADS depression subscale scores 
than healthy controls. Except for significantly higher mean VAS scores for Raynaud’s 
phenomenon in the limited SSc group than in the diffuse SSc group, there were no 
statistically significant differences between the 2 types of SSc for any of the clinical 
variables (results not shown).
Differences	 in	 sexual	 function	 and	 sexual	 distress	 between	 women	 with	 SSc	 and	
controls. The FSFI total score and all subscale scores (except for the subscales desire 
and satisfaction) were significantly lower in the SSc group than in the healthy controls 
(Table 2). In addition, FSDS scores were significantly higher in patients with SSc than 
in the healthy controls. FSFI total scores, subscales, and FSDS scores did not differ 
between limited and diffuse patients with SSc (data not shown). With the application 
of the cut off score of 26.55, 26 (70%) of 37 patients would be considered to have an 
impaired sexual function, whereas with the FSDS cut off score of 15, 21 (57%) of 37 
patients would be considered to have increased sexual distress. According to these cut 
off values, 18 (47%) of the 37 patients would be considered to have sexual dysfunction 
(defined as both impaired sexual function plus high levels of sexual distress).
Univariate	predictors	of	 sexual	 functioning.	Among patients, marital dissatisfaction 
and disease duration were significantly associated with the FSFI total score, with 
participants with more marital dissatisfaction and longer disease duration showing 
more impaired sexual function (Table 3). The usage of antidepressants, more depressive 
symptoms, and longer disease duration were statistically significantly associated with 
more sexual distress. 
In the hierarchical multiple linear regression models, only marital distress (β=-0.40, 
t= 2.32, P< 0.05) was significantly associated with the FSFI total score and it explained 
16% of the variance in the FSFI total score. Disease duration did not account for a 
significantly additional proportion of variance in the FSFI total score (P > 0.90). For 
the dependent variable FSDS score, after controlling for the use of antidepressants (β= 
0.31, t = 1.97, P=0.057), depression (β= 0.32, t= 2.05, P< 0.05) was entered into the 
equation, explaining an additional proportion of 10% of the variance in sexual distress 
(F[1,33] =4.2, P< 0.05). Disease duration did not account for a significant additional 
proportion of variance in the FSDS score (P> 0.70).
Repetition of these analyses in the healthy women yielded a similar pattern: higher 
levels of marital distress were significantly associated with more sexual problems and 
higher levels of depressive symptoms were significantly associated with higher levels 
of sexual distress (data not shown).
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Need for counselling. Six (16%) of the SSc patients reported a need to talk to someone 
about current sexual problems, none of the patients mentioned their rheumatologist 
as a care provider in whom they would confide, only 1 mentioned their General 
Practitioner 
Discussion
In this cross-sectional study it was found that sexual function was significantly impaired 
and more sexual distress was reported in women with SSc as compared with healthy 
controls. None of the specific disease characteristics of SSc were found to be associated 
with sexual problems or sexual distress in patients with SSc. Marital dissatisfaction was 
significantly associated with impaired sexual function, whereas depression was the 
only clinical variable that was associated with sexual distress. 
Considering the large variety of SSc-related impairments and limitations that could 
affect sexual functioning, the lack of studies on this subject is remarkable. There are 
multiple effects of SSc on the skin and musculoskeletal systems that could have an 
impact on sexual functioning, including skin thickening resulting in decreased sensibility, 
decreased hand function, pain, and contractures; Raynaud’s phenomena; digital ulcers; 
and muscle atrophy (28,29). Vaginal dryness and decreased lubrication may lead to 
dyspareunia (3). Vaginal ulcers and skin inflammation can result in fibrotic narrowing 
of the introitus (30). Fatigue and chronic pain may also influence sexual activity, as 
was demonstrated in patients with RA and chronic noncancer pain due to other 
musculoskeletal illness (31,32). Moreover, the physical consequences of the disease 
may have a negative effect on self-esteem and/or lead to depression and anxiety, which 
have been found to significantly affect sexual functioning in women (33–35).
In our study, a significant impairment of sexual functioning in women with SSc as 
compared with healthy women was seen. Our findings are difficult to compare directly 
with the currently available studies on sexual function in women with SSc due to 
differences in study design and outcome measures. The FSFI was used in only 1 study 
in patients with SSc, and an impairment of the FSFI in all domains, including desire 
and satisfaction, was observed (4). However, because only an abstract is available, no 
further information on the extent of the reduction is available. Similar to the results of 
our study, lubrication and frequency and intensity of orgasms were also found to be 
impaired by Bhadauria et al (3), whereas pain was also identified as a problem in the 
study by Sampaio-Barrros et al (1). However, the degree to which these complaints 
occurred cannot be compared with our data, because in these studies self-provided 
questionnaires were used. Bhadauria et al (3) reported a decrease of desire for 
intercourse in 57% of 60 women with SSc, but participants were not asked about sexual 
behaviours other than intercourse. In contrast, in our study desire and satisfaction were 
not impaired. In none of these studies was a comparison with controls made.
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Sexually related personal distress, which is considered an important feature of sexual 
dysfunction (14), was never evaluated in SSc. In our study, an evident increase as 
compared with controls was seen. In a population-based sample of middle-aged 
Australian women (7), 34 (21%) of 166 participants with sexual problems showed 
increased distress. 
In a population-based sample of heterosexual American women ages 18–60 years, it 
was found that sexual problems were associated with distress about the relationship 
(36). Furthermore, sexual distress was related to both emotional well-being and 
the emotional relationship with the partner. These associations were partly also 
demonstrated by our data. Furthermore, no disease-specific variable was found to be 
associated with sexual functioning or sexual distress in our study. We can conclude 
that sexual functioning and sexual distress in women with SSc are more strongly 
associated with psychological characteristics and to a lesser degree with disease-
specific characteristics. Considering the cross-sectional design, the findings of our 
study have to be interpreted with caution, because the correlational nature of the 
findings regarding SSc, sexual functioning, depression, and marital distress precludes 
conclusions concerning the causality of relationships between these variables.
Patients with limited SSc reported as many problems with sexual function as patients 
with diffuse disease. This finding is in accordance with the outcomes of Guerriere et al 
(4), who found that FSFI scores were unrelated to disease classification. Moreover, in 
both that study and the present research, no relationship between disease severity and 
sexual function was found, whereas depressive symptoms were. This would imply that 
in daily clinical practice, attention should be paid to sexual functioning in all women 
with SSc, irrespective of the subtype and severity of the disease, and attention should 
be paid to possible depressive symptoms.
Health care professionals, however, tend to neglect patients sexual health; often 
they find it difficult to address sexual issues. In a study performed in a medical and 
nursing staff of a nephrology department, 86% of the professionals admitted not 
giving sufficient attention to and 92% admitted never initiating discussion about sexual 
issues with patients (37). In a questionnaire survey on views of multidisciplinary health 
professionals about discussing sexual issues with patients, most respondents (90%) 
agreed that addressing sexual issues ought to be part of the holistic care of patients 
(38). However, most staff (86%) was found to be poorly trained and most (94%) were 
unlikely to discuss sexual issues with their patients. This suggests that training in 
sexuality and sexual issues should be implemented as part of the training of health 
care professionals. In a study on the effects of RA on sexual activity, 37 patients (66%) 
had never been asked by any health professional about the impact of their disease 
on their sexuality, and 29 (59%) of 49 said they would not talk to someone if they 
had a problem (32). Our results showed that only 6 (16%) of the 37 patients with SSc 
felt the need to talk with someone about their sexual problems, and if they did want 
to talk to someone, they preferred someone who was not a health professional. The 
impact of illness on sexuality thus seems to be a problem that both patients and health 
professionals find hard to discuss.
Some patients with SSc may have found their own way of coping with sexual problems. 
Still, patients may benefit from treatment or guidance by their rheumatologist or 
rheumatology nurse. Saad and Behrendt stated that an open discussion with patients 
with SSc on their concerns about sexuality, promoting communication between 
partners and proper information, is essential in patient care (39).
Specific suggestions in order to enhance comfort during sexual activity are usage of 
lubricants, providing a warm environment, avoiding meals and elevating the bed prior 
to sexual activity, and re-evaluating medical therapy if needed. Although alleviation 
of problems thus can be achieved, a holistic approach to impaired sexual function 
in patients with SSc is highly recommended. Referral to a gynaecology department 
should be considered, because a thorough physical examination may provide essential 
information. 
This study had a number of limitations. First, selection bias in the group of patients as 
well as the controls cannot be excluded. We could not make a comparison of those 
who refused participation because we did not gather information on the characteristics 
of the patients who declined participation or did not respond. Moreover, despite the 
fact that the response rates were comparable with those in other studies on sexual 
functioning, the sample sizes of patients and healthy controls were relatively small. 
Second, it would have been helpful to know the exact reasons for sexual inactivity in 
patients and controls. Unfortunately, no information was obtained about the length 
of the relationships between the patients and their partners, so the influence of the 
length of the relationship on sexual function could thus not be evaluated. Finally, we 
failed to ask our participants whether a rheumatologist had ever inquired about sexual 
problems. This would have been illustrative in demonstrating how often the subject 
was raised in an outpatient clinic setting. Despite these limitations, this study may 
contribute to a better understanding of the impact of SSc on well-being, as it is the first 
study to our knowledge to compare sexual function in patients with SSc with that of 
healthy controls. Moreover, no study to date has used multiple validated measures to 
evaluate sexual function in SSc.
In conclusion, impaired sexual function and more sexual distress are found in patients 
with SSc compared with healthy controls. Although our patients are reticent about 
discussing sexual problems with their rheumatologist, the subject should not be 
avoided during consultation. Inquiry about sexuality and offering the opportunity to 
identify problems will improve the quality of patient care. Patients may benefit from 
referral to proper counselling once sexual problems are openly discussed.
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Sexual	 function	 in	women	with	 systemic	 sclerosis:	 Comment	 on	 the	
article	by	Schouffoer	et	al.
Arthritis Care Res (Hoboken). 2010 Aug;62(8):1200 
Knafo R, Jewett LR, Bassel M, Thombs BD.
In an article published recently in Arthritis Care & Research, Schouffoer et al reported 
that women with systemic sclerosis (SSc; scleroderma) have greater sexual impairment 
and distress than healthy controls, and the authors recommended that health care 
professionals inquire about sexuality with all SSc patients (1). Two previous studies 
reported similarly that women with SSc have greater sexual impairment than women 
in the general population (2) or compared with women with other medical diseases 
where sexual problems are more routinely addressed (3). The broad recommendation 
of Schouffoer et al for routine inquiry about sexual problems, however, appears to be 
premature. Only 16% of patients in the study by Schouffoer et al expressed a desire to 
discuss sexual problems, and none wished to do this with their rheumatologist.
While there is a great need to better address sexuality in SSc, it is important to 
demonstrate the patient benefits of routine inquiry before a specific recommendation 
is made. A call for routine inquiry about sexuality should only be made once we have 
provided a way of doing this that is agreeable to patients, feasibly implemented by 
physicians, and linked to an effective intervention and patient benefit (4). In order 
to develop and test an intervention, it is also important that we understand which 
disease and psychosocial characteristics may lead to sexual dysfunction. Schouffoer 
et al reported that “none of the specific disease characteristics of SSc were found to 
be associated with sexual problems” (1). Previous studies, however, have found that 
women with diffuse SSc have significantly greater impairment than those with limited 
SSc (3) and that women with SSc are more likely to experience dyspareunia, vaginal 
dryness, and vaginal ulcerations/fissures than women with other rheumatic diseases 
(5). The study by Schouffoer et al did not include an assessment of key SSc variables 
that may be related to impaired sexual function.
Furthermore, based on the study’s small sample size, there was only 32% power to 
detect a moderate difference in sexual impairment between limited and diffuse 
patients (e.g., _ _ 0.50). Studies are needed that investigate multiple predictors of 
sexual impairment, including both physical symptoms of SSc and psychological factors, 
with sufficient power to detect potential upstream factors. The study by Schouffoer 
and colleagues is a step in the right direction and contributes to the limited body of 
researchon sexual function in SSc. However, more research is needed before broad 
recommendations to routinely inquire quire about sexuality can be made. Before we 
ask health providers to reach beyond their level of comfort and training
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to address sexual issues, we need to provide them with a way to do it effectively. In 
the interim, patients may benefit from a referral to a specialist, as Schouffoer et al 
suggest, or from the provision of information (e.g., in the form of a pamphlet) about 
common SSc sexual issues, which may normalize the subject and facilitate discussion 
with a health professional (3).
1.  Schouffoer AA, van der Marel J, ter Kuile MM, Weijenborg PT, Voskuyl A, Vliet Vlieland CW, 
et al. Impaired sexual function in women with systemic sclerosis: a cross-sectional study. 
Arthritis Rheum 2009;61;1601–8.
2.  Impens AJ, Rothman J, Schiopu E, Cole JC, Dang J, Gendrano N, et al. Sexual activity and 
functioning in female scleroderma patients. Clin Exp Rheumatol 2009;27 Suppl 54:S38–43.
3.  Knafo R, Thombs BD, Jewett LR, Hudson M, Wigley F, Haythornthwaite J. (Not) talking about 
sex: a systematic comparison of sexual impairment in women with systemic sclerosis and 
other chronic disease samples. Rheumatology (Oxford) 2009;48:1300–3.
4.  Raffle AE, Gray JA. Screening: evidence and practice. Oxford (UK): Oxford University; 2007.
5.  Saad SC, Pietrzykowski JE, Lewis SS, Stepien AM, Latham VA, Messick S, et al. Vaginal 




We thank dr Knafo and colleagues for their commentary on our study, and the summary 
of recent publications that further illustrate the negative impact that Systemic Sclerosis 
may have on sexual function in female patients. Several specifically scleroderma-
related problems were recently identified by Impens (1) as contributing factors to 
sexual difficulties, with fatigue, bodily pain, vaginal dryness and discomfort being most 
frequently mentioned by 101 female systemic sclerosis patients. We agree with the 
recommendation that more research is needed in order to identify predictors of sexual 
impairment. Indeed, the lack of correlation between levels of sexual functioning and 
disease classification in our study may be due to the small sample size. However, in the 
larger study by Impens also no correlation was found. 
Considering the growing evidence as previously discussed, we feel that a health 
professional’s simple question ‘are problems in sexual functioning present?‘ will 
be acceptable for most patients. Moreover, considering the frequently mentioned 
scleroderma specific complaints (1) it is very likely that a considerable number of 
female patients may benefit from simple health interventions (vaginal lubricants; 
medication advice, relaxation techniques and energy conservation), either provided by 
their rheumatologist, or other consulted health professional. 
In other chronic impairment it has been recognized that dealing with sexual problems 
should be addressed in medical rehabilitation (2, 3), although reluctance of both patients 
as well as health professionals to discuss sexuality is known. The low percentage of 16% 
of our patients indicating a need to talk about possible sexual problems cannot not 
easily be explained, and demonstrates the need for further studies. First, the reported 
proportion pertains to the whole group we studied, and not to the subgroup of 
patients with sexual impairments. Moreover there is research illustrating that patients 
expect sexual issues to be brought up by the health professional and not by themselves 
(4). Although patient mere education by pamphlets (as advocated by Knafo et al) 
contributes to open communication, it also leaves the initiative with the patient with a 
risk of avoidance of the subject. We agree with Knafo and colleagues that an important 
condition for discussing matters of sexuality is a health professional that is comfortable 
with the subject. In a large British survey it was found that doctors discussed sexual 
issues significantly more often than other health professionals (N = 813) (5). The self 
rated sexological competence (rate 0-10, 10 being excellent) of 42 physicians in the 
Netherlands (6) was found to be less then sufficient before training (mean 5.8 (SD 1.1) 
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Background	 and	Objective: The Mouth Handicap in Systemic Sclerosis (MHISS) is a 
French-generic questionnaire evaluating mouth-opening restriction, dryness and 
aesthetic concerns. The aim of this study was to translate and adapt the MHISS 
questionnaire into the Dutch language and evaluate its psychometric properties. 
Methods: The MHISS was translated according to international guidelines, field-tested 
among 16 systemic sclerosis (SSc) patients and adapted. Subsequently, the Dutch 
MHISS was administered to 52 SSc-patients visiting the outpatient or daypatient 
clinic of a university hospital, and re-administered after 2 weeks. Internal consistency 
was tested by computing Cronbach’s alpha. Test-retest reliability was determined by 
computing the intraclass-correlation coefficient (ICC), and validity by determining 
associations with measures of overall functioning (Health Assessment Questionnaire; 
HAQ), maximum mouth opening (MMO; mm), subjective xerostomia (Visual Analog 
Scale; VAS) and objective xerostomia (Saxon test). 
Results: Patients had mean ± standard deviation (SD) age and disease duration of 55±21 
and 7.2±7.3 years. Twenty-seven (52%) patients had diffuse cutaneous SSc. The mean 
Dutch MHISS score was 17.5 (SD 10.0) with Cronbach’s alpha being 0.862. Dutch MHISS 
scores differed significantly between patients with high and low disability levels (HAQ, 
MMO, and subjective and objective xerostomia divided according to the median; paired 
t-test). Spearman Rank correlations with HAQ (r=0.599, p=0.000), MMO (r=-0.518, 
p=0.000) and subjective xerostomia (r=0.536, p=0.000) were moderate, correlation 
with objective xerostomia did not reach statistical significance. The ICC was 0.94.
Conclusion: The Dutch version of the MHISS demonstrated good psychometric 
properties and is useful in assessing mouth disability in SSc-patients.
 
Introduction
Scleroderma or systemic sclerosis (SSc) is an auto-immune disease with skin fibrosis, 
involvement of multiple organs and impaired physical and mental functioning (1).Two 
major subtypes are distinguished, limited and diffuse cutaneous SSc. The face and 
mouth are frequently affected, resulting in nasal ala atrophy, a beaked nose, diminished 
expression and a diminished mouth opening. This may impair articulation, food intake, 
oral hygiene and result into difficulties for dental treatment (2-4). Mouth dryness is 
frequently present (5-7) and may further compromise dental health. 
Adequate identification and evaluation of limitations in mouth functioning in SSc 
patients by means of a specific measurement instrument is mandatory, as symptoms 
can be alleviated by treatments such as artificial saliva, advices on diet and oral hygiene, 
mouth opening exercises or intensive dental care, thus improving patient care (8,9).
For this reason, Mouthon et al. presented the Mouth Handicap In Systemic Sclerosis 
(MHISS) questionnaire in 2007. The MHISS is a short, easy to fill out questionnaire 
evaluating the degree of mouth disability in patients with SSc according three domains: 
mouth opening restriction, mouth dryness and aesthetic concerns (10). The MHISS 
score explained up to 36.5% of the variance of the Health Assessment Questionnaire 
(HAQ) in a study including 71 SSc patients (8). The MHISS was developed in French, and 
validated in French and Italian (10;11).
Given the necessity to identify and evaluate mouth handicap in Dutch patients with 
SSc, the objective of this study was to translate and adapt the MHISS into a Dutch 
language version and evaluate its internal consistency, reliability and validity. 
Patients	and	methods
Study design
This study had a cross-sectional design. It was executed at the outpatient and day 
patient clinics of the Department of Rheumatology of the Leiden University Medical 
Center between April 2009 and June 2009. The assessments were done once, except 
for the MHISS which was administered twice with an interval of two weeks. Ethical 
approval was obtained from the Institutional Review Board of the Leiden University 
Medical Center.
Translation and adaptation of the MHISS
The MHISS (see Appendix) consists of 12 items, with the score representing the 
frequency of the presence of symptoms or complaints: 0 (never), 1 (rarely), 2 
(occasionally), 3 (often) and 4 (always). Three domains are characterized: (a) mouth 
opening; items 1,3,4,5 and 6; (b) mouth dryness; items 2,7,8,9 and 10; (c) aesthetic 
concerns; items 11 and 12. The total scale score ranges from 0 to 48, with higher scores 
indicating more mouth functional limitations. 
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The MHISS was translated and adapted according to the international guidelines for 
cross-cultural adaptation of health-related quality of life measures (12;13). First, two 
bilingual, native Dutch speaking translators of whom one was medically educated 
and one was a lay person translated the MHISS from French into Dutch. The two 
translations were compared and combined into one draft version in Dutch. Secondly, 
this draft Dutch version was translated in French by two native French speaking 
translators, again one medically educated, one a lay person. Thirdly, an expert panel 
consisting of a methodologist (TPMV) and two rheumatologists (AAS, AJS) evaluated 
the final version of the questionnaire regarding grammatical issues, cultural relevance 
and content validity for the Dutch population. According to the review of the expert 
panel, no significant modifications needed to be made. 
The final version was field-tested among 16 SSc patients from the outpatient clinic of 
the Leiden University Medical Center (mean age 51.8 years, SD 12.4; mean disease 
duration 7.9 years, SD 6.7; six patients (40%) had diffuse SSc). They were asked to record 
the time it took to fill out the questionnaire and to give a written comment to each item 
of the Dutch MHISS if they felt the question was inappropriate, difficult to answer or 
not fully understood. Respondents were also asked if they felt that any important issues 
had been omitted. Patients could clarify their comments in a telephone interview that 
followed within one week after handing out the questionnaire. The comments and 
suggestions were subsequently discussed with the developer (LM). 
The median time needed to fill in the questionnaire was 10 min (interquartile range 
2-30 min). No comment was made regarding lay-out. Two patients felt questions 7 and 
8 showed overlap, none of the questions were considered contradictive. The other 
comments in the field test resulted in two major changes in the Dutch MHISS:
(a) Three patients had dentures, two of them felt they were not able to answer 
items 4 and 5 concerning ‘dental health’ and requested an extra score option ‘not 
applicable”. Subsequently for items 4 and 5 apart from the options 0 (never), 1 
(rarely), 2 (occasionally), 3 (often) and 4 (always), the option not applicable because 
of dentures was added. In case of a ‘not applicable’ option, the median of the 
answers to items 1, 3 and 6 of that patient was imputed as the score for items 4 and 
5.
(b)  For items 4, 5, 6 and 11 concerning difficulties taking care of teeth, altered dentition, 
retracted lips/sunken cheeks and altered appearance, patients felt the score range 
‘never-always’ was inappropriate. They argued that the symptom is ‘either present 
or not’. In accordance with their comment, instead of ‘never-always’ a score range 
‘0 (totally disagree), 1 (disagree), 2 (no opinion), 3 (agree) and 4 (totally agree)’ was 
formulated. 
The resulting final version of the Dutch MHISS is shown in the Appendix.
Patients
For this study, consecutive patients attending the outpatient clinic or the day care unit of 
the Department of Rheumatology of the Leiden University Medical Center in the study 
period were invited by the investigators (AAS, ES, AJ) to take part in the study. None of 
the patients refused participation. Inclusion criteria were: diagnosis SSc according to 
the criteria as set by the American College of Rheumatology criteria (14) and/or Leroy & 
Medsger criteria (15), age older then 18 year and fluently speaking Dutch. The disease 
duration (years), presence of Raynaud’s phenomenon (years), disease subset (limited 
or diffuse SSc), organ involvement (cardiac, pulmonary, gastro-intestinal, renal) and 
presence of other auto-immune manifestations (primary biliary cirrhosis, thyroiditis) 
were derived from the medical record (table 1). The local medical ethics committee 
approved the protocol, and all patients gave written informed consent. 
Assessments
Apart from the Dutch MHISS, the following assessments were done:
(a) Objective xerostomia (mouth dryness)
For the measurement of saliva production, the Saxon test was used (16). Patients were 
asked to swallow before initiation of the test, and next chew on a dry gauze sponge 
(10x 10 cm) for two minutes without swallowing. After the two minutes the gauze 
placed in a tube, and the amount of produced saliva was determined by subtracting 
the original weight of the gauze and weight of the tube from the weight obtained after 
chewing. Objective xerostomia is considered present if the saliva production is less 
than 2.75 grams (16) 
(b) Objective xerophthalmia 
Xerophthalmia was measured by the Schirmer’s test: Two small pieces of sterile filter 
papers were inserted into the lateral third in each lower eyelid, for a maximum of 
5 minutes. Patients were asked to close the eyes. Wetting of less than 5 mm in five 
minutes of both eyes was considered abnormal (17).
(c) Subjective xerophthalmia and xerostomia
Two VAS scores consisted of a 100 mm horizontal line, ranging from 0 on the left anchor 
being no symptoms, to 100 on the right anchor with the worst imaginable symptoms.
(d) Maximal mouth opening
For the maximal mouth opening the inter-incisor distance was measured in millimeter 
with a digital caliper (18). In case the mouth restriction was determined by the lips, the 




Age (year); mean (SD) 55 (21)
Female ; % 41 (79)
Smoking; % 4 (8)
HAQ (range 0-3); mean (SD) 0.83 (0.68)
ESR (mm); mean (SD) 21 (21)
Diffuse subtype SSc (%) 27 (52)
Disease duration, (year) median (25th-75thpercentile) 5 (2-10) 
Raynaud phenomenon present (%) 48 (92)
Digital ulcers present (%) 33 (64)
Maximal Mouth Opening (mm), mean (SD) 38.7 (10.1)
Autoantibodies (%) 
   anti-centromere 
   anti-Scl70
   anti-SSA






   subjective (VAS 0-100 mm); median (25th-75thpercentile)




   subjective (VAS 0-100 mm); median (25th-75thpercentile)
   objective; saxon test (gram)b ; mean (SD)
19 (0-58)
9 (17%) 
Organ involvement (%) 
   heart involvement 
   interstitial lung disease 
   gastrointestinal involvement 
   renal crisis 






Other autoimmune manifestations (%)
   primary biliary cirrhosis 
   anti-mitochondrial antibodies
   anti-smooth muscle antibodies
   thyroiditis
   anti-TPO antibodies







HAQ Health Assessment Questionnaire; ESR =Erythrocyte Sedimentation Rate; a Insufficient tear 
production if both eyes <5mm; b insufficient if saliva production <2.75 gram.
maximal mouth opening was measured as the distance between the nearest points of 
the two vermillion borders in the sagittal plane. 
(e) Overall physical functioning
To assess the overall level of physical functioning, the Systemic Sclerosis Health 
Assessment Questionnaire (SSc-HAQ) was filled in, a 20-item questionnaire comprising 
eight domains of activities of daily living with the final score ranging from 0 (no 
disability) to 3 (severe disability) and five scleroderma-symptom visual analogue scales 
(VAS); Raynaud’s disease, digital ulcers, intestinal complaints, pulmonary complaints, 
overall complaints, and pain. The SSc HAQ was found to be a reliable outcome measure 
for disease severity in SSc (19). 
Statistical	analysis
Statistical analyses were executed using SPSS 16.0 software. All continuous variables 
were expressed as means and standard deviations, or as medians and Inter Quartile 
Ranges (IQR), according to their distributions. Missing data for demographic and 
disease characteristics were not listed, unless more then 5% present. 
Internal consistency
The internal consistency of the Dutch MHISS (the extent to which the different items 
are correlated) was determined by calculating Cronbach’s alpha for both the total scale 
and two subscales (not for aesthetic concerns as this subscale has only 2 items). The 
internal consistency is considered to be good when Cronbach’s alpha is between 0.70 
and 0.95 (20). 
Construct validity
Two aspects of construct validity were used: discriminative or divergent validity (to be 
able to distinguish between ‘known groups’ with expected differences in scores) and 
convergent validity (how strongly a measure correlates with other related measures). 
To test the discriminative validity we hypothesized that patients with more global 
disability, smaller maximal mouth opening, more subjective as well as objective 
xerostomia would have higher MHISS scores. We dichotomized measures of global as 
well as mouth disability in two groups according (a) below and above median value 
(HAQ score, maximal mouth opening and subjective xerostomia (VAS score) scores) 
and (b) below and above 2.75 gram (objective xerostomia; considered cut-off score for 
normal saliva production). The Dutch MHISS scores were compared between the two 
groups using the independent Student t-test. 
To test the convergent validity, Spearman rank correlation coefficients were used to 
assess the correlation between the Dutch MHISS and measures of mouth symptoms 
or overall disability. We hypothesized that the Dutch MHISS score would be increased 
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in patients with more subjective xerostomia, more limitation of the mouth opening 
(decreased maximal mouth opening), more objective xerostomia (decreased saliva 
production) or more overall disability (increased HAQ). Spearman’s correlation was 
interpreted as excellent (>0.91), good (0.90–0.71), moderate (0.70–0.51), fair (0.50–
0.31), or little or absent (<0.30) (21).
Test-retest reliability 
Intra-class correlation coefficients (ICC) were computed between the scores of the 




The disease characteristics of the 52 participants are shown in Table 1. All participants 
returned both the Dutch MHISS questionnaires. There were no missing data in either 
the first or second returned MHISS questionnaires. The mean as well as median Dutch 
MHISS score was 17.5 (SD 10.0, range 0-41, two patients with score 0, one patient with 
score 41). With item 4 and/or 5, eleven patients reported having dentures. The Dutch 
MHISS scores were not significantly different between patients with diffuse or limited 
SSc (mean 17.2 versus 17.8, p=0.842). 
Internal consistency
The internal consistency of the Dutch MHISS total as well as different survey items was 
found to be adequate (20). Cronbach’s alpha was 0.88 for the total MHISS score, 0.86 
for the factor ‘mouth opening (items 1, 3, 4, 5 and 6), and 0.79 for the factor mouth 
dryness (items 7, 8, 9 and 10). 
Construct validity 
With respect to divergent validity, a significantly higher mean Dutch MHISS score 
was seen in patients with more global disability, more subjective xerostomia, more 
limitation of the mouth opening and more objective xerostomia (Table 2). 
Table	2:	Dutch	MHISS	scores	(SD)	compared	between	patients	with	low	and	high1 HAQ, maximal 
mouth	opening,	subjective	and	objective	xerostomia	scores
MHISS
Low group High group P valuea
Health Assessment Questionnaire (HAQ) 11.2 (7.6) 22.8 (8.5) 0.000
Maximal mouth opening (MMO) 21.5 (9.6) 13.5 (9.4) 0.004
Subjective xerostomiab 11.4 (7.4) 22.9 (9.0) 0.000
Objective xerostomiac 26.9 (9.2) 15.4 (9.8) 0.002
For HAQ, MMO, subjective xerostomia two groups defined as ≤ median and >median, for 
objective xerostomia low and high groups defined as ≤ 2.75 gram and >2.75 gram; a independent 
sample t-test; b Visual analogue scale for mouth dryness in the past 3 months; c Saxon test.
Regarding convergent validity, moderate to good correlations were seen between the 
Dutch MHISS and maximal mouth opening, subjective xerostomia and the HAQ score, 




Health Assessment Questionnaire (HAQ) 0.599 p=0.000
Maximal mouth opening (MMO) -0.518 p=0.000
Subjective xerostomiaa 0.536 p=0.000
Objective xerostomiab -0.200 p=0.177
a Visual analogue scale for mouth dryness in the past 3 months; b Saxon test.
Test-retest reliability 
Fourty-nine patients filled in a second Dutch MHISS after two weeks. The mean MHISS 
score of the second measurement was 16.5 (SD 10.0), (p-value 0.229 as compared 
to the first measurement, paired t-test). The ICC was 0.94 (p=0.000), demonstrating 
excellent reliability (20). 
Discussion
This study aimed to translate, adapt and validate the MHISS into the Dutch language. 
The properties of the Dutch MHISS regarding internal consistency, construct validity 
and test-retest reliability were found to be good, and comparable with the original 
version. 
In order to warrant equivalence of measurement in the Dutch language, international 
guidelines for cross cultural adaptation of health related measures were used. In this 
process small adaptations to the original French version were made, including adding 
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a response option ‘not applicable’ for the questions regarding dental hygiene. The 
fact that none of the patients in the original study (10) reported having dentures is 
remarkable. In the Netherlands, 27% of the persons (55-74 year of age) reported having 
dentures (22). The number of patients with dentures in our cohort (11/52) seems 
comparable with this proportion. In our study, it remained unknown if the presence of 
a denture was caused by SSc or other reasons. 
The mean Dutch MHISS total score in our patient group was comparable with the score 
of the original MHISS study (18.8 (SD 10.2) versus 20.3 (SD 9.7), despite differences in 
the patient characteristics: patients in the present study had a shorter disease duration 
(7.2 (SD 7.3) versus 13.7 (12.3) years), demonstrated less limitations in daily activities 
as measured by the HAQ (0.83 (SD 0.68) versus 1.20 (SD 0.68), but had a comparable 
maximal mouth opening as compared to the original study. In other studies similar 
values of the MHISS were found (10;23). 
The test-retest reliability of the Dutch MHISS was excellent and comparable with 
the measurement properties described for the original MHISS (10) . The internal 
consistency for the total score as well as two of the three factors (‘mouth handicap’ 
and ‘sicca’) were good, and confirm the results of the previous factor analysis.
In our study a good discriminative validity was demonstrated as the Dutch MHISS was 
significantly increased in patients with more global disability (HAQ), more subjective 
xerostomia, more limitation of the mouth opening and more objective xerostomia. 
Analysis of convergent validity resulted in remarkably better correlation in the total 
Dutch MHISS score with measures of overall physical functioning and maximal mouth 
opening compared with the original MHISS. 
A limitation of this study is the fact that the Dutch-MHISS was not compared with 
other measures of disability (physical or mental function) as was previously done 
(11). However, considering the good correlations of the Dutch MHISS with other 
relevant disability outcomes, good construct validity was demonstrated. The patients 
participating in this study were treated in a tertiary care hospital, whereas in the 
validation study by Mouthon all patients were assessed during the annual meeting 
of the French SSc patients association. Interestingly, it has recently been reported 
that association patients had significantly increased disability of the mouth (MHISS 
20.65 ± 10.8 vs 13.25 ± 9.3; p=0.0001) and impaired hand and wrist mobility (Kapandji 
score 38.05 ± 10.26 vs 43.90 ± 8.26, p=0.001) as compared with hospitalized patients 
(24) Therefore, a selection bias cannot be excluded. For a proper judgment of the 
applicability of the questionnaire, a validation in a more general population of SSc 
patients with possibly less disease severity is desirable. A remarkable finding in our 
study was the relatively low mean value of the mean VAS xerophthalmia as compared 
with the 19% of patients with abnormal Schirmer testing. An explanation for the 
asymptomatic presence of xerophthalmia is not easily found. It may however underline 
the need for an objective measure for xerophthalmia. 
In conclusion, we have successfully translated and adapted the MHISS into the Dutch 
language, with the final Dutch version demonstrating good psychometric properties. 
Research on the validity in other SSc populations as well as the responsiveness of the 
questionnaire in treatment settings is warranted. 
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English MHISS scale (10)
0 1 2 3 4
1 I have difficulties opening my mouth 0 1 2 3 4
2 I have to avoid certain drinks (sparkling, alcohol, acidic) 0 1 2 3 4
3 I have difficulties chewing 0 1 2 3 4
4 My dentist has difficulties taking care of my teeth 0 1 2 3 4
5 My dentition has become altered 0 1 2 3 4
6 My lips are retracted and/or my cheeks are sunken 0 1 2 3 4
7 My mouth is dry 0 1 2 3 4
8 I must drink often 0 1 2 3 4
9 My meals consist of what I can eat and not what I would like to eat 0 1 2 3 4
10 I have difficulties speaking clearly 0 1 2 3 4
11 The appearance of my face is modified 0 1 2 3 4
12 I have trouble with he way my face looks 0 1 2 3 4
0=never; 1=rarely; 2=occasionally; 3=often; 4=always.
French generic MHISS scale supplied by L.Mouthon 
0 1 2 3 4
1 Je suis géné(e) pour ouvrir la bouche 0 1 2 3 4
2 Je dois éviter certaines boissons (gazeuses, alcoolisées, acides) 0 1 2 3 4
3 J’ai des difficultés à mastiquer 0 1 2 3 4
4 Mon dentiste a des difficultés à effectuer les soins 0 1 2 3 4
5 L’état de mes dents s’est dégradé 0 1 2 3 4
6 Mes lèvres et/ou mes joues sont rétractées 0 1 2 3 4
7 Ma bouche est sèche 0 1 2 3 4
8 Je dois boire souvent 0 1 2 3 4
9
Je suis obligé(e) de choisir mon alimentation en fonction de ce 
que je peux manger et non en fonction de ce que j’ai envie de 
manger
0 1 2 3 4
10 Je suis géné(e) pour articuler les mots 0 1 2 3 4
11 L’apparence de mon visage s’est modifiée 0 1 2 3 4
12 J’ai une gène esthétique 0 1 2 3 4
0= Jamais ; 1=Rarement ; 2=Régulièrement ; 3=Souvent ; 4= Toujours
Dutch MHISS scale 
1 Ik vind het lastig om mijn mond te openen 0 1 2 3 4
2
Ik moet bepaalde dranken vermijden (bruisende, 
alcoholische en/of zure dranken)
0 1 2 3 4
3 Ik heb moeite met kauwbewegingen 0 1 2 3 4  
7 Ik heb een droge mond 0 1 2 3 4
8 Ik moet vaak drinken 0 1 2 3 4
9
Ik moet mijn voedsel kiezen op grond van wat ik kan eten, 
en niet op grond van waar ik zin in heb
0 1 2 3 4
10
Ik vind het lastig om te articuleren (woorden duidelijk uit 
te spreken)
0 1 2 3 4
12 Ik voel mij niet prettig met mijn uiterlijk 0 1 2 3 4  
4 Mijn tandarts heeft moeite om mijn gebit te behandelen 0* 1* 2* 3* 4*  NA
5 De toestand van mijn gebit is verslechterd 0* 1* 2* 3* 4*  NA
6 Mijn lippen en/of mijn wangen zijn strak getrokken 0* 1* 2* 3* 4*  
11 Het uiterlijk van mijn gezicht en mond is veranderd 0* 1* 2* 3* 4*  
0= Nooit ; 1= Zelden ; 2= Regelmatig ; 3= Vaak ; 4= Altijd; 5=gebitsprothese; 0*= helemaal oneens; 
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To assess the validity and responsiveness of the Michigan Hand Questionnaire (MHQ) 
in patients with Systemic Sclerosis (SSc).
Methods
Data were gathered in connection with a randomized, controlled trial comparing 
the effectiveness of a 12-week multidisciplinary team-care programme, including 
a handfunction treatment module, with regular care. All fifty-three patients (28 
intervention group and 25 control group) completed the MHQ (including 6 domains: 
function, activities of daily living, pain, work, aesthetics, and satisfaction) at baseline and 
after 12 weeks. Other measures included the HAQ (Health Assessment Questionnaire), 
Hand Mobility in Scleroderma (HAMIS), Sequential Occupational Dexterity Assessment 
(SODA), grip strength, pinch grip and Modified Rodnan Skin Score (MRSS). Validity was 
determined by computing Spearman correlation coefficients between the baseline 
MHQ total score and subscales and other measures of (hand)disability. Responsiveness 
in the intervention group was evaluated by the standardized response mean (SRM), 
effect size (ES), and responsiveness ratio (RR). In addition, pooled ES for the difference 
between the two groups were computed. 
Results
Significant correlations were seen between the MHQ total score and the HAQ (r=-0.62), 
HAMIS (r=-0.54), SODA (r=0.47), SODA Pain (r=0.32) and MRSS (r=0.46). The ES of the 
MHQ total score within the intervention group was 0.49, which was larger than those 
of all other outcome measures. Similar results were obtained for the SRM and RR. The 
pooled ES of the difference between intervention and control groups for the MHQ total 
score was 0.86. 
Conclusion
The MHQ demonstrated adequate validity and responsiveness in patients with SSc. 
Introduction	
Systemic sclerosis (scleroderma, SSc) is a chronic multi-system disease that may result 
in significant disability and impaired health related quality of life (1;2). In patients with 
SSc hand function is often impaired (3). Increased skin thickness, impaired range of 
motion in flexion and extension, digital ulcers, arthritis, loss of strength and Raynaud’s 
phenomenon may contribute to limitations in activities involving the hands. In addition 
to function, the altered appearance of the hands is an important feature in SSc, as a 
result of fibrosis, contractures, vascular complications and teleangieectasia. 
Given the significance of hand function disability in SSc, outcome measures with good 
clinimetric properties are needed to assess disease evolution and treatment efficacy 
in this patient group. Hand function in SSc patients can been evaluated by means of 
generic questionnaires including the Cochin Hand Function Scale (CHFS) (4),) as well 
as performance tests as the Hand Function in Systemic Sclerosis (HAMIS) (5), Hand 
Anatomic Index (HAI) (6;7), the delta finger-to-palm (FTP)(8), Kapandji indexes (9;10) 
and pinch grip and grip strength (11). Some of these were evaluated with respect to 
responsiveness over time (12), and others concerning their ability to detect treatment 
effect in patients with SSc(11;13;14). 
All of the abovementioned hand function instruments used in SSc do however not 
capture important aspects of hand function in SSc such as aesthetics, satisfaction with 
hand function and pain. Moreover, performance tests may be less suitable in routine 
care due to the required training and equipment for their use. The Michigan Hand 
outcomes Questionnaire (MHQ) is a self-reported, self-administered questionnaire 
that contains 37 items and requires approximately 15 minutes completing. It yields 
an overall summary score of hand function, as well as scores for 6 specific scales: 
hand function, ability to complete activities of daily living, pain, work performance, 
aesthetics, and patient satisfaction. The MHQ (15) was listed in a provisional core set 
of measures for assessment of disease activity and severity in clinical trials of SSc (16). 
It has however never been used for this purpose, since its validation in SSc patients 
has not completely been investigated yet (17). In contrast, in rheumatoid arthritis the 
clinimetric properties of the MHQ have been extensively documented (18).
Our aim was therefore to examine the validity of the MHQ in patients with SSc and its 
responsiveness to change.
Patients	and	methods
Study design and participants
The subjects were participants in a randomized controlled clinical trial comparing a 12-
week multidisciplinary team care programme with regular outpatient care. This study 
was conducted at the Leiden University Medical Center (19). Inclusion criteria were: 
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SSc according to Leroy’s criteria (20), age 18-75 year, being able to cycle on a bicycle 
ergo meter, stable anti-inflammatory medication over the past 2 months, and fluency 
in Dutch. Exclusion criteria were: cardio-pulmonary screening resulting in contra-
indications for physical exercises, engagement in another exercise therapy program 
and concomitant diseases interfering with ADL activities. Fifty-three patients were 
included; twenty-eight patients were randomly assigned to the intervention group and 
twenty-five to the control group. Measurements took place at baseline, after 12 weeks 
and 24 weeks. For the present study only the baseline and 12-week data were used.
Intervention and control condition
The multidisciplinary team care programme is described in detail in a previous 
publication. In brief, it consisted of standardized group sessions provided once per 
week in a day patient care setting. The group sessions included general exercises, hand/
mouth exercises and educational sessions. In addition, depending on the patients’ 
individual needs, individual treatments by the rheumatologist and health professionals 
were scheduled. Apart from the weekly treatment in the clinic, patients were required 
to participate in individual supervised exercises provided by a physical therapist near 
their own home in a private practice once a week and to perform a home-based 
exercise programme on at least 6 days per week. 
The hand exercises were to be performed daily, with each session lasting 10 minutes. 
During an exercise session the following angular motions were performed: opposition 
and reposition of the thumb, flexion and extension of the fingers, abduction an 
adduction of the fingers and making a fist. Active exercises were performed using the 
patient’s own muscle strength to stretch limited tissues, for example making a fist 
aiming to elongate dorsal skin on the fingers. In the passive exercises external forces 
were used to elongate limited tissues, for example, to stretch the fingers in extension 
the other hand was used to press the open hand on a flat surface like a table. In each 
session every muscle group that was related to limited motion was stretched for 10 
seconds in 3 repetitions. Exercise materials, like squeeze balls, were used according 
to the patient’s preferences and needs. The intensity of the stretching was monitored 
by recording discomfort and pain directly after the treatment session. If needed, the 
intensity was adjusted so that the discomfort or pain was at the patient’s normal level 
within 15 minutes after performing the exercises. To increase exercise compliance 
patients were instructed to monitor their own progress in hand range of motion. For 
this purpose callipers were provided to measure the distance between the fingertip 
and the proximal skin crease in the palm of the hand, as a measure of finger flexion. 
These measurements were recorded during the supervised sessions by the patient in a 
hand exercise diary, which also contained the exercise instructions. 




Data were gathered by means of review of the medical records, questionnaires, 
physical examinations and additional examinations consisting of laboratory tests. All 
clinical assessments were done by AAS.
Disease characteristics 
Disease characteristics were derived from the medical record and included: disease 
subset (limited or diffuse) the number of years since onset of Raynaud’s, the Modified 
Rodnan Skin Score (MRSS), auto-antibody profile , erythrocyte sedimentation rate 
(mm/hr) , C-reactive protein (mg/l), presence of interstitial lung disease or cardiac 
involvement (yes/no) 
General physical functioning 
The SSc-Health Assessment Questionnaire (SSc-HAQ) is a 20-item questionnaire 
comprising eight domains of activities of daily living, with the final score ranging from 
0 (no disability) to 3 (severe disability) and five visual analogue scales (21), Raynaud’s 
disease, digital ulcers, intestinal complaints, pulmonary complaints, overall complaints, 
and pain. The SSc-HAQ score was calculated using the aids/devices. It has been found 
to be a reliable outcome measure for disease severity in SSc (22). In addition, a Dutch 
HAQ-translation demonstrated good psychometric properties (23). The SSc-HAQ 
(8;24;25) is most frequently used to assess general disability. Hand disability has been 
shown to contribute to 75% of the HAQ variance in patients with SSc (10).
Measures of hand function
The Michigan Hand outcome Questionnaire(MHQ) . The MHQ is a 57-item questionnaire 
covering 6 domains: (1) overall hand function, (2) activities of daily living, (3) pain, (4) 
work performance, (5) aesthetics, and (6) patients’ satisfaction with hand function. 
Pain, work performance, aesthetics and satisfaction are scored for the right and left 
hands separately. The scoring method is described by the original authors of the MHQ 
(15). Each item is scored on a 1 to 5 scale, for each domain the sum of the responses of 
each item is converted into a scale ranging from 0 to 100. If both hands are affected the 
left and right-hand scale scores are averaged to get the score. A higher score indicates 
a better hand function, except for the pain domain where a higher score means more 
pain. The total score (the average of all domains) ranges from 0 to 100, with a higher 
score indicating a better hand function.
The Hand Mobility in Scleroderma (HAMIS) test. The HAMIS test consists of 9 items 
graded on a scale of 0-3, the final score ranges from 0 (normal function) to 27 (severe 
immobility). Each hand is assessed separately. Good clinometric properties were 
demonstrated (5;26).
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Sequential Occupational Dexterity Assessment (SODA). The SODA is a performance 
measure of dexterity (27). With the SODA, patients performs 12 standardized tasks (6 
bimanual and 6 one-handed) representing all major grips such as pinch grip, cylindrical 
grip, and writing grip. The assessor scores whether it is possible to perform the task in 
the standardized way, the effort that the activity takes, and the pain patients experiences 
when performing the task. The combination of the possibility to perform the tasks and 
the effort and pain scores forms the SODA score, ranging from 0 to 108, with a higher 
number meaning better hand function. The pain patients experience when performing 
the tasks forms the SODA pain score, ranging from 0 to 12, with a higher score indicating 
more pain. The SODA proved to be reliable, valid, and responsive to clinical changes in 
patients with RA (27). 
Grip-strength and Pinch grip (kg) The grip strength and pinch grip were measured with 
a Jamar dynamometer (R. Harkonen, j hand ther, 1993). After testing twice, the highest 
score of both hands was registered. For this study the right hand scores were used. 
Subjective opinion about change of hand function. At the follow-up assessment patients 
were asked to rate the changes in hand function by means of a 5-point Likert-scale (1, 
much worsened; 2, worsened; 3, not changed; 4, improved; 5, much improved).
Statistical	analysis
Data are presented as mean values with standard deviation. In case of skewed 
distribution a median and interquartile range were used. 
The internal consistency of the MHQ pertains to the extent to which the different 
subscales and subscale items are correlated. It was determined by calculating 
Cronbach’s alpha. The internal consistency is considered to be good when Cronbach’s 
alpha is between 0.70 and 0.95 (28). Pearson’s correlation coefficients of each subscale 
against the other subscales within the MHQ were determined to establish if the 
subscales behave in an expected manner.
To test the convergent validity, Spearman rank correlation coefficients were used to 
assess the correlation between the MHQ total score and subscale scores on the one 
side and other measures of (hand) disability on the other side. We hypothesized that 
the MHQ score would be worse in patients with more overall functional disability 
(HAQ), a worse hand function as measured with the HAMIS, grip strength and pinch 
grip strength and SODA, and more severe skin involvement. Correlation coefficients 
were interpreted as small (0.10-0.29), medium (0.30-0.49) or large (0.50-1.0).
To determine the responsiveness to changes over time, in both the intervention and 
control groups for all clinical measures mean change scores were calculated (baseline 
minus follow-up) with the 95% confidence intervals (CIs). Responsiveness within the 
intervention group was evaluated by means of various methods (29;30) the standardized 
response mean (SRM) pre-treatment mean – post treatment mean divided by the SD 
of the change score), the effect size (ES) (pre-treatment mean – post treatment mean 
divided by the SD of the pre-treatment mean) (31), and Guyatt’s responsiveness ratio 
(the mean change score of the improved patients divided by the SD of the baseline 
score in stable patients) (29). For the responsiveness ratio, patients were divided into 
improved, stable, or deteriorated according to their subjective opinions of changes in 
hand function on a Likert scale. For this purpose, the scores were recoded as follows: 
1 and 2 equals deteriorated, 3 equals stable and 4 and 5 equals improved. A negative 
value of the SRM, effect size, or responsiveness ratio indicates that the mean baseline 
score was smaller than the mean follow-up score. Values of .20, .50, and .80 or higher 
were considered to represent small, moderate, and large responsiveness for all 3 
measures of responsiveness, respectively (30) however, for the responsiveness ratio a 
cut off point of 1.96 for sufficient responsiveness has also been reported (28). For the 
SRM, values of 0.2 to 0.3 could be found in evaluating the effect of a placebo, values 
of 0.3 to 0.5 in assessing the effect of a moderately active drug, and large values of 1.0 
or greater in evaluating the effects of surgical procedures (32). The treatment effect of 
the MHQ was calculated with a pooled ES; the difference of the mean change score of 
the intervention group and the control group, divided by the pooled SD of the change 
scores of the two groups (33) .
Results
The characteristics of the patients are described in Table 1. Of the 53 patients included, 
28 patients were allocated to the intervention group, of which 25 completed the 
multidisciplinary team care programme and the assessment at 12 weeks. Twenty five 
patients were allocated to the control group, of whom 24 were assessed at 12 weeks.
Table 2 shows the baseline MHQ subscale and total scores in the total group. The MHQ 
demonstrated good internal consistency with high Cronbach’s alpha scores ranging 
from 0.720 in the aesthetic subscale for the right hand to 0.922 in the work subscale. 
Cronbach’s alpha score for the MHQ total score was 0.860. In the subscale pain a ‘floor 
effect’ was observed with a minimal score of 0 in 16 percent of the patients (34).  
Table 3 demonstrates the correlation coefficients of each scale against the other scales 
in the MHQ. Most of the correlations were found to be moderate to large, except for 
the aesthetic subscale, indicating that this subscale measures something different from 
the other subscales. 
In Table 4 the correlations between the baseline MHQ subscale and total scores and 
other measures of (hand) function are shown. Overall, the correlations between the 
MHQ scores for the subscales overall hand function, activities of daily living, work 
performance and satisfaction and the MHQ total score on the one side and the HAQ, 
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Sex, Female No. (%) 40 (76) 19 (68) 21 (84)
Age, years, mean (SD) 52.9 (10.7) 53.9 (10.8) 51.7 (10.8)
Right handed, no (%) 47 (89) 26 (96) 21 (88)
Disease subset: diffuse SSc, no (%) 30 (57) 15 (54) 15 (60)
Time since onset Raynaud phenomenon, 
years, median (IQR) 
9.2 (11.8) 8.6 (12.7) 10.2 (12.8)
MRSS‡ (0-51), median (IQR) 3 (6) 4 (7) 3 (5)
Auto-antibodies (% positive)




















Health Assessment Questionnaire, mean 
(SD)
0.77 (0.57) 0.81 (0.66) 0.73 (0.46)
VAS Raynaud’s phenomenon
(0-100 mm), median (IQR)
39 (42) 46 (40) 33 (50)
VAS Digital ulcers
(0-100 mm), median (IQR)
7 (26) 9 (40) 2 (17)
VAS Pain
(0-100 mm), median (IQR)
21 (38) 20 (43) 23 (39)
SSc= systemic sclerosis; IQR=interquartile range; dcSSc= diffuse cutaneous SSc; MRSS=modified 
Rodnan skin score; ANA=antinuclear antibody; ESR= erythrocyte sedimentation rate; CRP= 






















MHQ Work performance 63.4 (22.6) .922






























Pain -.65 -.56 -.57 -
Aesthetics .30 .32 .40 -.12 -
Patient 
satisfaction
.79 .60 .67 -.59 .35 -
Total MHQ .77 .73 .82 -.34 .66 .81
* MHQ= Michigan Hand Questionnaire; ADL = activities of daily living.














MHQ Function -0.416** -0.492** 0.127 0.140 0.363* -0.380* -0.520**
MHQ Activities of daily 
living
-0.734** -0.582** 0.442** 0.449** 0.641** -0.456** -0.534**
MHQ Work 
performance
-0.630** -0.505** 0.273 0.247 0.433** -0.420** -0.470**
MHQ Pain 0.240 0.243 0.039 0.008 -0.271 0.423 0.442
MHQ Aesthetics -0.269 -0.229 0.070 0.088 0.316 -0.165 -0.197
MHQ Patient 
satisfaction
-0.457** -0.383** 0.114 0.115 0.361* -0.218 -0.424**
MHQ total -0.623** -0.538** 0.259 0.265 0.472** -0.319* -0.457**
MHQ= Michigan Hand Questionnaire; HAQ=Health Assessment Questionnaire; HAMIS= Hand 
Mobility In Scleroderma; SODA= Sequential Occupational Dexterity Assessment; MRSS=Modifies 
Rodnan Skin Score; *p <0.05; **p <0.01, 
HAMIS, SODA scores and MRSS on the other side were moderate. Correlations of these 
scores with pinch and grip strength and SODA pain were however low. The MHQ pain 
and aesthetics subscale scores had in general very low correlations with any of the 
other outcome measures, except for the correlation between the MHQ pain score and 
the SODA pain score and the MHQ aesthetics score and the SODA score.
Table 5 shows that in the intervention group the hand function of patients improved 
significantly directly after a 12 week multidisciplinary treatment programme. For the 
MHQ subscales overall hand function, activities of daily living, work performance, 
satisfaction, as well as the MHQ total score the improvement reached statistical 
significance after 12 week follow up. Regarding the other measures of (hand) function 
the improvements of the HAQ, HAMIS and grip strength were statistically significant. 
The MHQ total score as well as the MHQ subscales activities of daily living, work 
performance, satisfaction demonstrated a moderate SRM, with values ranging between 
-0.68 and -0.74. As for the other measures of hand function, the SRM of the HAMIS 
(0.71) and grip strength (-0.74) were also moderate. The ES of the MHQ subscales work 
(-0.63) and satisfaction (0.55) were moderate. For all other measures, effect sizes were 
small. 
Regarding the RR 8 patients indicated an improved hand function, 11 rated their hand 
function as unchanged, and 1 a worsened hand function. Of five patients a rating 
was missing. The MHQ subscales work (-1.26), aesthetics (-0.83), an SODA (0.91) 
demonstrated a good responsiveness ratio, the MHQ total score (-0.74) and HAMIS 
(0.75) a moderate responsiveness ratio (30). None of the measures of (hand) function 
showed a responsiveness ratio above the strict cut off point of 1.96 (28).
Table 6 shows the difference in mean change scores and the pooled ES of the MHQ 
and subscales as well as other measures of (hand) function between the intervention 
and control groups. Except for the subscale scores pain and aesthetics (0.09 and 0.29, 
respectively), the pooled ES of the MHQ total and subscale scores was moderate to 
good (ranging between 0.56 and 0.86), with only the pooled ES for grip strength being 
larger (0.97).



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Difference (95% confidence 
interval) between mean change 
in treatment (n=28) and control 
group (n=25)
Pooled ES
MHQ Function 5.9 (0.3, 11.5) 0.61
MHQ Activities of daily living 8.1 (1.9, 14.3) 0.74
MHQ Work performance 14.1 (3.7, 24.5) 0.77
MHQ Pain -1.5 (-12.0, 8.9) -0.09
MHQ Aesthetics 5.8 (-6.4, 18.0) 0.29
MHQ Satisfaction 9.7 (-0.4, 19.9) 0.56
MHQ Total score 7.0 (2.5, 11.6) 0.86
HAQ (0-3) (SD) -0.30 (-0.53, -0.08) 0.82
HAMIS mean (0-27), (SD) -1.0 (-2.3, 0.3) 0.47
Grip strength right (J), (SD) 4.49 (2.0, 7.0) 0.97
Pinch grip right (N), (SD) -0.04 (-0.84, 0.75) 0.03
SODA 3.6 (-5.4, 12.6) 0.33
SODA pain 1.13 (-2.6, 0.3) 0.60
MHQ= Michigan Hand Questionnaire; HAQ=Health Assessment Questionnaire; HAMIS= Hand 
Mobility In Scleroderma; SODA= Sequential Occupational Dexterity Assessment;




In this study, in patients with SSc completing a 12-week multidisciplinary team care 
programme including a hand function treatment module, the MHQ and most of its 
subscales proved to have a good internal consistency and adequate convergent validity. 
The MHQ total score was found to be a responsive measure of hand function in patients 
with SSc, with in general more favourable results in detecting changes over time and 
discriminating between a treatment and a control condition than all other measures 
of (hand) function. 
The MHQ captures important aspects of hand function in SSc such as aesthetics, 
satisfaction with hand function and pain that are not addressed by other hand function 
tests .So far, data on the internal consistency, validity and responsiveness of the MHQ 
in SSc are scarce. No other studies have reported on the internal consistency in patients 
with SSc, with the results of the present study being quite favourable. Preliminary 
results of its validity have been presented in a cohort of 94 patients with SSc (17). 
In that study the correlations between the MHQ and its subscales on the one side 
and hand features such as skin score, digital ulcers and tendon involvement on the 
other side were assessed. Significant Spearman rank correlation coefficients were seen 
between the MHQ and tendon involvement, whereas associations with skin score and 
digital ulcers were weak. In our study the correlation between the MHQ and the MRSS 
was somewhat higher and the presence of digital ulcers or tendon friction rubs was 
not assessed. However, the present study showed a moderate correlation of the MHQ 
and its subscales with the HAQ, and to a lower extent with the HAMIS, SODA and SODA 
Pain scores. Overall, correlations between the MHQ and grip and pinch grip were weak, 
except for the association of the MHQ subscale activities of daily living with grip and 
pinch strength. 
Concerning the responsiveness of the MHQ, its performance was moderate to good. 
In comparison with the other measures of hand function, the ability of the MHQ and 
its subscales to detect changes over time or a difference between the intervention 
and control conditions was in the same range or better than that of other measures 
of (hand) function. The modest sensitivity to change may reflect a limited effect of the 
intervention. The lack of effect could be due to the mild disability hand disability of the 
patients participating in this study as well as moderate intensity of the hand treatment 
programme as compared tot other programmes (35) .  
The responsiveness of the MHQ subscale pain to detect changes over time was very 
low, and in line with the results of the SODA pain. Concerning the difference between 
the intervention and control group however, the pooled ES of the SODA pain was 
considerably larger than that of the MHQ subscale pain. Inconsistencies between the 
MHQ subscale pain and the SODA pain score can probably be explained by the different 
way pain is evaluated. In the SODA pain score patients indicate pain with standardized 
uni/bilateral ADL tasks, whereas the MHQ evaluates general pain using four out of five 
questions. 
Concerning the clinimetric properties of the MHQ in other rheumatic diseases with 
hand involvement, the MHQ demonstrated comparable measures of construct validity 
but proved to be less responsive to change (18;36). This may also be due to the mild 
disability hand disability of the patients participating in the present study as well as 
moderate intensity of the hand treatment program as compared to other interventions 
(18). 
A limitation of this study is the fact that no direct comparison was made with the Cochin 
Hand Function Scale (CHFS), a self-administered questionnaire that is frequently used 
in hand function assessment (4). The CHFS compromises 18 hand activity questions 
with 6 levels of answers with more detailed focus on activity of daily living, but lacks 
questions concerning pain, satisfaction and aesthetics. For this reason the MHQ and 
CHFS may complement each other well. 
In conclusion, the results of the present study indicate that the MHQ is a valuable 
instrument for the measurement of hand function in patients with SSc. As the present 
study concerned a selected group of patients with SSc, the results need to be confirmed 
in a larger population. 
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To describe work status and factors associated with work disability (WD) in patients 
with Systemic Sclerosis (SSc).
Methods:	
A systematic search strategy in various electronic databases from 1990 to 2011 
was performed. All clinical studies concerning SSc patients containing quantitative 
information on work status and/or factors associated WD were selected. Extracted 
were: study-characteristics, data on work status and/or factors associated with WD. 
The methodological quality was evaluated in three quality aspects (selection bias, 
information bias and statistical analysis bias). A best evidence synthesis was employed 
to analyze the association between potential determinants and WD.
Results:	
Twelve studies, described in 13 papers, including 2.758 SSc patients were selected. 
The methodological quality of one study was high. Employment rates varied between 
11% and 82% after an average disease duration ranging from 2.5 to 14 years. There 
was moderate evidence for an association between more functional disability, more 
disease specific symptoms and worse quality of life on one side and presence of WD 
on the other. There was moderate evidence for the absence of an association between 
WD and age, sex and disease subset. Inconsistent evidence was seen for an association 
between WD and education and disease duration. 
Conclusion: 
WD is a major consequence of the disease in patients with SSc and is associated with 
more functional disability, more disease specific symptoms and worse quality of life. 
This emphasizes the need for research into interventions to prevent or reduce WD in 
patients with SSc, especially in those with a worse health status.
Introduction
Systemic Sclerosis (SSc) is a chronic, multi-system disease with unknown etiology, 
characterized by skin sclerosis, vasculopathy and complications of internal organs (1). 
Despite the variable course of symptoms the associated morbidity is considered to be 
substantial. Two major subsets are defined: limited cutaneous systemic sclerosis (lcSSc) 
and diffuse systemic sclerosis (dSSc) (2). In lcSSc, Raynaud’s phenomenon and a slowly 
progressive thickening of the skin of distal extremities may have been present for years 
before patients seek medical attention. DcSSc has a rapid onset of skin thickening at 
proximal sites and involvement of internal organs. SSc disease manifestations include 
pain, fatigue and malaise, disabling digital tip ischemia, limited range of joint motion 
and flexion contractures, calcinosis, organ fibrosis and pulmonary arterial hypertension 
(3). Emotional distress is common in SSc, including depression, low self-esteem, 
concerns with physical appearance, and feelings of uncertainty about the future (4;5). 
Although medical treatment in SSc may alleviate symptoms, prevent complications or 
influence inflammation, so far a cure is not available.  
Using the International Classification of Functioning, Disability and Health to describe 
patients’ health status (6), considerable disability (impairments of body functions and 
structures, activity limitations and participation restrictions) has been demonstrated in 
SSc patients (7-9). Work disability in rheumatic conditions is usually defined as complete 
or partial work cessation due to the disease prior to the age of retirement (10), however 
in some studies a broader definition is used, also concerning any restriction in the work 
status, such as absenteeism or sick leave, or any reduction in productivity while present 
at work (so called presenteeism). Apart from work disability, productivity loss is also 
used as an umbrella term for work cessation, sick leave/absenteeism or reduction in 
productivity while present at work. 
The impact of the disease on participation in particular on work status, in other 
inflammatory rheumatic conditions is overall well-documented (11;12). The results of 
recent studies in SSc on this subject all point into the direction of substantial work 
disability (13-15). This is unfavorable as it was also found that in SSc patients greater 
work ability was associated with more satisfaction with occupations in general and 
better well-being (16). In addition, a number of recent studies aimed to identify risk 
factors for work disability in SSc patients (17;18). These studies found that lower 
educational level, less social support, poor functional ability and longer disease 
duration were associated with work disability. 
The growing number of publications on work status in SSc underlines the importance 
of the subject. So far, the literature has not been summarized by means of a systematic 
review. Therefore, the aim of the present study was to perform a systematic literature 
review on work status in SSc patients defined as the ability or inability to perform a paid 
job. More specific, we describe the prevalence of work disability in SSc as compared 
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with other inflammatory disease as well as the risk factors for work disability. For the 
latter purpose, medical and rehabilitative interventions were included as potential 
determinants of work status in SSc. 
Methods 
Search strategy. 
In cooperation with a trained librarian (JS), a search strategy was composed. The 
following databases were searched: PubMed, EMBASE (OVID version), Web of Science, 
COCHRANE Library, CINAHL (EbscoHost-version), PsycINFO (EbscoHost-version), 
Academic Search Premier and ScienceDirect. The search strategy consisted of the 
AND combination of two main concepts: Work Disability, and Systemic Sclerosis. For 
the different concepts, all relevant keyword variations were used, not only keyword 
variations in the controlled vocabularies of the various databases, but the free text 
word variations of these concepts as well (Appendix 1). 
The search strategy was optimized for all consulted databases, taking into account 
the differences of the various controlled vocabularies as well as the differences of 
database-specific technical variations (e.g., the use of quotation marks). The search 
was performed on the 23rd of May, 2011. 
Data collection and analysis.  
Five steps in the selection and data collection were defined. All steps were performed 
by two of the authors independently (AS and TPMVV) and any discrepancies were 
resolved by consensus. 
Step 1: Screening of titles and abstracts. First, duplicates were removed. Subsequently, 
titles and/or abstracts which were not directly related to a full-text paper were taken 
out.
For screening of the remaining titles and abstracts the following criteria were used: 
(i) the publication concerned a clinical study; (ii) the study population consisted of 
subjects with a diagnosis SSc according to the criteria as set by the American College 
of Rheumatology criteria and/or Leroy & Medsger criteria (2); studies with a mixed 
patient population were included if data on SSc patients were available separately; (iii) 
the publication contained information on work status or derivates.
Step 2: Selection of full-text papers. Titles and abstracts identified as potentially eligible 
were selected for full-article review. 
The following selection criteria were used for the full text papers: 
(i)  Studies contained quantitative information on work status including: working 
full-time, working part-time, number of hours working, early retirement, 
unemployment, absenteeism and/or presenteeism, permanent work disability 
(job loss and/or partial or full disability pension).
(ii)  The study concerned quantitative information on predictors for work status as 
defined under (i), including the potential impact of interventions such as medical 
treatment or vocational rehabilitation. 
(iii)  The article was written in the English language. 
Step 3: Data extraction. From the included full text papers the following study 
characteristics were systematically extracted: author, year of publication, country 
where the study was conducted, study design (cross-sectional or longitudinal), number 
of SSc patients, patient recruitment or selection criteria, average age (years), number 
of female patients (%), average disease duration (years), number of patients with a 
dcSSc (%). Regarding the outcomes of studies in terms of work status, the definition(s) 
of work status and associated outcome measures were recorded.
If a study included an analysis of determinants of work status, the following data were 
extracted: dependent variable (any outcome measure(s) related to work status) and the 
potential determinants examined, categorized into: i) sociodemographic characteristics 
(age, sex, educational level or other); ii) disease characteristics (SSc subset, disease 
duration, functional ability, disease specific symptoms, quality of life or other disease 
characteristics), iii) work characteristics; and iv) other. 
Step 4: Assessment of methodological quality
To assess the quality of the included studies, a quality checklist (Appendix 2) was 
developed, based on items described in a review of tools for quality assessment (19) 
and on a review on the quality of prognostic studies in systematic reviews (20). Two 
authors independently assessed the quality of each study by scoring 23 items (Appendix 
2), divided into three categories: i) selection bias (items 1-6); ii) information bias (items 
7-18); and iii) statistical analysis of potential determinants of work status (items 19-23). 
Bias was considered present if the majority of the items within a category pointed into 
this direction. The quality of the study was rated as high if there was no evidence for 
selection bias, information bias or analyses bias. The quality of the study was rated 
as moderate if there was evidence of bias in one out of two categories in descriptive 
studies (statistical analysis of factors associated with work disability not applicable), or 
two out of three categories in studies comprising an analysis of associations between 
various factors on the one side and work status on the other hand. The quality of 
the study was rated as low if there was evidence of bias in both two categories in 
descriptive studies and all three categories in the other studies.
Step 5: Best evidence synthesis
A best evidence synthesis was applied in order to synthesize the results of the studies, 
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while taking into account the number of studies, the methodological quality of the 
studies, and the consistency of the results. This rating system (Appendix 3) was based 




The bibliographic databases yielded 417 references in total (Figure 1). Twenty-four 
duplicates were excluded, in addition three titles were excluded because data were 
presented only in abstract form. 
The first screening of the remaining 390 titles and abstracts resulted in exclusion of 365 
abstracts because these did not concern a clinical study, did not include SSc patients or 
provided no information on work status or derivates. Full text screening of 25 remaining 
potentially eligible papers resulted in exclusion of twelve papers because (quantative) 
data on work status were missing (n=11) or they were not written in English (n=1). 
Finally, thirteen papers were selected for inclusion (13-18;21-27). In two included 
papers the same inclusion criteria were used, a similar number of patients was included 
and similar demographic characteristics were reported (16;27). Therefore, these two 























Papers screened for data on work 
status or determinants (n =390)
Papers excluded
because not concerning a 
clinical study, not including 
SSc patients or not providing 
information on work status or 
derivates (n =365)
Full-text papers 
assessed for eligibility 
(n =25 )
Full-text papers included 
(n =13 ), concerning 12 
studies
Exclusion of duplicates (n=24)
and data only in abstract (n=3)
Papers excluded
(n =12) because of missing 
(quantative) data on work 
status (n=11) or availability in 
English language (n=1) 
papers were considered as one study, resulting in a final number of studies of twelve. 
For data extraction and the assessment of quality the information of both studies was 
combined.
Study characteristics
The characteristics of the selected studies are presented in Table 1. The studies were all 
performed in Europe or North America. Eleven of the 12 studies had a cross-sectional 
design, whereas one study had a prospective design with a mean follow-up of 4.4 years 
(18). Eight out of twelve studies comprised an analysis of associations between various 
factors on the one side and work status on the other hand.
Patients were recruited through department registers of rheumatology centers/
outpatient clinics (14;16;21;22;27), multi-center registers (17;23), a national registry 
(24) or using various recruitment strategies including public announcements or 
advertisements (13;15;18;25). The numbers of participants
included in the studies varied from 36 to 802, the average ages from 47 to 58 years, 
the proportions being female from 82.8 to 100%, the proportions with diffuse subtype 
SSc from 0 to 59% and the mean/median disease duration from 2.5 to 14 years. Some 
of the studies employed an inclusion criterion regarding the maximum age of patients 
(16;21;24;26;27), in order to only include patients of working age. In addition, none of 
the studies included only patients who had a paid job at the time of diagnosis. 
Methodological quality 
Table 2 summarizes the result of the quality assessment. Four studies (22;23;25;26) 
were only descriptive with respect to work status (maximum 2 points) whereas 8 
studies (13-18;21;24;27) concerned an analysis of factors associated with work status 
(maximum 3 points). The methodological quality was rated as high in two studies 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Minier (22) 1 1 N.a. 2/2 L
Bernatsky (23) 1 0 N.a..@ 1/2 M
Sandqvist (26) 0 0 N.a. 0/2 H
Moser (25) 1 0 N.a..@ 1/2 M
Studies concerning an analysis of factors associated with work ability
Ouimet (14) 1 0 0 1/3 M
Mau (24) 1 0 0 1/3 M
Hudson (17) 0 0 0 0/3 H
Sandqvist (16, 27) 0 0 1 1/3 M
Berezne (15) 1 0 0 1/3 M
Nguyen (13) 1 0 0 1/3 M
Sharif (18) 1 0 0 1/3 M
Sandqvist (21) 0 0 1 1/3 M
§ 1=risk of bias; 0= no risk of bias present. *H= high quality; no evidence for selection bias, 
information bias or analyses bias. M= moderate quality: in one or two quality aspects 
evidence for risk of bias. L= low quality: all evidence for risk of bias; .@ multivariate analysis not 
concerning a work ability outcome
Work status in SSc
Measurement methods
Table 1 shows the measurement methods for work status of the 12 studies. One study 
used a standardized method using data from the general population (24). In that study 
standardized Employment Ratios (SER) were used, defined as the ratios of observed 
and expected numbers of patients with gainful employment. One study used the 
Work Ability Index (WAI), a combined measure of absenteeism, presenteeism, and 
work ability in relation to demands of the work, psychological resources, number of 
diagnosed diseases and estimation of own impairment and prognosis (21). One study 
reported work status in terms of productivity, defined as the number of self-reported 
days that the patient was unable to work (market work and unpaid labor) (23). The other 
included studies used various operationalizations of work status; mostly proportions of 
patients who were working, stopped working, were on sick leave or the combination 
of both (13-18;22;25-27)
In some studies, information on work status was gathered as part of other research 
questions and analyses, including cost-of-illness (22;23), psychosocial adjustment (25) 
and time use and satisfaction with occupation (27).  




In the one study which used work ability rates that were standardized using data from 
the general population SERs of 0.70 (95% CI 0.52-0.92) and 0.77 (95% CI 0.67-0.87) 
were observed in women with SSc in the new and old federal states of Germany, 
respectively. The SER of men with SSc also indicated work disability; however these 
results did not reach statistical significance.
Regarding the outcomes in terms of proportions of patients being employed, Table 1 
shows that all but one (23) study provided information in this way. The highest reported 
percentage was 82% in a Swedish study with 44 female patients with limited SSc and 
a median disease duration of 8 years (16). The lowest reported proportion of patients 
being employed (either part time or full time) was 11.3%, observed in a cross-sectional 
study with 80 patients with SSc with a mean age 57.4 years and mean disease duration 
of 6.2 years, of whom 90% were female (22). Direct comparisons of proportions of 
patients working need to be interpreted with caution as the selection of patients and 
disease duration varied widely among studies. 
With respect to sick leave rates six studies (13;15;16;22;26;27) reported proportions 
of patients being on partial or full-time sick leave in mostly cross sectional design, with 
the rates for full time sick leave ranging between 1.3 and 61% and part time sick leave 
ranging between 8% and 35% in patients with a disease duration varying from 6.2 to 
14 years. Two studies provided information on work status in terms of productivity; 
Berezne et al (15) reported an estimated SSc related decreased work productivity of 
3.4 hours/month (±3.8). Bernatsky et al (23) estimated a lost productivity of paid labor 
of 5345 Canadian dollars per patient per year.
Work status in patients with SSc as compared to other rheumatic conditions
Two studies included a direct comparison of work disability rates in patients with SSc 
as compared to other rheumatic diseases (14;24). In one study, more work disability 
was seen in SSc patients as compared to an age and sex matched cohort of Rheumatoid 
Arthritis (RA) patients ; 55.7 % versus 34.6 % (p=0.009) after a mean disease duration 
of 11 versus 12 year. (14). In another study (24) the SER was 0.77 in patients with 
SSc, 0.78 in rheumatoid arthritis (RA), 0.94 in ankylosing spondylitis, 0.92 in psoriatic 
arthritis, 0.81 in Systemic Lupus Erythematosus and 0.76 in polyangiitis (Wegener’s) 
with the SERs being significantly different from the general population for all these 
patient groups.
Determinants of work status
Table 3 shows the results of the 8 studies examining determinants of work status (13-
18;21;24). In case of both univariate and multivariate analyses only the results of the 
multivariate analyses were presented. Overall, there was a large heterogeneity in the 
included potential determinants of work status, the definitions of the work status, the 
possible confounders as well as the used analyses. 
Table 3 shows that there is moderate evidence for an association between more 
functional disability, decreased quality of life, more disease specific symptoms and more 
work disability. Also, moderate evidence was found for the absence of an association 
between age, sex and disease subset and work disability. Results concerning other 
predictors of work disability, including educational level and other demographic or job 
characteristics and disease duration, were not consistent. 
Discussion
This systematic review on work status and its determinants in SSc included 12 studies. 
Although the definitions of work status varied widely among studies, the results indicate 
substantial work disability. Moderate evidence was found for an association between 
functional disability, quality of life and disease specific symptoms and work disability. 
Also, moderate evidence was found for the absence of an association between age, 
sex and disease subset and work disability. Results concerning other predictors of work 
disability were not consistent. 
With respect to the extent of work disability, the majority of studies reported outcomes 
in terms of proportions of patients working as opposed to proportions of patients who 
stopped working or were on sick leave or the combination of both. In the included 
studies, the proportions of patients working varied from 11% (22) to 82% (16), the 
highest number concerning patients with limited SSc. Only one study (24) used 
standardized employment rates, demonstrating significantly reduced participation in 
patients with SSc. 
Most studies included in this review had a cross sectional design and used employment 
rates and permanent work disability as outcome measures, while data on sick leave 
or presenteeism were presented in relatively few (15;16;21;23). This is unfortunate as 
it was demonstrated in other inflammatory disease that sick leave is an independent 
risk factor for job loss (28). Moreover, information on any degree of productivity loss is 
essential in establishing the economic impact of SSc.
Comparisons of work disability rates among studies are hampered by differences in 
patient populations with respect to disease duration and severity, age and employment 
rate prior to the established diagnosis as well as definitions of work status. Comparison 
between studies performed in the various countries is further limited by differences in 
populations, differences in work force participation in female and general population 
and social security systems.
To facilitate the interpretation and comparison of work status rates within and among 
patient groups, standardized assessments of work disability are recommended, 
including consensus on the definitions of the various aspects of work status as well as 
standardization using data from the general population
In addition it is questionable whether cross-sectional studies are suitable to describe 
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the impact of SSc on work disability. Preferably, work ability should be regarded as a 
continuum, in which periods of decreased work productivity while present at work, 
temporary absence or sick leave may precede or follow periods during which patients 
are not working at all, due to official unemployment, work disability, early retirement 
and/or voluntary 
stopping work (29). Prospective cohort studies are needed to describe productivity 
gains and losses over time in this continuum model, taking factors such as age, sex, 
education and other socio-demographic variables, as well as an appropriate description 
of jobs and job demands, into account. 
As for the determinants of work disability, moderate evidence was found for an 
association between functional disability, quality of life and disease specific symptoms 
and work disability. Many factors may influence work disability; personal factors 
(personality, coping mechanisms, education), environmental influences (financial 
resources, social security systems), work characteristics (physical demanding or not, 
flexibility in working hours, aids and other occupational interventions), pharmacological 
or non-pharmacological treatment and vocational therapy. Sandqvist (16) observed 
less sick leave in patients with less physically demanding work. As for work dependent 
influences on work disability, no other determinants were evaluated, nor the effect of 
any kind of medical or rehabilitative treatment on work disability. Given the general 
observation that work disability in SSc is substantial, more research targeted at 
potentially modifiable factors (e.g. disease severity by optimizing medical treatment 
and job demands by vocational rehabilitation) is urgently needed.
The question remains how the severity of work disability in SSc compares to that in 
other rheumatic conditions. Comparisons with work disability rates in patients with 
other rheumatic conditions reported in other individual studies or reviews are difficult 
to make, as patient populations may differ largely with respect to age, sex, and disease 
duration and the definitions of outcomes related to work status also vary. However, 
two studies included in this review included one or more populations of patients with 
other inflammatory rheumatic conditions, allowing a direct comparison. In one study 
it appeared that work disability in SSc was more frequent than in RA then SSc (14), 
whereas in another study the relative risk of higher/lower SER was comparable with 
RA (24). 
Limitations of this review include the fact that statistical pooling of data was not applied 
due to the heterogeneity of data. A best evidence synthesis was employed, which 
accounted for the methodological quality of the studies. Moreover, this systematic 
review focused on paid labor only. The feminine predominance and older age in SSc 
patients warrants more research on the impact of the disease on unpaid labor. Future 
studies on work disability should therefore distinguish between paid and non paid 
work in order to establish the full impact of SSc on any kind of productivity.  
Although the differences in outcomes and definitions of work disability make 
generalization of results challenging, this review shows that work disability in SSc is 
substantial. The validity of data on work disability and its predictors could be improved 
by prospective studies with clearly defined patient characteristics as well as end points 
for all dimensions of work productivity loss. An important question remains if a patient’s 
risk of permanent work disability can be diminished. Much knowledge could be gained 
if work status was used as an outcome measure in trials concerning pharmacological 
or non-pharmacological treatment. In other rheumatic disease, effectiveness of 
biological therapy (30) and vocational therapy on prevention of work disability (31) 
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Appendix 1 search strategy
Database Strategy
PubMed
(“Working Disability” OR “work disability” OR “working ability” OR “work ability” OR 
employment status OR socioeconomic burden OR socio-economic burden OR professional 
activity OR employment OR Work Capacity Evaluation OR Vocational Rehabilitation 
OR Absenteeism OR Presenteeism OR “Vocational Guidance”(mesh] OR Workers’ 
Compensation OR Eligibility Determination OR sick leave OR ((Occupational Medicine OR 
Occupations OR Occupation OR Occupational OR employment OR work) AND (Disease 
severity OR Disability Evaluation OR Evaluation OR disability)) OR Cost OR Costs OR 
Economics OR economics OR “Health care usage” OR “Health care utilization” OR “Health 
care use” OR “Health care system usage” OR “Health care system utilization” OR “Health 
care system use”) AND (“Systemic Sclerosis” OR “Scleroderma, Systemic”(mesh] OR 
“Systemic Scleroderma” OR “Diffuse Scleroderma” OR “Sudden Onset Scleroderma” OR 
“Progressive Systemic Sclerosis” OR “Progressive Scleroderma” OR “Limited Scleroderma” 
OR “Limited Systemic Scleroderma” OR “CREST Syndrome” OR “CREST Syndromes” OR 
“Telangiectasia Syndrome” OR “CRST Syndrome” OR “CRST Syndromes” OR (Calcinosis AND 
Raynaud AND Sclerodactyly AND Telangiectasia))
EMBASE 
(OVID-version
1. Focus on Systemic Sclerosis
(work disability/ OR “Working Disabilit*”.mp OR “work disabilit*”.mp OR “working abilit*”.mp 
OR “work abilit*”.mp OR work capacity/ OR exp work/ OR exp occupation/ OR employment 
status/ OR employment status.mp OR exp employment/ OR socioeconomic*.mp OR exp 
socioeconomics/ OR socio-economic*.mp OR professional activity.mp OR employment.mp 
OR Work Capacit*.mp OR vocational rehabilitation/ OR Vocational Rehabilitation.mp OR 
Absenteeism/ OR Absenteeism.mp OR Presenteeism.mp OR productivity/ OR Vocational 
Guidance/ OR vocational guidance.mp OR Workers’ Compensation.mp OR workman 
compensation/ OR Eligibility Determination.mp OR medical leave/ OR sick leave.mp OR 
medical leave.mp OR ((occupation* OR employment OR work OR worker*) AND (Disease 
severity OR Disability Evaluation OR Evaluation OR disability)).mp OR Cost.mp OR Costs.
mp OR Economic*.mp OR exp economic aspect/ OR health care utilization/ OR “Health 
care usage”.mp OR “Health care utilization”.mp OR “Health care use”.mp OR “Health care 
system usage”.mp OR “Health care system utilization”.mp OR “Health care system use”.
mp) AND (exp *systemic sclerosis/ OR (“Systemic Scleros*” OR “Systemic Scleroderma*” 
OR “Diffuse Scleroderma*” OR “Sudden Onset Scleroderma*” OR “Progressive Systemic 
Scleros*” OR “Progressive Scleroderma*” OR “Limited Scleroderma*” OR “Limited 
Systemic Scleroderma*” OR “CREST Syndrome*” OR “Telangiectasia Syndrome*” OR “CRST 
Syndrome*” OR (Calcinosis AND Raynaud AND Sclerodactyly AND Telangiectasia)).ti)
2. No focus on Systemic Sclerosis, and combined with intervention-terms
(work disability/ OR “Working Disabilit*”.mp OR “work disabilit*”.mp OR “working abilit*”.mp 
OR “work abilit*”.mp OR work capacity/ OR exp work/ OR exp occupation/ OR employment 
status/ OR employment status.mp OR exp employment/ OR socioeconomic*.mp OR exp 
socioeconomics/ OR socio-economic*.mp OR professional activity.mp OR employment.mp 
OR Work Capacit*.mp OR vocational rehabilitation/ OR Vocational Rehabilitation.mp OR 
Absenteeism/ OR Absenteeism.mp OR Presenteeism.mp OR productivity/ OR Vocational 
Guidance/ OR vocational guidance.mp OR Workers’ Compensation.mp OR workman 
compensation/ OR Eligibility Determination.mp OR medical leave/ OR sick leave.mp OR 
medical leave.mp OR ((occupation* OR employment OR work OR worker*) AND (Disease 
severity OR Disability Evaluation OR Evaluation OR disability)).mp OR Cost.mp OR Costs.
mp OR Economic*.mp OR exp economic aspect/ OR health care utilization/ OR “Health 
care usage”.mp OR “Health care utilization”.mp OR “Health care use”.mp OR “Health care 
system usage”.mp OR “Health care system utilization”.mp OR “Health care system use”.
mp) AND (exp systemic sclerosis/ OR (“Systemic Scleros*” OR “Systemic Scleroderma*” 
OR “Diffuse Scleroderma*” OR “Sudden Onset Scleroderma*” OR “Progressive Systemic 
Scleros*” OR “Progressive Scleroderma*” OR “Limited Scleroderma*” OR “Limited 
Systemic Scleroderma*” OR “CREST Syndrome*” OR “Telangiectasia Syndrome*” OR “CRST 
Syndrome*” OR (Calcinosis AND Raynaud AND Sclerodactyly AND Telangiectasia)).mp) AND 
(exp *drug therapy/ OR intervention*.mp OR medication*.mp OR exp *therapy/ OR exp 
intervention study/ OR drug*.mp)
Web of 
Science
1. Focus on Systemic Sclerosis
TS=(“working disabilit*” OR “work disabilit*” OR “working abilit*” OR “work abilit*” OR 
“work capacit*” OR occupation* OR employment* OR socioeconomic* OR socio-economic* 
OR “professional activity” OR “vocational rehabilitat*” OR Absenteeism OR Presenteeism 
OR “Vocational Guidance” OR “Workers Compensation” OR “workman compensation” 
OR “Eligibility Determination” OR “medical leave” OR “sick leave” OR ((occupation* OR 
employment OR work OR worker*) AND (“Disease severity” OR disabilit*)) OR Cost OR Costs 
OR Economic* OR “Health care usage” OR “Health care utilization” OR “Health care use” 
OR “Health care system usage” OR “Health care system utilization” OR “Health care system 
use”) AND TI=(“systemic scleros*” OR “Systemic Scleroderma*” OR “Diffuse Scleroderma*” 
OR “Sudden Onset Scleroderma*” OR “Progressive Systemic Scleros*” OR “Progressive 
Scleroderma*” OR “Limited Scleroderma*” OR “Limited Systemic Scleroderma*” OR 
“CREST Syndrome*” OR “Telangiectasia Syndrome*” OR “CRST Syndrome*” OR (Calcinosis 
AND Raynaud AND Sclerodactyly AND Telangiectasia))
2. Focus on Working disability
TI=(“working disabilit*” OR “work disabilit*” OR “working abilit*” OR “work abilit*” 
OR “work capacit*” OR work OR occupation* OR employment* OR socioeconomic* 
OR socio-economic* OR “professional activity” OR “vocational rehabilitat*” OR 
Absenteeism OR Presenteeism OR “Vocational Guidance” OR “Workers Compensation” 
OR “workman compensation” OR “Eligibility Determination” OR “medical leave” OR 
“sick leave” OR ((occupation* OR employment OR work OR worker*) AND (“Disease 
severity” OR disabilit*)) OR Cost OR Costs OR Economic* OR “Health care usage” OR 
“Health care utilization” OR “Health care use” OR “Health care system usage” OR 
“Health care system utilization” OR “Health care system use”) AND TS=(“systemic 
scleros*” OR “Systemic Scleroderma*” OR “Diffuse Scleroderma*” OR “Sudden Onset 
Scleroderma*” OR “Progressive Systemic Scleros*” OR “Progressive Scleroderma*” OR 
“Limited Scleroderma*” OR “Limited Systemic Scleroderma*” OR “CREST Syndrome*” 













(working disability OR work disability OR working ability OR work ability OR work 
capacity OR occupation* OR employment* OR socioeconomic* OR socio-economic* OR 
professional activity OR vocational rehabilitation OR Absenteeism OR Presenteeism OR 
Vocational Guidance OR Workers Compensation OR workman compensation OR Eligibility 
Determination OR medical leave OR sick leave OR ((occupation* OR employment OR work 
OR worker*) AND (Disease severity OR disabilit*)) OR Cost OR Costs OR Economic* OR 
Health care usage OR Health care utilization OR Health care use OR Health care system 
usage OR Health care system utilization OR Health care system use) AND (systemic 
sclerosis OR systemic scleros* OR systemic scleroderma OR Systemic Scleroderma* 
OR Diffuse Scleroderma* OR Sudden Onset Scleroderma* OR Progressive Systemic 
Scleros* OR Progressive Scleroderma* OR Limited Scleroderma* OR Limited Systemic 
Scleroderma* OR CREST Syndrome* OR Telangiectasia Syndrome* OR CRST Syndrome* 
OR (Calcinosis AND Raynaud AND Sclerodactyly AND Telangiectasia))
ScienceDirect
(working disability OR work disability OR working ability OR work ability OR work 
capacity OR occupation OR employment OR socioeconomic OR socio-economic OR 
professional activity OR vocational rehabilitation OR Absenteeism OR Presenteeism OR 
Vocational Guidance OR Workers Compensation OR workman compensation OR Eligibility 
Determination OR medical leave OR sick leave OR Cost OR Costs OR Economic OR “Health 
care usage” OR “Health care utilization” OR “Health care use” OR “Health care system 
usage” OR “Health care system utilization” OR “Health care system use”) AND TITLE-
ABSTR-KEY(systemic sclerosis OR systemic scleroderma OR crest)





1. Is there a theoretical background for the hypothesis? 
Study participation
2. Is the study population clearly described in terms of age, gender, and important SSc 
characteristics? 
3. Is the percentage of eligible subjects who participated in the study (response 
rate) adequate? (more than 30% is considered inappropriate)
Sampling
4. Are patients who participated in the study similar to eligible non-participants, in terms of age, 
gender, and important disease characteristics?
Study attrition
5. Is the percentage of subjects available for analysis adequate? (< 30% not too many missing 
values or loss to follow-up)? 
6. Were reasons for loss to follow-up presented and assessed during the study for possible 
systematic attrition? (subjects that did not finish the study)
B.	Information	bias
Determinants/correlates measurement
      Definition of determinant/correlate
7. Are clear definitions of each determinant and/or correlate provided?  
8. Are clear operationalizations of each determinant and/or correlate provided? How is it 
measured
      Measurement of determinants/correlates
9. Are the measurement instruments used for the measurement of the determinants and 
correlates reliable and valid?
       Method and setting of the determinants/correlates
10. Were the measurement approach, time and place of measurement of the determinants 
and/or correlates standardized or conducted in a way that limits systematically different 
measurement?
Outcome measurement
       Definition of outcome variable(s)
11. Are clear definitions of each outcome variable provided? 
12. Are clear operationalizations of each outcome variable provided? How is it measured.
      Measurement of outcome variable(s)
13. Are the measurement instruments used for the measurement of the outcome variable(s) 
reliable and valid? 
       Method and setting of the outcome variable(s)
14. Were the measurement approach, time and place of measurement of the outcome variable(s) 
standardized or conducted in a way that limits systematically different measurement?
Study confounding
       Definition of potential confounders
15. Are clear definitions of each confounder provided? 
16. Are clear operationalizations of each confounder provided?
       Measurement of  potential confounders
17. Are the measurement instruments used for the measurement of the confounder(s) reliable 
and valid?
       Method and setting of the confounder(s)
18. Were the measurement approach, time and place of measurement of the confounder(s) 
standardized or conducted in a way that limits systematically different measurement?
C.	Statistical	analyses	bias
Is the percentage of missing values adequate? (less < 30%)
Appendix	2:	quality	checklist For association studies: 
19. Was the outcome measure adjusted for potential confounders in the analysis?
For prediction studies: 
20. Were multivariable analyses performed? If yes
21. Was it clearly described which variables were included in the (multivariable) model(s)?
Final question
22. Were there any other important flaws in the design or analyses of the study?
Appendix 2 Quality assessment
Appendix	3:	level	of	Evidence
Findings Level of evidence
Consistent findings in multiple (≥2) high quality studies Strong evidence (S)
Consistent findings in one high quality study and at least one moderate quality 
study or consistent findings in multiple moderate quality studies.
Moderate evidence (M)
Only one study available or inconsistent findings in multiple studies (≥2) Inconsistent evidence (I)
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Objective: To examine the needs and preferences regarding the delivery of health care 
services and information provision and their determinants in patients with systemic 
sclerosis (SSc). 
Methods: A questionnaire was sent to 77 SSc-outpatients, comprising 27 items on health 
care needs within the domains physical, psychological, social support, employment/
daily activities or other health problems and 13 items on information needs. Moreover, 
the patients’ preferences regarding the provision of health care services and information 
were listed. Additional assessments included sociodemographic characteristics, 
physical functioning (SSc-Health Assessment Questionnaire) and quality of life (Short 
Form-36; SF-36).
Results: Sixty-four patients (83%) returned the questionnaire. Twenty-six patients 
(41%) reported one or more unmet health care needs, with the highest proportions 
of patients with unmet needs seen in the physical (28%) and psychological (20%) 
domain. The highest percentages of patients with information needs were observed 
for medical subjects (20-28%). A lower mental component summary scale score and 
younger age were associated with the presence of at least one health care need in the 
psychological domain. Worse physical functioning, a diagnosis of diffuse SSc and having 
a partner were associated with higher information need score. A yearly, standardized 
multidisciplinary assessment program was most frequently mentioned as a preferred, 
but not yet existing health care model (59%) and the rheumatologist as a preferred 
source of information supply (75%).
Conclusion:	 Unmet health care and information needs are common among SSc-
patients. To improve SSc-health care more attention should be paid to health care 
services for specific physical and psychological problems and medical information 
supply by the rheumatologist. In addition, the development of new models of care, 
such as a yearly, standardized multidisciplinary diagnostic program seems warranted.
Introduction
Systemic sclerosis (SSc) is a multisystem disease of unknown origin characterized by 
fibrosis of the skin and considerable morbidity (15). Patients may suffer from dysfunction 
of lungs, kidneys, heart, gastrointestinal tract and the musculoskeletal system, as well 
as digital ulcers, Raynaud’s phenomenon and joint contractures. Two major subtypes 
are distinguished; diffuse SSc with skin thickening proximal to elbow and knees, and 
limited cutaneous SSc with involvement of the distal extremities. Given the complexity 
of the disease, SSc-patients require multidisciplinary treatment by specialty physicians, 
health professionals such as physical therapists, occupational therapists, dieticians 
and psychologists (3;12;18). In recent years, SSc specific educational and rehabilitation 
programs have been developed (2;7;24). 
Until now, little is known about how the available services relate to the health care 
needs of patients with SSc themselves. Rubenzik (23) found health care needs in 
the psychological/spiritual/existential domain in a group of 25 patients with SSc. In 
addition, in a Dutch study in 123 patients with SSc, the need for practical information 
on disease background, medication usage and dealing with pain was identified (25). 
However, in both studies it remained unclear to what extent the patients’ needs were 
met by current health care services delivery. Moreover, the association between needs 
and patient characteristics has only in part been studied (23). None of these studies 
evaluated the patients’ preferences regarding the provision of their care, including 
their views on the institution of services that are not yet available.
The aim of this study was to identify unmet health care and information needs and their 
determinants as well as preferences for health care services delivery and information 
provision in patients with SSc. 
Patients	and	methods
Study design
The study had a cross-sectional design. Ethical approval for this study was obtained 
from the Institutional Review Boards of the Leiden University Medical Center. All 
participants gave written informed consent. 
Patients
Patients were recruited between May and July 2007. Inclusion criteria were: diagnosis 
of SSc as established by their treating rheumatologist according to ACR criteria (1), 
current treatment in the Leiden University Medical Center, being able to comprehend 
the Dutch questionnaire and age 18 years or older. A questionnaire was sent to all 
patients fulfilling these criteria, accompanied by an invitation letter, an information 
leaflet explaining the aim and the methods of the study and a consent form. A follow-
up letter was sent to participants who did not return the surveys within a month.




Survey on health care and information needs and preferences.
a. Health care needs 
Based on the Systemic Lupus Erythematosus Needs Questionnaire (SLENQ)(21), we 
developed a questionnaire including health problems relevant for patients with SSc 
within the following domains: physical (12 items), psychological (9 items), social support 
(3 items), and daily living/employment (3 items). In addition to the 12 physical items, 
patients were invited to report ‘other physical issues’ in 2 text fields, in case these were 
not covered by the previous items. With every item, patients were asked to score the 
presence of a problem (no/sometimes/frequently/always; range 0-3). Per domain, the 
number of problems per patient was computed (score ranges physical domain 0-42, 
psychological domain 0-27, social domain 0-9 and daily living employment domain 
0-9). In addition, a total problem score was calculated (range 0-87). 
If a problem was present, patients were then asked if they had discussed it with a health 
care provider (yes/no) and if not, whether there was an unmet need for contact with 
a health care provider regarding this problem (yes/no). A total score of unmet health 
care needs could be computed by adding up the number of unmet needs, ranging from 
0 to 29. 
The internal consistency of the questionnaire and its subscales was determined by 
computing Cronbach’s alpha for the health care problem score. In general, a Cronbach’s 
alpha of ≥0.70 is considered acceptable. For scales with a small number of items (social 
support and daily living/employment) and a low Cronbach’s alpha, a mean inter-item 
correlation was computed (optimal range recommended 0.2 to 0.4). Cronbach’s alpha 
of the total health care problem questionnaire was 0.90, whereas for the subscales 
Cronbach’s alpha was 0.79 for the physical domain, 0.89 for the psychological domain, 
0.54 for the social support domain (inter-item correlation 0.34), and 0.78 for the daily 
living/employment domain.
As there is no gold standard for perceived health care needs, we determined the 
convergent validity of the questionnaire by examining the association between problem 
scores of the questionnaire and measures of physical and mental functioning. For this 
purpose, correlations were computed between the problem score of the physical 
domain on the one side and the Physical Component Summary Scale of the SF-36; 
PCSS) and disability (HAQ score) on the other side and between the problem score 
of the psychological domain and the Mental Component Summary Scale of the SF-36 
(MCSS) (Pearson correlation coefficients). There were significant correlations between 
the physical symptoms score on the one side and the PCSS (r=-0.603, p<0.01) and the 
HAQ (r- 0.598, p<0.01) on the other side and between the psychological symptoms 
score and the MCSS (r=-0.740, p<0.01)
b. Information needs. 
Again based on the SLENQ (21), 13 questions assessed the need for information on the 
following topics: Test results, Medical treatment of SSc, Knowing when to see a doctor, 
General information on medical tests, Information on SSc, Physical therapy, Exercise 
and sports, the SSc patients society, Occupational therapy, Dental health, Dietary 
information, Counseling services, Home (nursing) care. As compared to the SLENQ, 
the questions about physical activities and sports, physical therapy and home (nursing) 
care were added. With every topic, the information need was scored on a five-point 
Likert scale: 1= no need, 2=low need, 3=indifferent, 4=moderate need, 5= high need. 
The scores were later dichotomized in two categories in the same manner as was done 
in the SLENQ: 0 ‘no need, low need or indifferent’ and 1 ‘moderate or high need’, so a 
total information need score could be computed, ranging from 0 to 13.
c. Preferences for health care delivery specifically for patients with SSc. 
Patients’ preferences regarding the delivery of health care in addition to regular 
outpatient clinic care included the following options: (i) multidisciplinary treatment 
if needed; (ii) a yearly multidisciplinary diagnostic program with standardized 
measurement of disease activity and other medical assessments; (iii) a yearly 
multidisciplinary diagnostic program with standardized measurement of disease 
activity and other medical assessments as well as an inventory of the patient’s personal 
need for health professionals’ care and information supply. Preferences were assessed 
on a five point scale (1= no need, 2=low need, 3=indifferent, 4=moderate need, 5= high 
need).
d. Preferences regarding the provision of information 
Patients were asked if they were to look for information in the next year, how they 
would rate their preferences for the following sources of information: internet, written 
information (leaflets), others coping with SSc, patient support group, information 
meeting in the hospital, group educational program (with or without family present), 
rheumatologist, general practitioner or nurse specialist. Preference was evaluated by a 
five point scale (1=not at all preferred -5=highly preferred).
An expert panel of three rheumatologists (AAS, GSB, JMvL) and a physician/
epidemiologist (TVV) was responsible for the translation and adaptation of the SLENQ 
and the development of additional questions concerning preferences. Pilot-testing 
by two SSc patients resulted in a few minor adjustments of the final questionnaire 
(appendix 1).
Socio-demographic characteristics
Socio-demographic variables included age, (status of living (living with a partner yes/
no), educational level: primary education (0-8 years; low education level), secondary 
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education (9-16 years; medium education level) and higher vocational education/ 
university (post secondary; high education level) and paid employment (yes/no).
Disease	characteristics	and	function
Disease duration and disease subset (limited or diffuse) (15), were derived from 
the medical record. Disease onset was defined as time since diagnosis by the 
rheumatologist in either the Leiden University Medical Cennter (LUMC) or if applicable 
in another medical centre (in years). In addition, patients were asked to fill in the SSc 
Health Assessment Questionnaire (SSc HAQ), a 20-item questionnaire comprising eight 
domains of activities of daily living, with the final score ranging from 0 (no disability) 
to 3 (severe disability) with scleroderma-symptom visual analogue scales (VAS 0-100 
mm) in addition; Raynaud’s disease, digital ulcers, intestinal complaints, pulmonary 
complaints, overall complaints, and pain (4).The SSc HAQ has been found to be a 
reliable outcome measure for disease severity in SSc (20). 
Quality of life 
Quality of life was measured with the Short Form-36, which includes eight domain 
scores: physical functioning, role limitation due to physical problems, bodily pain, 
general health perception, vitality, social functioning, role limitation due to emotional 
problems, and mental health. The scores of the SF-36 subscales range from 0-100, with 
higher scores indicating better quality of life. The subscales can be converted into two 
summary scales: the physical and mental component summary scale, standardized to a 
score with a mean of 50 and a standard deviation of 10 in the general population. For 
that purpose, we used the scores from an age- and sex-matched, normative sample, 
drawn from a large, random, nationwide sample of adults (n=1742) from the general 
Dutch population Frequency Table and factor score coefficients (26). The psychometric 
properties of this questionnaire have been found to be adequate (6). 
Data analysis
Data entry was performed using Microsoft Office Access 2003. Statistical analyses were 
executed using SPSS 16.0 software. Frequencies or means and standard deviations 
were calculated for each sociodemographic measure and disease characteristic, where 
appropriate. Comparisons of sociodemographic and disease characteristics of patients 
with limited and diffuse SSc were done with unpaired t-tests, Chi-Square or Fisher’s 
exact tests, where appropriate.
Descriptive statistics were employed for the patients’ needs and preferences regarding 
health care services and information delivery. 
To determine which factors were associated with health care needs, logostic regression 
analysis was performed with socio-demographic and disease characteristics as 
independent variables and the health care need score, dichotomized into no need (0) 
and at least 1 need (≥1) as dependent variable. This analysis was repeated for each 
domain with the domain score dichotomized into no need (0) and at least 1 need (≥1) 
as dependent variable. To determine which factors were associated with information 
needs, linear regression analysis was performed, with socio-demographic and disease 









Age, years ; mean (SD) 55.3 (13.2) 53.1 (10.7) 57.8 (15.5)
Female, N (%) 50 (78) a 23 (68%) 27 (90%)
Disease duration, years ; mean (SD) 8.5 (6.4) † 6.4 (4.7) 10.3 (7.3)
ANA/ anti-Scl70/ anti-centromere/ anti-RNP
ESR, mm; median, mean (SD)
CRP, mg/dl; median, (25th–75th percentile)
Creatinin, umol/l; mean (SD)
Interstitial lung disease, N
Vital Capacity, % expected; mean (SD)
Pulmonary hypertension, N 





















SSc-HAQ (0-3); median (25th–75th percentile)
      VAS Raynaud’s disease (0-100 mm)
      VAS digital ulcers (0-100 mm)
      VAS intestinal complaints (0-100 mm)
      VAS pulmonary complaints (0-100 mm) 
      VAS overall complaints (0-100 mm)






















SF-36; median, (25th–75th percentile)
      Physical Component Summary Scale 







Living with partner, N (%) 46 (72) 23 (68) 23 (77)
Education level , N (%)
      Low
      Medium










Paid employment, N (%) 22 (34) 14 (41)d 8 (27)
Internet access , N (%) 50 (78)e 29 (85) 21 (70)
SSc systemic Slerosis, N number, SD standard deviation, HAQ Health Assessment Questionnaire, VAS 
visual analogue scale, SF-36 Short Form-36; a p<0.05 diffuse compared to limited cSSc , b Data not 
available for five diffuse and four limited cSSc patients, c Data not available for two diffuse and one 
limited cSSc patients, d Data not available for nine diffuse SSc patients, e Data not available for one 
diffuse and five limited SSc patients









has not been 
discussed with 
health care 
provider, N (% a)
c. Patient has not 
discussed the problem 
with health care 
provider, but would 
have liked to; unmet 
needs, N (% b).
Physical Domain
1. Lung problems 31 (48) 9 (29) 1 (11)
2. Digital ulcers 25 (39) 5 (20) 0
3. Gastro-intestinal  complaints 39 (61) 19 (49) 6 (32)
4. Pain 49 (77) 25 (51) 7 (28)
5. Dealing with cold fingers 58 (91) 30 (52) 7 (23)
6. Impaired strength 38 (59) 21 (55) 5 (24)
7. Difficulty swallowing 26 (41) 14 (54) 2 (14)
8. Headache 24 (38) 18 (75) 4 (22)
9. Tiredness 59 (92) 43 (73) 9 (21)
10. Dry mouth 39 (61) 28 (74) 4 (14)
11. Sleeping problems 42 (66) 33 (77) 4 (12)
12. Difficulty thinking clearly 29 (45) 25 (86) 1 (4)
Other physical problems (1) 28 (43) 7 (25) 5 (71)
Other physical problems (2) 13 (20) 3 (23) 1 (33)
Number of patients ≥1 need 18 (28%)
Psychological Domain
1. Worried about appearance 31 (48) 25 (81) 6 (25)
2. Uncertain regarding future 43 (67) 35 (81) 8 (23)
3. Fear of physical disability 45 (70) 22 (49) 7 (32)
4. Feeling lonely 24 (36) 19 (83) 4 (19)
5. Fear of disease progression 39 (61) 28 (72) 5 (18)
6. Feeling useless 26 (41) 22 (85) 3 (14)
7. Unable to do things you used to do 39 (61) 31 (79) 4 (13)
8. Feeling out of control 26 (41) 23 (88) 1 (4)
9. Feeling down/depressed 35 (55) 28 (80) 1 (4)
Number of patients ≥1 need 13 (20%)
Social Domain; difficulty with
1. Maintaining friendship 13 (20) 10 (77) 3 (30)
2. Coping with changes in sexual 
relation
35 (55) 28 (80) 6 (21)
3. support of family/friends * 21 2 (10)
Number of patients ≥1 need 9 (14%)
Daily living/Employment Domain; difficulty with
1. Maintaining job/study performance 46 (72) 32 (70) 4 (13)
2. Keeping appointments* 25 (39) 19 (76) 1 (5)
3. Work around the house 31 (48) 19 (61) 1 (5)
Number of patients ≥1 need 4 (6%)
All Domains
Number of patients ≥1 need 26 (41%)
Median number of needs 3 (1-17) (n=26)
* number of patients unknown due to lack of clarity in question
Results
Sociodemographics and disease characteristics
48/77 patients responded to the initial mailing. After a reminder another 16 returned 
the questionnaire, resulting in 64 responders (83%), 4 male and 9 female non-
responders. Socio-demographic and disease characteristics are presented in Table 1. 
In the limited SSc group there were more females (p=0.031) and patients with limited 
SSc had a significantly longer disease duration than patients with diffuse SSc (p=0.019). 
There were no statistically significant differences in any other socio-demographic or 
disease characteristics between the two groups of patients. 
Unmet health care needs
Table 2 presents the frequencies of reported health problems in the physical, 
psychological, social support and daily living/employment domains, contacts with 
physicians and/or health professional, and unmet health care needs regarding these 
issues. ‘Tiredness’ (92%) and ‘Dealing with cold fingers’ (91%) were problems that were 
most frequently mentioned. In total, twenty-six patients (41%) reported one or more 
unmet health care needs regarding the above mentioned problems. The mean score 
for the physical problem scale was 17.2 (SD 8.1), psychological problem scale 6.7 (SD 
5.3), daily living/employment problem scale 2.4 (SD 2.0), and social support 2.0 (SD 
1.9), total problem score 28.3 (SD 14.0). 
The highest percentages of patients with an unmet need were seen within the physical 
domain. The highest percentages of patients indicating at least one need was observed 
in the physical domain (28%), followed by the psychological (20%), social (14%) and 
daily living/employment (6%) domains. 
Associations between sociodemographic and disease characteristics and health care 
needs
None of the socio-demographic and disease characteristics were significantly 
associated with a higher overall health care need (see Table 3). Patients with least 
one need in the physical domain were younger (50.3 (SD 16.1) versus 57.2 (11.5), 
although the association was not significant (OR 0.96 (95%CI 0.92 to 1.0), p=0.69). For 
the psychological domain, a lower mental component summary scale score (OR 0.92 
(95%CI 0.87 to 0.99), p=0.02 and younger age (OR 0.92; 95%CI 0.87 to 0.98), p=0.01 
were significantly associated with a higher health care need (Results not shown).
Information needs 
Table 4 shows the results of the patients’ needs regarding information. In the total 
group, the median total information need score was 6 (range 0-13). Fifty-five patients 
(86%) reported an information need regarding one or more of the 13 items. The topics 
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Table	 3.	 Association	 between	 the	 presences	 of	 at	 least	 one	 healthcare	 need	 (in	 either	 the	
physical, psychological, social, daily living domain) and socio-demographic and disease 
characteristics	in	64	systemic	sclerosis	patients.
No need ≥ 1 Need OR (95% CI)
Age (years), mean (SD)
Female gender (% total)
Partner present (% total)
Diffuse subtype SSc (% total)
Disease duration (years), mean (SD)
HAQ (range 0-3), mean (SD)
Education, N (% total)
   Low
   Medium
   High
SF-36, 0-100, mean (SD)
   PCSS


































OR= Odds Ratio; CI= confidence interval; SSc= Systemic Slerosis;  HAQ= Health Assessment 
Questionnaire; SF-36= Short Form-36; PCSS= Physical Component Summary Scale; MCSS= 
Mental Component Summary Scale; * p=0.088
Table	4.	Information	needs	of	64	patients	with	systemic	sclerosis*,	N	(%)
No need Low need Indifferent Moderate 
need
High Need
Test results 1 (2) 5 (8) 5 (8) 30 (47) 18 (28)
Medical treatment of SSc 4 (6) 8 (12) 10 (16) 22 (34) 16 (25)
Knowing when to see a doctor 4 (6) 8 (13) 10 (16) 23 (36) 15 (23)
Medical tests you need 2 (3) 6 (9) 9 (14) 31 (48) 13 (20)
Information on SSc, 8 (13) 10 (16) 15 (23) 17 (27) 11 (17)
Physical therapy 6 (9) 14 (22) 10 (16) 18 (28) 10 (16)
Exercise and sports 7 (11) 15 (23) 10 (16) 17 (27) 9 (14)
SSc society 15 (23) 14 (22 10 (15) 9 (14) 7 (11)
Occupational therapist 12 (19) 11 (17) 10 (16)  20 (31) 6 (9)
Dental health 9 (14) 14 (22) 13 (20) 13 (20) 5 (8)
Dietary information 10 (16) 14 (22) 13 (20) 13 (20) 5 (8)
Counseling services 10 (16) 18 (28) 15 (23) 7 (11) 4 (6)
Home (nurse) care 12 (19) 17 (27) 15 (23) 10 (16) 4 (6)
* numbers of patients and percentages, missing numbers not listed
showing the highest proportions of patients with a moderate or high information 
need included: test results (75%), medical tests you need (68%), medical treatment 
of SSc (59%) and knowing when to see a doctor (59%). A higher information need was 
significantly associated with diffuse SSc (adjusted for disease duration; Beta 2.4, 95%CI 
0.1 to 4.6, p=0.039), a lower physical component summery scale SF-36 (Beta 0.09, 95% 
CI 0.01 to 0.05, p=0.048) and having a partner (Beta 2.6, 95% CI 0.5 to 5.1, p=0.046). 
Preferences regarding specific health care services additional to regular outpatient 
clinic care.
Table 5 shows the proportion of patients interested in specific forms of the delivery of 
multidisciplinary services specifically for patients with SSc. Overall, 45/64 (70%) of the 
patients had a moderate or high need for at least one of the comprehensive services 
specifically for SSc 
patients.
Preferences regarding the provision of information 
The rheumatologist was indicated as the preferred source of information in the nearby 
future by 75% of the patients (Table 6). Leaflets/books (63%), the Internet (61%) and 
group educational program in the hospital (58%) were more frequently indicated as a 
desired method of information delivery than information meetings organized by the 
Dutch Society of SSc patients, individual information provision by medical specialists 
other than the rheumatologist or by clinical nurse specialists (<50%). 
Table	5.	Preferences	for	health	care	delivery	in	addition	to	regular	outpatient	clinic	care	of	64	
patients	with	systemic	sclerosis*




   planned if needed, N (%)
12 (19) 2 (3) 13 (20) 19 (30) 9 (14)
Yearly program with
   multidisciplinary standardized
   medical assessment, N (%)
5 (8) 5 (8) 8 (13) 15 (23) 23 (36)
Yearly program also including 
   an inventory of the patient’s
   needs regarding health
   professionals’ care, N (%)
8 (13) 4 (6) 13 (20) 15 (23) 16 (25)
* numbers of patients and percentages, missing numbers not listed





No need Low need Indifferent Moderate 
need
High Need
Rheumatologist 1 (2) 3 (5) 4 (6) 22 (34) 26 (41)
Internet 7 (11) 2 (3) 2 (3) 20 (31) 19 (30)
Brief lets/books 6 (9) 1 (2) 7 (11) 28 (44) 12 (19)
Other specialty physician or
   general practitioner
6 (9) 10 (16) 12 (19) 14 (22) 9 (14)
* numbers of patients and percentages, missing numbers not listed
Discussion
In this study on the needs of patients with SSc regarding the provision of health 
services and information, it was found that a number of patients indicated an unmet 
need for help regarding physical and/or mental problems. Information needs were 
most frequently mentioned with respect to medical issues. A substantial proportion of 
patients showed interest in various multidisciplinary services, and the rheumatologist 
was most often mentioned as the preferred provider of information.
Considering the impact of SSc on physical and psychosocial functioning and the usage 
of a high volume of physician services by SSc-patients (3;10) the lack of studies on 
patients’ needs, satisfaction and preferences in health care is remarkable. In other 
rheumatic conditions, a high information need as well as a high percentage of unmet 
health care needs has been demonstrated (11;14;16). 
In our study patients the highest proportion of patients with at least one unmet need 
was seen in the physical domain. Our findings are difficult to compare directly with 
the published studies on unmet needs in SSc. Rubenzik (23) evaluated the needs of 
25 SSc patients, nine diffuse, nine limited and seven unsure subtype, but with the 
methodology employed in that study, questions based on a four-point scale (ranging 
from no need to high need) it remained unclear to what extent their indicated need for 
contact with a health professional was already satisfied. In patients with systemic lupus 
erythematosus (21), the physical domain had the highest proportion of participants 
with al least one unmet need. Rubenzik on the other hand, found high health care 
needs in nine out of ten items of the psychological/spiritual/existential domain and 
four out of 12 items in the physical domain, suggesting more needs in the psychological 
domain. 
As compared to the needs of SLE patients (21) (where the number of patients with 
a need that was already satisfied were taken into account), our study demonstrate a 
relatively low percentage of patients with unmet needs. This may be because of the 
mild functional disability as demonstrated bij SF-36 and SSc HAQ outcomes in both the 
diffuse and limited cSSc group. 
Concerning the association between disease characteristics and health care needs, 
worse mental functioning was significantly associated with the presence of at least 
one unmet need in the psychological domain. A previous study by Rubenzik did not 
examine the relationship of disease characteristics and health care needs, except for 
subtype. In 1193 patients with rheumatoid arthritis and ankylosing spondylitis (14) 
unmet health care needs were likewise associated with worse health status. The lack 
of association between physical functioning and health care needs in our study may be 
were explained by the relatively mild average level of 
functional disability. This may partly be due to the fact that 19 patients with diffuse 
systemic sclerosis had been effectively treated.  
With respect to sociodemographic characteristics, in our study a younger age was 
significantly associated with needs in the psychological domain. Rubenzik (23) found 
higher need in the social domain in patients with a rural background, and a higher need 
in measures from the physical, psychological, daily living and social domain in patients 
without a partner. In patients with rheumatoid arthritis and ankylosing spondylitis (14) 
no association of sex or age with health care needs was seen, whereas education was 
not evaluated. 
Our study identified a considerable proportion of patients with a need for information, 
in particular on medical issues, including test results, medical treatment and knowing 
when to see a doctor. These findings are in line with a Dutch study (25), where the need 
for information on various subjects was evaluated by a 4-point Likert scale. Information 
on SSc (mean 2.29) had the highest score, followed by medication usage (1.77) and 
dealing with pain (1.77). In contrast, Rubenzik (23) concluded that there was not much 
need for medical information, possibly because of the presumed increased publicly 
accessible information. Due to differences in study design, a direct comparison of the 
magnitude of the need for medical information between these studies is difficult. In 
recent years publications on unmet information needs in other rheumatic diseases have 
demonstrated that patients have high desire for information (14;19;22). Leung found 
the highest unmet information need in psoriatic arthritis was advice on exercise (68%) 
(16). Studies evaluating knowledge and information need of patients with rheumatoid 
arthritis (RA) mainly focused on the disease and on specialist medical care (9;5;17). In 
general, these studies report a lack in of knowledge about the disease, medical care 
and medication. This is partly in line with our results.
We found that more information needs were associated with a subtype SSc as well as 
worse physical functioning and having a partner. The latter is surprising; discussing SSc 
related problems with a partner may generate more information needs. Rubenzik (23) 
found more unmet needs in the domains health services, health information and social 
support in patients with less education. In patients with RA it was demonstrated the 
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female gender (14) and lower age (8) were predictive for the presence of information 
needs. A significant difference in need for information between men and women, or 
lower and higher education was not observed in our results. 
The preferences of SSc patients regarding the provision of SSc specific health care 
programs and information have never been evaluated previously. Important findings 
are the preference of patients for their rheumatologist as source of information supply 
over any other type of information gathering, and the patients’ interest in a yearly 
daycare program with standardized assessment of the disease course in addition to 
regular outpatient clinic care. These findings are in line with results among patients 
with psoriatic arthritis, showing that a large proportion of patients are motivated to 
participate in various additional care programs (16).
Our study has a number of limitations. First, the study group is relatively small, 
although the number of participants is greater than the 25 patients studied in a 
previously published paper on unmet needs in systemic sclerosis (23). Also, the cohort 
has relatively long disease duration, this is especially the case for the patients with 
diffuse systemic sclerosis (average 6.4 years (SD 4.7). Therefore, the group of patients 
could probably be considered a survival cohort, which could explain the relatively mild 
level of functional disability as compared to other cohorts of patients with SSc (10;13). 
This selection bias could hamper the generalization of our data to patients with shorter 
disease duration and/or more active disease. As correlations between disease activity 
and stage and unmet needs may be identified by a larger study group cohort, further 
research is warranted.
Comparison with other patients groups may further be hampered by differences in 
healthcare systems and socio-economic background of patients.
Second, the questionnaire we used was based on the SLENQ, but was not yet validated 
in Dutch. Unfortunately, data collection was established prior to publication of the 
study by Rubenzik, who employed the SUNI, which was also based on the SLENQ. 
The items included in our questionnaire and the SUNI are largely comparable, but not 
identical. Finally, selection bias can not be fully excluded since the response rate was 
83%. On the other hand, a response rate of 83 % is relatively high, and might probably 
express patients’ willingness to be engaged in the optimization of health care services.
In daily practice our results imply that SSc patients may face several physical or 
psychological problems that are, according to a considerable number of patients, not 
sufficiently addressed by rheumatologists. These include physical symptoms as pain 
and or Raynaud’s phenomenon. The concurring need for guidance with respect to 
psychological issues, e.g. the uncertainty and fears patients that have to deal with, 
substantiates the need for a multidisciplinary approach. In our study it was indeed 
demonstrated that a substantial proportion of patients showed interest in various 
multidisciplinary services. Another important finding in this study is the high information 
need in SSc-patients, and the preference of the rheumatologist as information supplier. 
This suggests that health care in SSc should also focus on patient education. In 
outpatient clinic care a rheumatologist can pay more attention to information supply. 
At the same time, patient education programs, involving a rheumatologist, may further 
improve the quality of SSc patient care.  
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1. Hieronder staat een lijst met mogelijke lichamelijke problemen of ongemakken die u gehad 
zou kunnen hebben als gevolg van Sclerodermie. Wilt u voor elk genoemd probleem / ongemak 
afzonderlijk nagaan of u die in de afgelopen 12 maanden heeft gehad en aangeven hoe vaak en 
hoe in welke mate u daar last van heeft gehad. Kunt u ook aangeven of u hierover contact heeft 
gehad of behoefte heeft gehad aan contact met een professionele zorgverlener (bijv.: huisarts, 
medisch specialist, verpleegkundige, etc.). Indien u van het genoemde probleem/ongemak nooit 
last heeft gehad de afgelopen twaalf maanden dan kunt u door naar de volgende vraag. Wilt u 
alstublieft geen enkele vraag overslaan. (Kruis aan welk antwoord van toepassing is.)
1. Heeft u de afgelopen 12 maanden last gehad van vermoeidheid?
nooit Dagelijks wekelijks maandelijks
q q q q
Indien u last heeft gehad van vermoeidheid, kunt u dan op de onderstaande lijn met een 
kruisje (X) aangeven in welke mate u in de afgelopen 12 maanden daar last van heeft gehad.
helemaal niet    _______________________________________________________    heel erg
Indien u last heeft gehad van vermoeidheid, heeft u dan hierover persoonlijk contact gehad 
met een professionele zorgverlener?
 q ja
 q nee       heeft u hieraan wel behoefte gehad?   q ja
   q nee
2. Heeft u de afgelopen 12 maanden last gehad van pijn?
nooit dagelijks Wekelijks maandelijks
q q q q
Indien u last heeft gehad van pijn, kunt u dan op de onderstaande lijn met een kruisje (X) 
aangeven in welke mate u in de afgelopen 12 maanden daar last van heeft gehad.
helemaal niet    _______________________________________________________    heel erg
Indien u last heeft gehad van pijn, heeft u dan hierover persoonlijk contact gehad met een 
professionele zorgverlener?
 q ja
 q nee       heeft u hieraan wel behoefte gehad?   q ja
   q nee
3. Heeft u de afgelopen 12 maanden last gehad van slecht slapen?
nooit dagelijks wekelijks maandelijks
q q q q
Indien u last heeft gehad van slecht slapen, kunt u dan op de onderstaande lijn met een 
kruisje (X) aangeven in welke mate u in de afgelopen 12 maanden daar last van heeft gehad.
helemaal niet    _______________________________________________________    heel 
ergIndien u last heeft gehad van slecht slapen, heeft u dan hierover persoonlijk contact gehad 
met een professionele zorgverlener?
 q ja
 q nee       heeft u hieraan wel behoefte gehad?   q ja
   q nee
4. Heeft u de afgelopen 12 maanden last gehad van een droge mond?
nooit dagelijks Wekelijks maandelijks
q q q q
Indien u last heeft gehad van een droge mond, kunt u dan op de onderstaande lijn met een 
kruisje (X) aangeven in welke mate u in de afgelopen 12 maanden daar last van heeft gehad.
helemaal niet    _______________________________________________________    heel erg
Indien u last heeft gehad van een droge mond, heeft u dan hierover persoonlijk contact gehad 
met een professionele zorgverlener?
 q ja
 q nee       heeft u hieraan wel behoefte gehad?   q ja
   q nee
5. Heeft u de afgelopen 12 maanden last gehad van longproblemen?
nooit dagelijks Wekelijks maandelijks
q q q q
Indien u last heeft gehad van longproblemen, kunt u dan op de onderstaande lijn met een 
kruisje (X) aangeven in welke mate u in de afgelopen 12 maanden daar last van heeft gehad.
helemaal niet    _______________________________________________________    heel erg
Indien u last heeft gehad van longproblemen, heeft u dan hierover persoonlijk contact gehad 
met een professionele zorgverlener?
 q ja
 q nee       heeft u hieraan wel behoefte gehad?   q ja
   q nee
6. Heeft u de afgelopen 12 maanden last gehad van krachtverlies?
nooit dagelijks Wekelijks maandelijks
q q q q
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Indien u last heeft gehad van krachtverlies, kunt u dan op de onderstaande lijn met een 
kruisje (X) aangeven in welke mate u in de afgelopen 12 maanden daar last van heeft gehad.
helemaal niet    _______________________________________________________    heel erg
Indien u last heeft gehad van krachtverlies, heeft u dan hierover persoonlijk contact gehad 
met een professionele zorgverlener?
 q ja
 q nee       heeft u hieraan wel behoefte gehad?   q ja
   q nee
7. Heeft u de afgelopen 12 maanden last gehad van	concentratiestoornis?
nooit dagelijks wekelijks Maandelijks
q q q q
Indien u last heeft gehad van concentratiestoornis, kunt u dan op de onderstaande lijn met 
een kruisje (X) aangeven in welke mate u in de afgelopen 12 maanden daar last van heeft 
gehad.
helemaal niet    _______________________________________________________    heel erg
Indien u last heeft gehad van concentratiestoornis, heeft u dan hierover persoonlijk contact 
gehad met een professionele zorgverlener?
 q ja
 q nee       heeft u hieraan wel behoefte gehad?   q ja
   q nee
8. Heeft u de afgelopen 12 maanden last gehad van koude gevoelloze handen?
nooit dagelijks wekelijks Maandelijks
q q q q
Indien u last heeft gehad van koude gevoelloze handen, kunt u dan op de onderstaande lijn 
met een kruisje (X) aangeven in welke mate u in de afgelopen 12 maanden daar last van heeft 
gehad.
helemaal niet    _______________________________________________________    heel erg
Indien u last heeft gehad van koude gevoelloze handen, heeft u dan hierover persoonlijk 
contact gehad met een professionele zorgverlener?
 q ja
 q nee       heeft u hieraan wel behoefte gehad?   q ja
   q nee
9. Heeft u de afgelopen 12 maanden last gehad van wondjes aan de vingers?
nooit dagelijks wekelijks Maandelijks
q q q q
Indien u last heeft gehad van wondjes aan de vingers, kunt u dan op de onderstaande lijn met 
een kruisje (X) aangeven in welke mate u in de afgelopen 12 maanden daar last van heeft 
gehad.
helemaal niet    _______________________________________________________    heel erg
Indien u last heeft gehad van wondjes aan de vingers, heeft u dan hierover persoonlijk contact 
gehad met een professionele zorgverlener?
 q ja
 q nee       heeft u hieraan wel behoefte gehad?   q ja
   q nee
10. Heeft u de afgelopen 12 maanden last gehad van maag en darm problemen?
nooit dagelijks wekelijks Maandelijks
q q q q
Indien u last heeft gehad van maag en darm problemen, kunt u dan op de onderstaande lijn 
met een kruisje (X) aangeven in welke mate u in de afgelopen 12 maanden daar last van heeft 
gehad.
helemaal niet    _______________________________________________________    heel erg
Indien u last heeft gehad van maag en darm problemen, heeft u dan hierover persoonlijk 
contact gehad met een professionele zorgverlener?
 q ja
 q nee       heeft u hieraan wel behoefte gehad?   q ja
   q nee
11. Heeft u de afgelopen 12 maanden last gehad van slikproblemen/passageklachten?
nooit dagelijks wekelijks Maandelijks
q q q q
Indien u last heeft gehad van slikproblemen/passageklachten, kunt u dan op de onderstaande 
lijn met een kruisje (X) aangeven in welke mate u in de afgelopen 12 maanden daar last van 
heeft gehad.
helemaal niet    _______________________________________________________    heel erg
Indien u last heeft gehad van slikproblemen/passageklachten, heeft u dan hierover 
persoonlijk contact gehad met een professionele zorgverlener?
 q ja
 q nee       heeft u hieraan wel behoefte gehad?   q ja
   q nee
12. Heeft u de afgelopen 12 maanden last gehad van hoofdpijn?
nooit dagelijks wekelijks Maandelijks
q q q q
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Indien u last heeft gehad van hoofdpijn, kunt u dan op de onderstaande lijn met een kruisje 
(X) aangeven in welke mate u in de afgelopen 12 maanden daar last van heeft gehad.
helemaal niet    _______________________________________________________    heel erg
Indien u last heeft gehad van hoofdpijn, heeft u dan hierover persoonlijk contact gehad met 
een professionele zorgverlener?
 q ja
 q nee       heeft u hieraan wel behoefte gehad?   q ja
   q nee
13. Zijn er andere lichamelijk problemen waar u de afgelopen 12 maanden last van hebt 
gehad? 
Bij deze vraag kunt u indien van toepassing 1of 2 problemen vermelden. Per probleem kunt u 
aangeven hoeveel last u er van heeft gehad en of u contact heeft gehad met een professionele 
zorgverlener.
 q nee   
 q ja, namelijk van ____________________________________________________
Kunt u aangeven in welke mate u van dit lichamelijke probleem last heeft gehad? 
 
nooit dagelijks wekelijks Maandelijks
q q q q
Indien u last heeft gehad van dit probleem, kunt u dan op de onderstaande lijn met een 
kruisje (X) aangeven in welke mate u in de afgelopen 12 maanden daarvan last heeft gehad.
helemaal niet    _______________________________________________________    heel erg
Indien u last heeft gehad van dit probleem, heeft u dan hierover persoonlijk contact gehad 
met een professionele zorgverlener?
 q ja
 q nee       heeft u hieraan wel behoefte gehad?   q ja
   q nee
q ja, namelijk van ____________________________________________________
Kunt u aangeven in welke mate u van dit lichamelijke probleem last heeft gehad? 
nooit dagelijks Wekelijks Maandelijks
q q q q
Indien u last heeft gehad van dit probleem, kunt u dan op de onderstaande lijn met een 
kruisje (X) aangeven in welke mate u in de afgelopen 12 maanden daarvan last heeft gehad.
helemaal niet    _______________________________________________________    heel erg
Indien u last heeft gehad van dit probleem, heeft u dan hierover persoonlijk contact gehad 
met een professionele zorgverlener?
 q ja
 q nee       heeft u hieraan wel behoefte gehad?   q ja
   q nee
2. Hieronder volgt een lijst met mogelijke emotionele en cognitieve problemen die u gehad 
zou kunnen hebben door de SLE/Sclerodermie. Wilt u voor elk genoemd probleem afzonderlijk 
nagaan of u dat in de afgelopen maand heeft gehad en aangeven hoe vaak en in welke mate u 
daar last van heeft gehad. Kunt u ook aangeven of u hierover contact heeft gehad of behoefte 
heeft gehad aan contact met een professionele zorgverlener (bijv.: huisarts, medisch specialist, 
verpleegkundige, etc.)? Indien u van het genoemde probleem nooit last heeft gehad de afgelopen 
maand dan kunt u door naar de volgende vraag. Wilt u alstublieft geen enkele vraag overslaan. 
(Kruis aan welk antwoord van toepassing is.)
1. Heeft u zich de afgelopen maand neerslachtig	gevoeld?
nooit soms regelmatig altijd
q q q q
Indien u last heeft gehad van neerslachtigheid, kunt u dan op de onderstaande lijn met een 
kruisje (X) aangeven in welke mate (hoe erg) u in de afgelopen maand daar last van heeft 
gehad.
helemaal niet    _______________________________________________________    heel erg
Indien u last heeft gehad van neerslachtigheid, heeft u dan  hierover persoonlijk contact 
gehad met een professionele zorgverlener?
 q ja
 q nee       heeft u hieraan wel behoefte gehad?   q ja
   q nee   q nee
2. Is het de afgelopen maand voorgekomen dat u niet in staat was de gebruikelijke dingen te 
doen?
nooit soms Regelmatig altijd
q q q q
Indien het is voorgekomen dat u niet in staat was de gebruikelijke dingen te doen, kunt u dan 
op de onderstaande lijn met een kruisje (X) aangeven in welke mate u in de afgelopen maand 
daar last van heeft gehad.
helemaal niet    _______________________________________________________    heel erg
Indien het is voorgekomen dat u niet in staat was de gebruikelijke dingen te doen heeft u dan 
hierover persoonlijk contact gehad met een professionele zorgverlener?
 q ja
 q nee       heeft u hieraan wel behoefte gehad?   q ja
   q nee
3. Is het de afgelopen maand voorgekomen dat u zich eenzaam gevoeld heeft? 
nooit soms Regelmatig altijd
q q q q
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Indien het is voorgekomen dat u zich eenzaam heeft gevoeld, kunt u dan op de onderstaande 
lijn met een kruisje (X) aangeven in welke mate u in de afgelopen maand daar last van heeft 
gehad.
helemaal niet    _______________________________________________________    heel erg
Indien het is voorgekomen dat u zich eenzaam hebt gevoeld heeft u dan hierover persoonlijk 
contact gehad met een professionele zorgverlener?
 q ja
 q nee       heeft u hieraan wel behoefte gehad?   q ja
   q nee
4. Is het de afgelopen maand voorgekomen dat u bang was dat de ziekte zou verergeren?
nooit soms Regelmatig altijd
q q q q
Indien het is voorgekomen dat u bang was dat de ziekte zou verergeren, kunt u dan op de 
onderstaande lijn met een kruisje (X) aangeven in welke mate u in de afgelopen maand daar 
last van heeft gehad.
helemaal niet    _______________________________________________________    heel erg
Indien het is voorgekomen dat u bang was dat de ziekte zou verergeren heeft u dan hierover 
persoonlijk contact gehad met een professionele zorgverlener?
 q ja
 q nee       heeft u hieraan wel behoefte gehad?   q ja
   q nee
5. Is het de afgelopen maand voorgekomen dat u onzeker was over de toekomst?
nooit soms Regelmatig altijd
q q q q
Indien het is voorgekomen dat u onzeker was over de toekomst, kunt u dan op de 
onderstaande lijn met een kruisje (X) aangeven in welke mate u in de afgelopen maand daar 
last van heeft gehad.
helemaal niet    _______________________________________________________    heel erg
Indien het is voorgekomen dat u onzeker was over de toekomst heeft u dan hierover 
persoonlijk contact gehad met een professionele zorgverlener?
 q ja
 q nee       heeft u hieraan wel behoefte gehad?   q ja
   q nee
6. Is het de afgelopen maand voorgekomen dat u zich zorgen maakte over lichamelijke 
beperkingen?
nooit soms Regelmatig altijd
q q q q
Indien het is voorgekomen dat u zich zorgen maakte over lichamelijke beperkingen, kunt u 
dan op de onderstaande lijn met een kruisje (X) aangeven in welke mate u in de afgelopen 
maand daar last van heeft gehad.
helemaal niet    _______________________________________________________    heel erg
Indien het is voorgekomen dat u zich zorgen maakte over lichamelijke beperkingen heeft u 
dan hierover persoonlijk contact gehad met een professionele zorgverlener?
 q ja
 q nee       heeft u hieraan wel behoefte gehad?   q ja
   q nee
7. Is het de afgelopen maand voorgekomen dat u zich zorgen maakte over veranderingen in 
uw uiterlijk?
nooit soms Regelmatig altijd
q q q q
Indien het is voorgekomen dat u zich zorgen maakte over veranderingen in uw uiterlijk, kunt 
u dan op de onderstaande lijn met een kruisje (X) aangeven in welke mate u in de afgelopen 
maand daar last van heeft gehad.
helemaal niet    _______________________________________________________    heel erg
Indien het is voorgekomen dat u zich zorgen maakte over veranderingen in uw uiterlijk heeft u 
dan hierover persoonlijk contact gehad met een professionele zorgverlener?
 q ja
 q nee       heeft u hieraan wel behoefte gehad?   q ja
   q nee
8. Is het de afgelopen maand voorgekomen dat u zich nutteloos	voelde?
nooit soms Regelmatig altijd
q q q q
Indien het is voorgekomen dat u zich nutteloos	voelde, kunt u dan op de onderstaande lijn 
met een kruisje (X) aangeven in welke mate u in de afgelopen maand daar last van heeft 
gehad.
helemaal niet    _______________________________________________________    heel erg
Indien het is voorgekomen dat u zich nutteloos voelde heeft u dan hierover persoonlijk 
contact gehad met een professionele zorgverlener?
 q ja
 q nee       heeft u hieraan wel behoefte gehad?   q ja
   q nee
9. Heeft u de afgelopen maand het gevoel gehad niet alles onder controle te hebben? 
nooit soms Regelmatig altijd
q q q q
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Indien het is voorgekomen dat u het gevoel had niet altijd alles onder controle te hebben, 
kunt u dan op de onderstaande lijn met een kruisje (X) aangeven in welke mate u in de 
afgelopen maand daar last van heeft gehad.
helemaal niet    _______________________________________________________    heel erg
Indien het is voorgekomen dat u het gevoel had niet altijd alles onder controle te hebben 
heeft u dan hierover persoonlijk contact gehad met een professionele zorgverlener?
 q ja
 q nee       heeft u hieraan wel behoefte gehad?   q ja
   q nee
3. Hieronder volgen een aantal problemen/beperkingen of veranderingen op sociaal en 
maatschappelijk gebied die door uw ziekte veroorzaakt kunnen zijn. Wilt u voor elk genoemd 
probleem/beperking of verandering afzonderlijk nagaan of het in de afgelopen 12 maanden 
voor u van toepassing was en aangeven hoe vaak en in welke mate u daar last van heeft gehad. 
Kunt u ook aangeven of u hierover persoonlijk contact heeft gehad of behoefte heeft gehad aan 
contact met een professionele zorgverlener (bijv.: huisarts, medisch specialist, verpleegkundige, 
etc.). Indien u van het genoemde probleem/ongemak nooit last heeft gehad de afgelopen twaalf 
maanden dan kunt u door naar de volgende vraag. Wilt u alstublieft geen enkele vraag overslaan. 
(Kruis aan welk antwoord van toepassing is.)
1. Heeft u de laatste 12 maanden problemen gehad bij het uitoefenen van uw werk/studie of 
dagelijkse bezigheden?
nooit soms Regelmatig altijd
q q q q
Indien u problemen heeft gehad bij het uitoefenen van uw werk/studie of dagelijkse 
bezigheden, kunt u dan op de onderstaande lijn met een kruisje (X) aangeven in welke mate u 
de afgelopen 12 maanden daar last van heeft gehad.
helemaal niet    _______________________________________________________    heel erg
Indien u problemen hebt gehad bij het uitoefenen van uw werk/studie of dagelijkse 
bezigheden, heeft u dan hierover persoonlijk contact gehad met een professionele 
zorgverlener?
 q ja
 q nee       heeft u hieraan wel behoefte gehad?   q ja
   q nee
2. Is het de afgelopen 12 maanden voorgekomen dat u niet in staat was gemaakte afspraken 
of verplichtingen na te komen vanwege uw ziekte?
nooit soms Regelmatig altijd
q q q q
Indien het is voorgekomen dat u niet in staat was gemaakte afspraken of verplichtingen na te 
komen, kunt u dan op de onderstaande lijn met een kruisje (X) aangeven in welke mate u in 
de afgelopen maand daar last van heeft gehad.
helemaal niet    _______________________________________________________    heel erg
Indien het is voorgekomen dat u niet in staat was gemaakte afspraken of verplichtingen na te 
komen heeft u dan hierover persoonlijk contact gehad met een professionele zorgverlener?
 q ja
 q nee       heeft u hieraan wel behoefte gehad?   q ja
   q nee
3. Zijn er de afgelopen 12 maanden veranderingen geweest in de door u uit voeren taken 
thuis? 
nooit soms Regelmatig altijd
q q q q
Indien het is voorgekomen dat er veranderingen in de door u uit te voeren taken zijn geweest, 
kunt u dan op de onderstaande lijn met een kruisje (X) aangeven in welke mate u in de 
afgelopen 12 maanden daar last van heeft gehad.
helemaal niet    _______________________________________________________    heel erg
Indien het is voorgekomen dat er veranderingen in de door u uit te voeren taken op het 
werk/studie of thuis zijn geweest, heeft u dan hierover persoonlijk contact gehad met een 
professionele zorgverlener?
 q ja
 q nee       heeft u hieraan wel behoefte gehad?   q ja
   q nee
4. Is het de afgelopen 12 maanden voorgekomen dat u door uw ziekte problemen kreeg in uw 
relatie met anderen (bijvoorbeeld partner, kinderen, familie, vrienden of kennissen)?
nooit soms Regelmatig altijd
q q q q
Indien het is voorgekomen dat u door uw ziekte problemen kreeg in uw relatie met anderen, 
kunt u dan op de onderstaande lijn met een kruisje (X) aangeven in welke mate u de 
afgelopen 12 maanden daar last van heeft gehad.
helemaal niet    _______________________________________________________    heel erg
Indien het is voorgekomen dat u door uw ziekte problemen kreeg in uw relatie met anderen 
heeft u dan hierover persoonlijk contact gehad met een professionele zorgverlener?
 q ja
 q nee       heeft u hieraan wel behoefte gehad?   q ja
   q nee
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5. Heeft u de laatste 12 maanden problemen gehad op seksueel gebied? 
nooit soms Regelmatig altijd
q q q q
Indien het is voorgekomen dat u door uw ziekte problemen kreeg op seksueel gebied, kunt 
u dan op de onderstaande lijn met een kruisje (X) aangeven in welke mate u de afgelopen 12 
maanden daar last van heeft gehad.
helemaal niet    _______________________________________________________    heel erg
Indien het is voorgekomen dat u door uw ziekte problemen kreeg op seksueel gebied heeft u 
dan hierover persoonlijk contact gehad met een professionele zorgverlener?
 q ja
 q nee       heeft u hieraan wel behoefte gehad?   q ja
   q nee
6. Heeft u de laatste 12 maanden voldoende steun en begrip gekregen van de mensen uit uw 
omgeving?
nooit soms Regelmatig altijd
q q q q
Indien het is voorgekomen dat u geen of te weinig steun en begrip de laatste 12 maanden van 
mensen uit uw omgeving hebt gekregen, kunt u dan op de onderstaande lijn met een kruisje 
(X) aangeven in welke mate u in de afgelopen maand daar last van heeft gehad.
helemaal niet    _______________________________________________________    heel erg
Indien het is voorgekomen dat u geen of te weinig steun en begrip de laatste 12 maanden van 
mensen uit uw omgeving hebt gekregen heeft u dan hierover persoonlijk contact gehad met 
een professionele zorgverlener?
 q ja
 q nee       heeft u hieraan wel behoefte gehad?   q ja
   q nee
VRAGENLIJST	ZORGAANBOD
1. Hieronder volgen enkele vragen over uw	behoefte	aan informatie	over Sclerodermie. 
Wilt u voor alle uitspraken aangeven in hoeverre u het er mee eens bent.










1. … de ziekte Sclerodermie q q q q q
2. ... de medische behandeling van 
Sclerodermie
q q q q q
3. ... bij welke veranderingen in mijn 
gezondheidstoestand ik een arts moet 
raadplegen
q q q q q
4. ... het belang van bloedonderzoek en 
andere onderzoeken
q q q q q
5. … de betekenis van de uitslagen 
van bloedonderzoek en andere 
onderzoeken
q q q q q
6. ... de thuiszorg (huishoudelijke 
ondersteuning, wijkverpleging, e.d.)
q q q q q
7. ... hulpmiddelen, voorzieningen, 
vergoedingen en aanpassingen in huis
q q q q q
8. ... lichamelijke activiteit en sport q q q q q
9. ... oefentherapie en fysiotherapie q q q q q
10. ... ergotherapie q q q q q
11. ... de mondhygiënist q q q q q
12. ... de diëtist q q q q q
13. ... de reumaconsulent q q q q q
14. ... het maatschappelijk werk q q q q q
15. … patiëntenverenigingen en 
lotgenotencontact





2. De volgende vragen gaan over de	manier	waarop	u	het	liefst	informatie	wilt	ontvangen.	Wilt 
u voor alle uitspraken aangeven in hoeverre u het er mee eens bent.
Als ik meer informatie over Sclerodermie 
wil krijgen dan zou ik in de komende twaalf 









a.  Internet (een website) q q q q q
b.  Folders of boeken q q q q q
c.  Lotgenotencontact (persoonlijk contact    
met andere patiënten) q q q q q
d.  Informatiebijeenkomsten georganiseerd    
door de patiëntenvereniging q q q q q
e.  Informatiebijeenkomsten georganiseerd   
door het ziekenhuis q q q q q
f.  Een groepsvoorlichtingsprogramma    
georganiseerd door het ziekenhuis q q q q q
g.  Via mijn behandelend reumatoloog q q q q q
h.  Via een andere behandelend medisch    
specialist of de huisarts q q q q q
i.  Via een gespecialiseerd verpleegkundige q q q q q
3. De afdeling Reumatologie van het LUMC wil met de resultaten van dit onderzoek een 
zorgprogramma gaan ontwikkelen voor mensen met Sclerodermie. Graag willen we u vragen de 
onderstaande vragen te beantwoorden, zodat we weten op welke wijze we het zorgprogramma 
kunnen invullen. 
A.
Als de volgende vormen van zorg beschikbaar zouden zijn, dan zou ik in de komende 











Een multidisciplinaire dagbehandeling 
in het LUMC.
q q q q q
Een jaarlijkse, uitgebreide controle 
van mijn medische situatie (naast 
de gebruikelijke bezoeken aan de 
reumatoloog en/of andere medisch 
specialisten) in het LUMC.
q q q q q
Een jaarlijkse, uitgebreide controle 
van mijn persoonlijke situatie en mijn 
behoefte aan zorg of begeleiding (naast 
de gebruikelijke contacten met mijn 
zorgverleners) in het LUMC
q q q q q
A randomized comparison of a 
multidisciplinary	team	care	program	with	
usual	care	in	patients	with	Systemic	Sclerosis
Arthritis Care Res (Hoboken). 2011 Jun;63(6):909-17
A.A.Schouffoer, M.K. Ninaber, L.J.J. Beaart-van de Voorde, F.J.van der Giesen, 
physiotherapist1,, Z. de Jong, J.Stolk, A.E. Voskuyl, R.W.C Scherptong, J.M. van Laar, 






Objective:	To compare the effectiveness of a multidisciplinary team care program with 
usual outpatient care in patients with systemic sclerosis (SSc).
Methods:	 We performed a randomized controlled trial comparing a 12-week 
multidisciplinary team care program (1 day per week; individual treatments, group-
exercises and group-education) with outpatient clinic care. Outcome measures included 
the HAMIS (Hand Mobility in Scleroderma), grip strength, maximal mouth opening 
(MMO), 6-minute walk distance (6MWD), maximum aerobic capacity (VO2max), 
Checklist Individual Strength (CIS-20), SSc Health Assessment Questionnaire (HAQ) 
and Short-form 36 (SF-36), assessed at 0, 12 and 24 weeks. Statistical comparisons of 
change scored included analysis of covariance. 
Results: Twenty-eight patients were assigned to the intervention group (mean age 53.9 
years, 15/28 diffuse SSc) and 25 to the control group (mean age 51.7 years, 15/25 diffuse 
SSc). Twenty-five (89%) patients in the intervention group completed the treatment 
program. At 12 weeks there was a significantly greater improvement in grip strength 
(2.2 versus -1.8 kg; p=0.001), MMO (1.4 versus -0.9 mm; p=0.011), 6MWD (42.8 versus 
3.9 meter; p=0.021) and HAQ (-0.18 versus 0.13; p=0.025) in the intervention group, 
whereas the differences for the other outcome measures did not reach significance. At 
24 weeks the effect on the grip strength persisted.
Conclusion:	 In patients with SSc a 12 week multidisciplinary day patient treatment 
program was more effective than regular outpatient care with respect to 6MWD, grip-
strength, MMO and HAQ but not for VO2max, HAMIS, CIS-20, SF 36 and visual analog scale 
for pain. This study provides a first step in quantifying the effect of a multidisciplinary 
team care program and warrants the conduct of further intervention studies.
Introduction
Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of multiple 
organs (1). Two main subtypes are distinguished: limited cutaneous SSc (lcSSc) and 
diffuse cutaneous SSc (dcSSc) (2). Despite improvements in medical treatment, SSc is 
associated with significant morbidity and mortality (3-6). 
To help patients cope with the consequences of the disease, rehabilitative strategies 
are often provided. Rehabilitation in SSc may include psychoeducational interventions; 
exercise therapy; the application of physical modalities; assistive devices and ortheses; 
joint protection; and energy conservation; dietary interventions and comprehensive 
multidisciplinary team care interventions. 
Whereas in other rheumatic conditions, especially rheumatoid arthritis (RA), the 
effectiveness of multidisciplinary team care has been consistently demonstrated 
(7), in SSc the evidence on comprehensive rehabilitation is scarce (8). A few studies 
demonstrated a significant improvement of measures of global health and hand 
function (9;10), as well as mouth function (10;11) in patients participating in a 
rehabilitation program. However, no direct statistical comparisons of the changes in 
outcome between the intervention group and control group were made. Studies on 
rehabilitation with single interventions as patient education (12;13), aerobic exercise 
(14), finger (15) or mouth (16) and hand massage and manipulation (17) showed 
promising results, although most of them (12-16) had a non-controlled design.  
Considering the paucity of data on comprehensive rehabilitative treatment strategies 
in SSc, this proof-of-concept study was designed to provide preliminary evidence of 
efficacy of a multidisciplinary treatment team care program on multiple outcome 




This randomised controlled clinical trial was conducted from September 2006 until 
September 2008. Ethical approval was obtained from the Institutional Review Board 
of the Leiden University Medical Center. The patients’ written informed consent 
was obtained at enrolment. Randomisation was performed by an independent 
administrative assistant by means of a four-block randomisation list, made up with a 
random digit generator. Patients were stratified according to the type of SSc (1). Patients 
allocated to the control group were offered to participate in the multidisciplinary team 





The medical records of patients with SSc listed in the SSc-registry of our hospital and 
referrals from other hospitals within the enrollment period were screened for global 
eligibility by the principle investigator (AAS). Inclusion-criteria were: SSc according to 
Leroy’s criteria (1), age 18-75 year, being able to cycle on a bicycle ergometer, stable 
anti-inflammatory medication over the past 2 months, and fluency in Dutch. Exclusion-
criteria were: engagement in another exercise therapy program or concomitant 
diseases interfering with the performance of daily activities. 
Patients fulfilling the inclusion-criteria were informed about the study and invited 
for a further screening to judge their exercise tolerance. The screening consisted of 
history taking, physical examination and the following additional investigations: blood 
pressure (at rest), chest radiograph, 24 hours monitoring electrocardiography, Doppler 
ultrasonography of the heart, exercise test by means of a bicycle ergo meter and 
pulmonary function testing. All test results were evaluated by a consulting cardiologist 
(RWCS) and pulmonologist (MKN) and, if necessary, additional examinations were 
scheduled. 
The	multidisciplinary	team	care	program	(intervention)
The multidisciplinary team care program was delivered at the day patient clinic of the 
department of rheumatology of a university medical center during 12 consecutive 
weeks, one day per week. The multidisciplinary team comprised a rheumatologist, 
an occupational therapist, a physical therapist, a social worker and a clinical nurse 
specialist. For every patient, individual treatment goals were set and discussed during 
3 weekly multidisciplinary team conferences. The program consisted of standardized 
group sessions (general exercises, hand/mouth exercises and educational sessions) 
and, depending on the patients’ individual needs, of individual treatments by the 
rheumatologist and rheumatology health professionals. In addition, patients were 
required to participate in individual supervised exercises provided by a physical therapist 
near their own home in a private practice once a week and to perform a home-based 
exercise program on at least 6 days per week. The program was delivered to groups 
with a minimum of 6 and a maximum of 10 patients (Appendix A). After completion 
of the multidisciplinary team care program, patients were advised to continue the 
exercises supervised by the local physical therapist. All other interventions or referrals 
after the intervention period of 12 weeks were left to the treating rheumatologist.
Safety	and	adherence	monitoring	of	the	multidisciplinary	team	care	program
Safety was monitored by recording all terminations or adaptations of exercise sessions 
or other components of the treatment program due to pain, exertion or other reasons; 
adaptations were made based on a questionnaire evaluating the occurrence of pain 
during or after training, and the time to recovery after each group session. In addition, 
any alteration in medication, in particular analgesics were recorded. 
The adherence to the supervised group exercises (general and hand/mouth exercises) 
in the clinic and the supervised exercises at the private practices was monitored by 
attendance lists and records of individual progress. For the home based individual 
exercises (hand/mouth) a diary was filled in, with weekly evaluation by the 
physiotherapist in the hospital. Compliance with the group educational sessions was 
monitored by an attendance list kept by the clinical nurse specialist in the hospital.
Control	condition
Patients in the control group received usual outpatient care as initiated by their 
attending rheumatologist. Attending rheumatologists had a free choice with respect 
to any diagnostic or therapeutic interventions including referral to a physical therapist, 
except for referrals to group exercises, group educational programs or multidisciplinary 
team care programs. 
Assessments 
Assessments took place at baseline (T0), 12 weeks (T1) and 24 weeks (T2). All 
assessments were done by a trained assessor (FJvdG) blinded for the treatment 
condition. Sociodemographics, disease-characteristics, past/current medication and 
Modified Rodnan Skin Score (18) were assessed at baseline.
Recording of individual treatments
All individual treatments by rheumatologists, physical therapists, occupational 
therapists, nurses, and social workers in both the intervention and control groups 
during the duration of the trial were recorded in the medical files by the treating 




The Hand Mobility in Scleroderma (HAMIS) test consists of 9 items graded on a scale 
of 0-3, the final score ranges from 0 (normal function) to 27 (severe immobility). It 
was found to be a reliable instrument in evaluation of hand function in SSc (19) and 
longitudinal assessment of hand mobility in early SSc (20). An average value of the left 
and right hand was computed.
Grip-strength (kg) was measured with a Jamar dynamometer (JA Preston Corporation) 
(21). After testing twice, the highest score was registered. An average value of the grip-
strength of the left and right hand was computed. 
The maximal mouth opening (MMO) was measured with a digital caliper as the maximal 
interdental distance. Measurement of the MMO was used in several studies evaluating 




The 6-minute-walk-distance (6MWD) evaluates the global and integrated responses of 
all the systems involved during exercise, including the pulmonary and cardiovascular 
systems, systemic circulation, peripheral circulation, blood, neuromuscular units, and 
muscle metabolism (23). It reflects daily exercise and has good construct validity as 
demonstrated in patients with SSc and associated pulmonary arterial hypertension.  
The maximum aerobic capacity (VO2max) a standard exercise test on an electronically 
braked cycle ergo meter performed according to the ATS/ACCP Statement on 
Cardiopulmonary Exercise Testing (24). At baseline (forehead) pulse oximetry, blood 
pressure, heart rate and gas exchanges were recorded. Pulse-oximetry and heart rate 
were monitored during 1 min of rest, 2 min of unloaded cycling at 60 revolutions per 
minute followed by an increasing load to maximum tolerance, and 3 min of recovery. 
Each exercise test was supervised by a pulmonary physician [MKN]. Apart from the 
VO2max, maximal load, heart rate and ventilation at maximal tolerated work rate were 
monitored. 
The Checklist Individual Strength-20 (CIS-20) is a Dutch generic 20-item questionnaire 
measuring 4 dimensions of fatigue: fatigue, concentration, impaired motivation and 
impaired activity on a seven-point Likert scale (25). Higher scores indicate a higher 
degree of fatigue, more concentration problems, reduced motivation, and less activity. 
The CIS-20 was developed for patients with chronic fatigue syndrome, and has good 
psychometric properties (25). 
Functional ability. The SSc Health Assessment Questionnaire (HAQ) is a 20-item 
questionnaire comprising eight domains of activities of daily living, with the final score 
ranging from 0 (no disability) to 3 (severe disability) and visual analog scales. The SSc 
HAQ score was calculated using the aids/devices. It has been found to be a reliable 
outcome measure for disease severity in SSc (26). In addition, a Dutch HAQ-translation 
demonstrated good psychometric properties (27). 
Quality of life. The Short Form-36 (SF-36) is a generic measure of quality of life that can 
be converted into two summary scales: the physical component summary scale (PCS) 
and mental component summary scale, standardized to a score with a mean ± SD of 
50 ± 10 in the general population. For this purpose, we used the scores from an age- 
and sex-matched, normative sample, drawn from a random sample of Dutch adults 
(n=1,742) (28) and factor score coefficients (29). The SF-36 has been found to be a 
reliable outcome measure for disease severity in SSc (26).
Statistical	 analysis.	 The target study sample size was based on the expected 
improvement of the 6MWD, HAQ and the PCS of the SF-36, since these outcomes are 
frequently used in rehabilitation studies aiming for improvement of exercise tolerance 
and functional status in patients with other chronic disease (30-34). At the time of this 
study design, no information on outcome parameters of other rehabilitation programs 
in SSc was available. In a non controlled study (35) a similar 12-week exercise program 
for dermatomyositis patients resulted in a 30% improvement of a 7-minute-walk-
distance (from 312 meter [range 81-422 to 404 meter [range 124-549). Assuming a 
30% improvement in the intervention group and 0% in the control group, α=0.05 and β 
=0.20 (power of 0.80), 22 patients per group would be needed to detect this difference 
(n = 7.85 x 0.15[0.85] x 2 / [0.3]2). A power calculation based on the PCSS gave similar 
results. In a study on a similar rehabilitation program in rheumatoid arthritis (RA) 
patients, a 22% improvement of the HAQ was seen (33). Assuming a 22% improvement 
in the intervention group and 0% in the control group, α=0.05 and power of 0.80, 28 
patients per group would be needed to detect this difference (n = 7.85 x 0.11[0.78] x 
2 / [0.22]2). Based on an average of these calculations we aimed to enroll 50 patients 
in the study. 
Data entry was performed using Microsoft Office Access 2003. All results were reported 
according to the Consolidated Standards of Reporting Trials Statement to Randomized 
Trials of Non-pharmalogic Treatment (36). Analysis was performed by the intention-to- 
treat principle. 
Statistical analyses were executed using SPSS 16.0 software. Measures with a Gaussian 
distribution on histogram are expressed as the mean ± SD, measures with a non-
Gaussian distribution as median and Inter Quartile Range (IQR; expressed as the net 
result of 75th -25th percentiles) or range. In case of more than 20% of missing data 
for one variable the group mean value for that variable would be imputed. Descriptive 
statistics were calculated for all variables, comparisons of baseline characteristics 
and numbers of patients using individual treatments were done by a Chi Square test, 
independent t-test, Mann Whitney U test or Fisher exact test where appropriate. The 
level of statistical significance (two sided) was set at P values less than 0.05.
In both the intervention and the control groups, the changes in the outcome measures 
between the baseline and 12 weeks assessments (Change 0-12 weeks) as well as 
between the baseline and 24 weeks assessments (Change 0-24 weeks) were assessed 
with a paired t-test. Comparison of the change scores between the intervention and 
control groups were done by performing analysis of covariance with correction for 
baseline values. 
Results
Patient	 inclusion	 and	 characteristics.	 Ninety-one patients were considered to be 
potentially eligible for the study according to their medical records and were contacted 
(Figure 1). 
Sixty patients were interested and took part in the further screening. Fifty-three 
patients (88%) met the inclusion criteria; 28 participants were randomly assigned to 
the multidisciplinary team care program, and 25 to the control group. The study was 
completed by 24 (86%) of 28 patients in the intervention group and by 23 (92%) of 
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Endpoints of effectiveness 
Less than 20% of the values were missing at any time point and the missing data were completely at 
random for all of the endpoints, so no imputation of data was employed. Table 3 shows the baseline 
values and change scores of all outcome measures. At 12 weeks the improvement of the grip-
strength, MMO, 6MWD and HAQ was significantly greater in the intervention group than in 
the control group. The changes of the other outcomes were comparable between the groups. At 24 
weeks, this significance was sustained for the grip strength.   
 
Figure 1: Flow diagram of a randomized comparison of a multidisciplinary treatment program with 
regular outpatient care in patients with SSc. 
Screening n=60 
Patients excluded n=7:  
Disease activity (2) 
Cardiac dysfunction (2) 
Lumbar disc herniation (1) 
refusal (2) 
 
Allocated to regular  
outpatient clinic care n=25 
 
Allocated to intervention n=28 
24 week assessment n=24 
1 lost to follow up (arthritis) 
Baseline assessment n=25 
 
12 week assessment n= 25 
3 lost to follow up and discontinued 
intervention (tendon rupture, 
painful skin, malignancy) 
 
Eligible patients n=91 
Patients not interested n=31: 
Hospital too far away (2) 
Too busy (12) 
Too few complaints (9) 
Too many complaints (1) 
Reluctance fellow patient contact (2) 
Other/unknown (5) 
Baseline assessment n=28 
 
12 week assessment n=24 
1 lost to follow up (family 
circumstances) 
Included n=53 
24 week assessment n=23 
1 lost to follow up (disease 
progression) 
Figure	1:	Flow diagram of a randomized comparison of a multidisciplinary treatment program 
with regular outpatient care in patients with SSc.
25 patients in the control group (p=0.671). Reasons for discontinuation of the study 
were family circumstances and disease progression in the control group, and tendon 
rupture, painful skin, malignancy and arthritis in the intervention group. 
Table 1 shows the demographic and disease-characteristics of patients in the 
intervention and control groups. None of the differences between the two groups 
reached statistical significance.  
Individual	treatments	in	intervention	and	control	groups.	
Table 2 shows the numbers of patients receiving individual treatments provided by the 
rheumatologist and other rheumatology health professionals in both the intervention 
and the control groups. For the rheumatologist and all health professionals, significantly 
more patients in the intervention group received individual treatments.  
Adverse	effects	and	adherence	to	the	multidisciplinary	intervention.	
Two patients in the intervention group had adverse effects related to the treatment 
program. One experienced a progressively painful skin in 3 weeks of participation, 
resulting in discontinuation of the program. An increased thickening or inflammation 
of the skin was not seen. The other patient suffered an Achilles tendon rupture during 
the circuit training in the second week. One patient discontinued the intervention 
prematurely because of an osteosarcoma requiring surgical intervention. During the 
bicycle training, six patients in the intervention group trained with a intensity lower then 
60% of the specific maximum heart rate, because of pain diagnosis of osteoarthritis: 
n=4, exertion: n=2). Changes in usage of analgesics were not seen during the program 
for any of the patients in the intervention group.
Of the 25 patients completing the program, 20 (80%) attended 10 or more of both the 
12 supervised group exercise (general) sessions and the 12 supervised group exercise 
(hand/mouth) sessions. For the supervised 21 patients (84 %) attended 10 or more 
of the 12 scheduled individual exercise sessions at the private practices. Twenty-one 
(84%) of the patients performed their exercise of hand and mouth on at least five days 
of the recommended six days per week. Twenty-three patients (92%) attended 5 or 
more of the 6 group educational sessions.
Endpoints	of	effectiveness
Less than 20% of the values were missing at any time point and the missing data were 
completely at random for all of the endpoints, so no imputation of data was employed. 
Table 3 shows the baseline values and change scores of all outcome measures. At 12 
weeks the improvement of the grip-strength, MMO, 6MWD and HAQ was significantly 
greater in the intervention group than in
the control group. The changes of the other outcomes were comparable between the 





controlled	 trial	 evaluating	 the	 effectiveness	 of	 a	 multidisciplinary	 team	 care	 program	 as	






Sex, Female No. (%) 19 (67.9) 21 (84.0) 0.297 
Age, year, mean (SD) 53.9 (10.8) 51.7 (10.8) 0.459 
Disease duration, year, median (IQR) 6.5 (8.2) 8.2 (10.5) 0.708 
Disease subset diffuse SSc (%) 15 (53.6) 15 (60.0) 0.846 
Onset Raynaud phenomenon, months, 
median (IQR) 
8.6 (12.7) 10.3 (12.9) 0.694
MRSS‡ (0-51), mean (SD) 5.0 (4.0) 5.2 (6.2) 0.865 
Auto-antibodies (% positive)




















Interstitial Lung Disease, no. (%)







FVC§, % predicted, mean (SD) 91.0 (21.9) 95.0 (21.1) 0.994 
DLCO†, % predicted, mean (SD) 61.4 (17.5) 61.3 (18.1) 0.498 













Previous treatment no (%)
  cyclophosphamide















*Chi Square, student T test, Mann Whitney U test or Fisher exact test where appropriate; 
‡Modified Rodnan Skin Score; ♦ ESR=erythrocyte sedimentation rate; ◊CRP=C-reactive protein; 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































This proof of concept randomized trial shows that a 12-week day patient multidisciplinary 
rehabilitation program resulted in a greater improvement of grip-strength, mouth 
opening, 6MWD and the HAQ than regular outpatient care. Although differences 
were still present at 24 weeks, the significance of most of them was not sustained. No 
differences were seen for VO2max, HAMIS, CIS-20, SF 36 and visual analog scale for pain.
The results of previous evaluations of comprehensive rehabilitation programs in SSc 
are similar to our study with respect to significant improvements of mouth opening 
(10;11;16), hand function (9;10) and overall functional ability (10) in the intervention 
group. The mean increase of mouth opening in our patients was considerably less then 
in two other studies (10;16). However, compared with these studies, the patients in 
our study had a less impairment: 8% had a normal mouth opening (>50.0 mm), and 
36% had a mouth opening >40.0 mm (22), making an overall group improvement more 
difficult to achieve. The hand exercises in our program resulted in a moderate decrease 
of the HAMIS as compared to 20 patients completing a 9 week rehabilitative treatment 
(mean ±SD 6.8 to 5.6 (±1.2) versus 11.4 to 7.0 ± 4.4) (17). This difference may also be 
explained by a lower level of baseline hand disability in our patients, and the different 
type of intervention. 
In both previous studies (9;10) an improvement of quality of life was seen. Although 
our study showed a greater improvement of overall physical health in the intervention 
group as compared to the control group, the difference did not reach significance. The 
significant improvement of the 6MWD and the HAQ but not of the SF-36 PCS scale is 
suggests that these outcomes may reflect different dimensions of physical functioning. 
This is in line with a study by Khanna et al (26) on the responsiveness of change the 
HAQ-DI compared with the SF-36 in patients with dcSSc. The HAQ-DI had a larger 
magnitude of responsiveness if clinical measures were considered, while the SF-36 had 
a larger magnitude of responsiveness in overall disease activity (patient and physician 
global assessment). On the other hand, Antonioli (9) found a statically significant 
improvement of both of the subscales after a 2-week rehabilitation program. In the 
absence of a gold standard to measure the effect of rehabilitation interventions in 
SSc, we employed different endpoint measures. In this respect, this trial should be 
considered as a proof of concept study with its results warranting further research. 
Comparisons among studies are hampered by a number of differences. With respect to 
the intervention, previous studies had a strong focus on physical therapy interventions 
(9;10;14;17). Maddali Bongi (10) used a 9-week tailored rehabilitation program, with 
education, mostly passive treatment of hand and face for one hour twice a week and a 
general exercise program for one hour once week. Antonioli’s (9) 2-week program with 
exercise therapy and physical modalities had a shorter duration, but was followed by 




(including occupational therapists, clinical nurse specialists and social workers) and a 
greater variety of treatments was provided, including group education and individual 
interventions tailored to patients’ needs. A similar multidisciplinary team care model 
as employed in the present study was found to be effective in patients with RA (33;37). 
Second, the two previous studies (10, 11) used other outcome measures. Third, 
in neither of the two previous studies a direct comparison was made between the 
intervention and the control groups, so that the changes reported can not be interpreted 
as treatment effects. Finally, there were differences in the baseline characteristics of the 
patients. In general, it can be assumed that in patients with lower levels of impairment 
an improvement of disability is more difficult to achieve. In SSc a classification of the 
HAQ has been proposed into no-to-mild disability (0.00–1.00), moderate disability 
(1.01–2.00) and severe disability (2.01-3.00) (38). Using this classification, participants 
in our study (HAQ score of 0.81) and Antonioli et al (9) (HAQ score of 0.63) had a mild 
disability, and in the study by Maddali Bongi, participants had moderate disability (HAQ 
score of 1.2).   
Exercise performance in SSc may be limited because of circulatory, pulmonary or joint–
muscle impairment (39). There are only two studies available on exercises aiming to 
improve exercise tolerance in SSc. A two-week rehabilitation including lower extremity 
exercises showed no improvement of the 6MWD (9), whereas our program resulted in 
a mean improvement of 42.8m of the 6MWD (8.5%). The considerably longer duration 
of our supervised training may be a reason for the difference. An eight-week program 
with moderate intensity aerobic exercise (14) resulted in a significant improvement 
of Vo2max in seven SSc patients, whereas in our study no improvement of the Vo2max 
was seen. This discrepancy may be due to the fact that almost half of the patients 
in our study had interstitial lung disease (ILD); an improved 6MWD, but not Vo2max 
was found after physical training for people with ILD (40). Unfortunately the number 
of patients participating in this study did not permit subgroup analysis for patients 
without ILD. The benefits of dynamic exercise have been documented in conditions 
such as dermatomyositis and polymyositis (41), SLE (42) and RA (43). Moreover, it is 
considered appropriate to include patients with ILD in pulmonary rehabilitation (34), 
despite the absence of improved Vo2max. 
Although the improvement of most outcomes was still present at 24 weeks, the 
significance was not sustained. This is in line with literature rehabilitation outcomes in 
SSc (10), ILD (34) and RA (43), underlining the importance of continued exercises and 
physical activity incorporated in patient’s daily life. This is substantiated by Antonioli’s 
study (9); the 2-week program of individual sessions was followed by home exercises, 
patients were asked to keep a dairy of activities, and patients were regularly asked 
for compliance, resulting in an increasing improvement of quality of life as measured 
by the SF-36 after 2 and 4 months. These results suggest that by promoting lifelong 
exercises and physical activity as a part of the standard treatment in SSc health care 
providers may contribute to sustained improvement of physical functioning and quality 
of life.
The dynamic exercise program as employed in the present study appeared to be safe 
and well tolerated by the majority of SSc-patients. However, considering the rupture 
of an Achilles tendon in one SSc-patient despite stretching in advance, extra attention 
should be paid to warming up. One patient ended participation because of painful 
skin, without visible skin inflammation. Whether this painfulness was due to increased 
inflammation is unclear. Increased anti-interleukin-6 and circulating leucocytes were 
demonstrated in SSc patients after cardiopulmonary exercise testing (44). In healthy 
subjects, participation in regular exercise (i.e.,training) can reduce basal or resting levels 
of many inflammatory markers (45). In RA patients, 12 weeks of progressive resistance 
exercises did not lead to the biologically important alterations in immune response 
after an acute bout of exercise as compared to healthy controls (46). Finally, no signs 
of increased inflammation were seen in a muscle biopsy sample in nine patients with 
chronic dermatomyositis and polymyositis after 7 weeks of intensive resistance training 
(41).
Concerning the educational part of the program, similar programs have been described 
(12;13) and were found to be well appreciated by SSc patients. The effectiveness 
of patient education on coping, depression or illness perception has not yet been 
established. Our program did not result in improvement of mental status, probably 
because in our study patients had impairment of physical rather then mental health. A 
number of studies however have described a high prevalence of depressive symptoms 
(6), pain (47) and body image dissatisfaction in SSc (48). In RA tailored cognitive-
behavioral therapy only offered to patients with a high psychosocial risk profile 
was effective in reducing depression and fatigue (49). Cognitive-behavioral or other 
psychosocial interventions has not yet been evaluated in SSc, but they could gain in 
effectiveness if offered to patients with a high risk profile. 
Our study has several limitations. First, the sample size did not permit subgroup 
analysis to identify patients with the greatest benefits. Mugii (15) illustrated that early 
dcSSc patients would benefit more from ROM exercises than patients in later stages. 
In our study, most of the dcSSc patients participating had non-active SSc with longer 
disease duration. As previously discussed, it is likely that ILD also determines outcome 
in rehabilitation interventions. Secondly, our program focused on improving physical 
functioning more than on mental functioning. Thirdly, in case of a multidisciplinary 
approach, it is difficult to establish which component of the team care contributes 
most to the treatment effect. More knowledge on the effects of single techniques can 
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Chapter 1 is a general introduction including the definition of SSc, epidemiology, 
disease manifestations in terms of body function and structures and activities and 
participation, measurement instruments and an overview of both pharmacological and 
non-pharmacological treatment. 
In Chapter 2 myocardial function in SSc patients was assessed by echocardiography 
using speckle tracking strain analysis, and the relationship of this technique with 
functional capacity and ventricular arrhythmias was investigated. In 104 SSc patients 
cardiopulmonary exercise testing, 24-hour electrocardiography (EKG) Holter 
monitoring, and trans-thoracic echocardiography was performed. For comparison, 37 
matched healthy controls were included. No significant difference between patients 
and controls was seen in ventricular volumes or left ventricular ejection fraction (LVEF). 
However, estimated pulmonary arterial systolic pressure (PASP) was significantly 
higher and diastolic function, global longitudinal and circumferential strains were 
significantly more impaired in SSc patients as compared to controls. Global longitudinal 
and circumferential strains demonstrated a correlation with cardiopulmonary exercise 
capacity as measured by the peak oxygen uptake (VO2), and multivariate analysis 
confirmed the independent association of each strain measure with the peak VO2. 
Moreover, compared to SSc patients with normal results on ECG Holter monitoring, SSc 
patients with abnormal results showed impaired global longitudinal and circumferential 
strain, and each strain measure was independently associated with abnormal Holter 
findings. 
A negative impact of SSc on sexual function in men with SSc has been established 
previously. However studies on sexuality in women with SSc were are scarce until 
recently. In Chapter 3, a cross-sectional study aimed to compare sexual functioning and 
distress in 37 women with SSc with those of 37 healthy controls and furthermore to 
assess the association between sexual function and disease characteristics. Validated 
questionnaires to evaluate sexual complaints included the Female Sexual Function Index 
(FSFI), Female Sexual Distress Scale (FSDS). It was found that women with SSc reported 
significantly more impaired sexual functioning and more sexual distress then healthy 
controls. Impaired sexual function was established in 70% of the patients, increased 
sexual distress in 57%, whereas 47% of the 37 patients would be considered to have 
sexual dysfunction (defined as both impaired sexual function plus high levels of sexual 
distress). More marital dissatisfaction and longer disease duration was seen in patients 
with more impaired sexual function. The usage of antidepressants, more depressive 
symptoms, and longer disease duration were statistically significantly associated with 
more sexual distress. 
Multivariate analyses indicated that marital distress was the only variable significantly 
associated with low sexual function in patients with SSc, whereas depression was 
the only variable significantly associated with sexual distress. The same pattern of 
associations was found in the healthy control group. 
Six patients (16%) with SSc reported a need to talk to someone about current sexual 
problems, none of the patients mentioned their rheumatologist as a care provider 
in whom they would confide, and only 1 mentioned her general practitioner. It 
was concluded that in daily practice, inquiring about sexuality and screening for 
depressive symptoms is indicated in every patient with SSc, irrespective of their clinical 
characteristics. 
In a comment on Chapter 3, Knafo et al argued that they felt routine inquiry about 
sexuality to be inappropriate. Their concerns included the low number of patients 
reporting a need to talk to someone about current sexual problems, and the need for 
further investigation of predictors of sexual impairment with sufficient power to detect 
potential upstream factors. The comment concluded that before health providers can 
be asked to reach beyond their level of comfort and training to address sexual issues, 
there’s a need to provide them with a way to do so effectively. Moreover, clear patient 
benefit and effective interventions were proposed as conditions for active inquiry about 
sexuality. Knafo et al suggested the provision of general information by pamphlet as 
an alternative strategy to normalize the subject and facilitate discussion with a health 
professional. 
In a response, it was clarified that the low percentage of patients indicating a need 
to talk about possible sexual problems concerned the whole group and not to the 
subgroup of patients indicating sexual impairment. The justification for the simple 
question by a rheumatologist “do you experience problems in sexual activity?” is found 
in several arguments. First, in other chronic impairment it has been recognized that 
dealing with sexual problems should be addressed in medical rehabilitation. Second, 
the reluctance of both health professionals as well as patients to discuss sexuality is 
known; relying on a patient’s initiative to discus problems in sexuality leads to the risk 
of avoidance of the subject. Third, considering the frequently mentioned SSc specific 
complaints it is very likely that a considerable number of female patients may benefit 
from simple health interventions as vaginal lubricants, medication advice or referral 
to another specialist. However, it was acknowledged that an important condition for 
discussing matters of sexuality is a health professional that is comfortable with the 
subject. Clearly there is a need for improvement of competences in this direction. 
In Chapter 4 the French-generic Mouth Handicap in Systemic Sclerosis (MHISS) 
questionnaire, evaluating mouth-opening restriction, dryness and esthetic concerns 
was translated , field-tested among 16 systemic sclerosis (SSc) patients and adapted 
into Dutch language. The validity of the Dutch MHISS was assessed by determining 
associations with measures of overall functioning (Health Assessment Questionnaire 
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(HAQ)), maximum mouth opening (MMO, in millimeter), subjective xerostomia (visual 
analog scale), and objective xerostomia (Saxon test) in 52 SSc patients. Dutch MHISS 
scores differed significantly between patients with high and low disability levels (HAQ, 
MMO, and subjective and objective xerostomia divided according to the median; 
paired t test). Spearman rank correlations with HAQ (r=0.60, p=0), MMO (r=-0.52, p=0), 
and subjective xerostomia (r=0.54, p=0.) were moderate; correlation with objective 
xerostomia did not reach statistical significance. Internal consistency was adequate as 
expressed by a Cronbach’s alpha of 0.86. Test-retest reliability was established by an 
intraclass correlation coefficient (ICC) of 0.94. It was concluded that the Dutch version 
of the MHISS demonstrates good psychometric properties and is useful in assessing 
mouth disability in SSc patients.
In Chapter 5 the validity and responsiveness of the Michigan Hand Questionnaire (MHQ) 
in SSc patients was assessed. The MHQ contains 57 items and 6 domains: function, 
activities of daily living, pain, work, aesthetics, and satisfaction. Data were gathered 
in connection with a randomized, controlled trial comparing the effectiveness of a 12-
week multidisciplinary team care programme (including a hand function treatment 
module) with regular care. All fifty-three patients (28 intervention group and 25 control 
group) completed the MHQ at baseline and after 12 weeks. Other measures included 
the HAQ (Health Assessment Questionnaire), Hand Mobility in Scleroderma (HAMIS), 
Sequential Occupational Dexterity Assessment (SODA), grip strength, pinch grip and 
Modified Rodnan Skin Score (MRSS). Validity was determined by computing Spearman 
correlation coefficients between the baseline MHQ total score and subscales and other 
measures of (hand) disability. Responsiveness in the intervention group was evaluated 
by the standardized response mean (SRM), effect size (ES), and responsiveness ratio 
(RR). In addition, pooled ES for the difference between the two groups were computed. 
Significant correlations were seen between the MHQ total score and the HAQ (r=-0.62), 
HAMIS (r=-0.54), SODA (r=0.47), SODA Pain (r=0.32) and MRSS (r=0.46). The ES of the 
MHQ total score within the intervention group was 0.49, which was larger than those 
of all other outcome measures. Similar results were obtained for the SRM and RR. The 
pooled ES of the difference between intervention and control groups for the MHQ total 
score was 0.86. It was concluded that the MHQ demonstrated adequate validity and 
responsiveness in patients with SSc. 
The objective of Chapter 6 was to describe work status and factors associated with 
work disability (WD) in SSc patients based on a systematic review of literature available 
from 1990 to 2011. Clinical studies concerning SSc patients, data on work status and/or 
factors associated with WD. Twelve clinical studies containing quantitative information 
on work status in SSc patients and/or factors associated WD were selected, including 
2.758 SSc patients. The methodological quality was evaluated in three quality aspects 
(selection bias, information bias and statistical analysis bias) and was found high in 
1/12 study. Employment rates varied between 11% and 82% after an average disease 
duration ranging from 2.5 to 14 years. There was moderate evidence for an association 
between more functional disability, more disease specific symptoms and worse quality 
of life on one side and presence of WD on the other. There was moderate evidence 
for the absence of an association between WD and age, sex and disease subset. 
Inconsistent evidence was seen for an association between WD and education and 
disease duration. It was concluded that WD is a major consequence of the disease 
in patients with SSc and is associated with more functional disability, more disease 
specific symptoms and worse quality of life. This emphasizes the need for research into 
interventions to prevent or reduce WD in patients with SSc, especially in those with a 
worse health status.
The aim of Chapter 7 was to explore health care and information needs of SSc patients 
and the extent the patients’ needs were met by current health care services delivery. 
Also, the association between needs and patient characteristics was studied. For this 
purpose a questionnaire was sent to 77 SSc-outpatients, comprising 27 items on health 
care needs within the domains physical, psychological, social support, employment/
daily activities or other health problems and 13 items on information needs. Also, the 
patients’ preferences regarding the provision of health care services and information 
were listed. Sixty-four of seventy-seven patients (83%) returned the questionnaire. 
Twenty-seven patients (42%) reported one or more unmet health care needs, with 
the highest proportions of patients with unmet needs seen in the physical (30%) and 
psychological (20%) domains. The highest percentages of patients with information 
needs were observed for medical subjects (20-28%). Worse mental functioning was 
associated with a higher unmet health care need score, whereas worse physical 
functioning and a diagnosis of diffuse SSc were associated with higher information 
need score. A yearly, standardized multidisciplinary assessment program was most 
frequently mentioned as a preferred, but not yet existing, health care model (59%) and 
the rheumatologist as a preferred source of information supply (75%).
In Chapter 8 a randomized controlled trial is described, evaluating the safety and 
effectiveness of a 12 week multidisciplinary team care program in SSc patients by 
comparison with usual outpatient care. The team care program was provided by the 
Rheumatology Ambulatory department of the Leiden University Medical Centre, with a 
frequence of one day per week and a total duration of 12 weeks. It consisted of:
a) Group sessions compromising general exercises, hand/mouth exercises, educational 
sessions 
b) Individual treatments by the rheumatologist, occupational therapist, a physical 
therapist, a social worker, and a clinical nurse depending on the patients’ individual 
needs. 
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c) Individual supervised exercises provided by a physical therapist near their own home 
in a private practice once a week and a home-based exercise program on at least 6 days 
per week. 
Outcome measures included the Hand Mobility in Scleroderma (HAMIS) test, grip 
strength, maximal mouth opening (MMO), 6-minute walk distance (6MWD), maximum 
aerobic capacity (VO2max), Checklist Individual Strength 20 (CIS-20), SSc Health 
Assessment Questionnaire (HAQ), and Short Form 36 (SF-36), assessed at 0, 12, and 24 
weeks. Statistical comparisons of change scores were done by analysis of covariance. 
Twenty-eight patients were assigned to the intervention group (mean age 53.9 years, 
15 of 28 with diffuse SSc) and 25 were assigned to the control group (mean age 51.7 
years, 15 of 25 with diffuse SSc). Twenty-five patients (89%) in the intervention group 
completed the treatment program. At 12 weeks, there was a significantly greater 
improvement in grip strength (2.2 versus -1.8 kg; P < 0.001), MMO (1.4 versus -0.9 
mm; P= 0.011), 6MWD (42.8 versus 3.9 meters; P = 0.021), and HAQ score (-0.18 versus 
0.13; P= 0.025) in the intervention group, whereas differences for the other outcome 
measures did not reach statistical significance. At 24 weeks, the effect on MMO 
persisted. It was concluded that in SSc patients a 12-week multidisciplinary day patient 
treatment program was more effective than regular outpatient care with respect to 
6MWD, grip strength, MMO, and HAQ score, but not for VO2max, HAMIS test, CIS-20, 
SF-36, and visual analog scale for pain.
Discussion
Aims of this thesis were: to acquire more insight into the impact of SSc on a number 
of aspects related to the ICF chapters as well as into the patients’ needs regarding 
information and health care in these areas; to examine the clinical and scientific value 
of a number of relevant disease outcome measures; and to evaluate the safety and 
effectiveness of a multidisciplinary rehabilitation program for patients with SSc. For this 
purpose cross sectional studies, a randomized controlled trial and a systematic review 
were performed. Two assessment methods, the Michigan Hand Questionnaires and 
the Mouth Handicap in Systemic Sclerosis questionnaire, were found to be valuable 
instruments to assess limitations in mouth and hand function. Also, a considerable 
impact of SSc on cardiac function, sexuality and work status was established, and 
despite relatively high health care usage, unmet needs related to health care provision 
were demonstrated in SSc patients. A multidisciplinary team care program which was 
developed to meet a part of these needs, proved to be effective in improving hand, 
mouth and global disability and mobility. 
General methodological issues
A limitation of the studies presented in this thesis is that the majority of the patients 
concerned a selected group; for chapters 3 and 5 patients were recruited in the Leiden 
University Medical Center (LUMC), a specialized hospital for SSc care. For the studies 
described in chapters 2, 6, 7 and 8 patients were mainly recruited in the LUMC, and a 
small number of them were referred by rheumatologists working in general hospitals 
in the region. Because of this, selection bias can not be ignored; patients may have 
been referred to the academic hospital because of SSc complications or active 
disease and subsequent need of intensive immune modulatory treatment, resulting 
in a cohort of patients with relatively active or more complicated disease. However, 
a number of the patients in the studies included in this thesis had participated in the 
ASTIS trial (Autologous Stem Cell Transplantation International Scleroderma) a multi-
center, prospective randomized study comparing autologous hematopoietic stem cell 
transplantation with intravenous pulse therapy cyclophosphamide treatment. This 
study included 25 LUMC patients with severe SSc. A considerable number of these 
patients achieved stable disease, in most of them skin fibrosis improved. 
It is unclear to what extent characteristics differ between patients visiting hospitals 
specialized for SSc care and hospitals with general rheumatology departments. It may 
seem likely that in smaller hospitals a greater percentage of patients with limited 
subtype SSc is monitored, however this needs further study. Larger recruitment of 
mild-to-moderate clinical variants, which better reflect the entire SSc spectrum may 
influence the results. 
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In conclusion, due to probable selection bias in a number of the studies in this thesis, 
generalizability of the results is limited.  
Part	I:	Body	function	and	structure
Left	ventricular	systolic	dysfunction	
Once myocardial involvement is clinically evident, it is recognized as a poor prognostic 
factor in SSc patients (1). In order to improve long term outcome in SSc patients with 
primary myocardial involvement, it is important to identify those patients without 
overt clinical signs, but at high risk of cardiac deterioration. The purpose of screening 
and early detection is to identify mildly symptomatic patients, as well as those with 
pre-clinical disease in order to prevent or delay progression of disease through early 
treatment (2). SSc myocardial disease is a challenging subject for research. Vasodilators, 
such as calcium channel blockers and angiotensin converting enzyme inhibitors, 
have shown tot improve both myocardial perfusion and function abnormalities (3). 
Moreover, observational data suggest a role for calcium channel blockers in prevention 
of LV systolic dysfunction (4). 
Screening for subclinical cardiac disease may contribute to the identification of high 
risk patients, however, unlike ILD and PAH, there are fewer data on optimal screening 
for direct cardiac involvement in SSc. Important questions remain that need to be 
addressed, such as; which abnormalities on cardiac screening tests are associated with 
functional limitation and/or adverse outcomes? Does treatment of SSc patients with 
asymptomatic cardiac involvement (detected on screening tests) improve outcome? 
What is a safe screening strategy, with acceptable risk for patients and preferably low 
costs? Is there a potential role for biomarkers in screening for myocardial involvement? 
In chapter 2, direct evidence is provided, by speckle tracking strain analyses, that 
subclinical LV systolic dysfunction contributes to impaired aerobic capacity in patients 
with SSc. This is not a surprising finding, but this correlation has not yet been 
established in SSc patients by conventional echocardiographic measures of systolic 
function such as ejection fraction or TDI. Another finding was the fact that LV systolic 
dysfunction as assessed by speckle tracking strain analysis was the only independent 
predictor of ventricular arrythmias (ventricular ectopics and non-sustained ventricular 
tachycardias). Thus, speckle tracking strain analysis may contribute in improvement 
of risk stratification among patients with SSc as arrhythmias are concerned. It is not 
yet clear however if the rhythm abnormalities as defined for the analysis contribute 
directly to morbidity or mortality. Considering its safety, low costs and easy accessibility, 
speckle tracking strain analysis may contribute as a screening tool for assessment of 
primary cardial involvement in SSc. 
Body	function	measured	by	patient	reported	questionnaires	
In rheumatology, health status measures on the level of body functions and structures 
and activities and participation, preferably complying with OMERACT Principles (5), are 
recommended for assessment, intervention management and outcome evaluation. 
Examples of such measures are the Health Assessment Questionnaire, Short Form-36 
(6;7) and the (UCLA) Scleroderma Clinical Trial Consortium GI Tract Instrument (8). In 
this thesis two patient-reported questionnaires for the evaluation of body function 
were evaluated: the MHISS (mouth handicap in Systemic Sclerosis) and the MHQ 
(Michigan Hand questionnaire).
- The MHISS questionnaire, which was translated and adapted into the Dutch 
language, is a questionnaire addressing SSc specific mouth and face symptoms. It 
has been used in a number of publications (9;10). 
- The MHQ was developed for general hand disorders and validated for other 
inflammatory conditions as Rheumatoid arthritis (11). In this thesis the MHQ 
demonstrated both adequate validity and responsiveness in patients with SSc. The 
MHQ contains questions addressing a broad spectrum of hand complaints; overall 
hand function, activities of daily living, pain, work performance, aesthetics, and 
patient satisfaction with hand function. In contrast, the Cochin Hand Function 
Scale (a frequently used and SSc validated patient reported questionnaire (12;13), 
contains 18 items focusing on functional tasks (kitchen, dressing, hygiene, office 
and other items include turning a doorknob, cutting with scissors, and turning a key 
in a lock). 
Moreover, we used the FSFI (Female Sexual Function Index). No recommendation exists 
on measures how to address sexual complaints. However, since the publication of the 
study presented in Chapter 3, several studies addressed sexual function in SSc women 
using the FSFI as outcome measurement (14-18). It has thus been confirmed that the 
impact of SSc on sexual activity is considerable. Women with SSc were less likely to be 
sexually active and significantly more likely to be sexually impaired than women from a 
general population and had significantly worse lubrication and pain scores (15). Other 
correlates with sexual function in women with SSc are: body image dissatisfaction, 
longer disease duration and not being married (18), body esteem and depression (14). 
As was explained in chapter 1, the ICF classification may be helpful in clarifying to 
what extent these questionnaires describe disease experience. Linking rules have 
been developed to relate each item of a health-status measure to the ICF category 
representing its content in a specific and precise manner (19) . One item, domain or 
questionnaire may refer to categories in multiple ICF domains such as a body structure, 
a body function, an activity or a contextual factor. For rheumatoid arthritis (RA), the 
content of two of the most widely used health status measures, the HAQ and AIMS2, 
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was compared with the comprehensive ICF Core Set (20). It was found that the HAQ is an 
instrument that exclusively covers the component activity and participation, whereas 
the AIMS2, which can be considered a generic health status measure specific to RA, 
also covers aspects of the component body functions, particularly emotional functions, 
sleep functions, pain and stiffness and more detailed activities. A similar analysis in 
osteoarthritis resulted in the recommendation for the comprehensive measurement 
of functioning to select a instrument with a low diversity ratio (for disease-specific 
aspects) as well as another instrument with a high diversity ratio (for broader aspects 
of functioning in other ICF domains) (21). 
Although an ICF core set for SSc is currently being developed, the present lack of such 
a core set hampers a formal comparison of the relevance of the content of measures 
such as previously described questionnaires. For example, MHISS items could be linked 
to the ICF; “My lips are retracted and/or my cheeks are sunken“, referring to the domain 
body structures and “I have difficulties speaking clearly” referring to body function. 
Certainly, future studies on this subject would provide more knowledge on specific 
patient reported outcomes (range and level of precision). Moreover, a systematic 
evaluation of SSc outcomes can identify domains not covered by a specific instrument. 
Part	II:	activities	and	participation;	work	ability
Work is an significant part of patient’s involvement in daily life and society and has been 
recognized as an important outcome of disease (22). A systematic review included in 
this thesis demonstrated considerable work disability in SSc. However, most included 
studies had a cross sectional design and used employment rates and permanent work 
disability as outcome measures while data on sick leave or presenteeism (productivity) 
were presented in a few. Moreover, there was no uniformity in the definitions of 
work disability that were employed. It was concluded that future studies are needed, 
preferably with a prospective and international design and clear definitions of all 
outcomes, including sick leave and presenteeism, taking differences in age, sex and 
other socio-demographic variables such as education into account.
In a recent study including 2327 patients from 18 European countries enrolled in the 
Digital Ulcer Outcome (DUO) Registry, patients reported more im pairment in work 
and daily activities and required more support from others with increasing numbers 
of digital ulcers (23). For this study, an adapted functional assessment questionnaire 
was used based on the existing, validated Work Productivity and Activity Impairment 
Questionnaire (WPAI) (24) in which work impairment is determined based on 
employment status, work days or hours missed, normal working hours per week, and 
productivity im pairment while working. The score included a patients score for their 
productivity impairment due to DU (range 0-10), impairment of daily activities other 
than work due to DU (range 0-10) and need for help quantified as days or hours of 
paid and unpaid help needed. In future research, work ability should be included as 
outcome measure in trials evaluating pharmalogical or nonpharmalogical treatment. 
For this purpose, validated outcome measures for work ability are essential.
Part	III:	Contextual	factors
Delay or incorrect diagnosis, lack of information or support at time of diagnosis and 
difficulties in access to treatment, rehabilitation and care are some of the problems 
that patients with a rare disease as systemic sclerosis may experience (25). The 
patients’ perspective is essential when evaluating health services in Systemic Sclerosis 
from a qualitive point of view. A survey included in this thesis exploring health care and 
information needs of SSc patients confirmed unmet health care needs in the physical 
and psychological domains, and unmet information needs on medical subjects. In a 
recent survey on online information needs, 185 / 469 (43%) SSc patients responded 
to a questionnaire evaluating current disease-related internet use, the perceived 
importance of diverse information topics, and their usefulness of 8 widely used online 
health services. 151/185 (82%) SSc patients had internet access, and used this to search 
for information on their disease (85%), treatment, medication, and lifestyle (58–63%), 
or visiting a peer support forum (39%).
In a recent cross sectional survey 94 % (237/251) of Dutch Rheumatoid Arthritis patients 
reported insufficient knowledge about the contents and accessibility of at least one 
health care service (including information on what health services offer and how to 
access them). However, 69% of the patients reported an information need about the 
content and 61% on the accessibility (26). An important finding was thus the fact that 
a perceived lack of knowledge did not automatically imply an information need, since 
fewer patients reported an information need than a knowledge deficit and correlations 
between knowledge and information need were weak.  
Hardly any information can be found on SSc patients’ knowledge of their disease. In a 
survey including 1437 members of 12 provincial chapters of the Scleroderma Society 
of Canada, 54% indicated they had limited scleroderma, 18% diffuse disease, and 
23% did not know what type of scleroderma they had. Adequate level of knowledge 
concerning their disease is a prerequisite for effective self-management (27), but 
forcing information to patients who are not open for it may diminish the chance of 
a successful behavioral change (28). Examples of relevant behavioral changes or self 
management are; timely consulting physicians in case of medical urgencies or issues, 
giving up smoking, usage of aids and devices, applying energy conservation techniques 
and home based exercise programs.   
Another important improvement of health care in SSc lies within standard of care in 
diagnostics and treatment according to evidence based assessment (29-32). Screening 
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programs consisting of regular clinical assessment, pulmonary function testing, 
echocardiography, and lung radiology resulted in improved identification of SSc patients 
with cardiopulmonary involvement and better identification of patients with less 
advanced lung disease (33;34). Specific recommendations can also be found for gastro-
intestinal disease (35) and PAH (34). Despite annually performed ‘basic’ diagnostic tools 
including echocardiograms and pulmonary function tests (PFT), significant practice 
variability in diagnosing PAH was demonstrated (36) between Canadian hospitals 
suggesting that SSc experience does play a role in diagnosing complications. Moreover, 
differences in approach to patient care in PAH between specialists was demonstrated, 
with rheumatologists being more involved with overall patient function and quality 
of life (more use of functional and quality of life tools) while the cardiologists/ 
pulmonologists were more comfortable with the specific quantification and effects of 
the pulmonary status perse (37). These findings strongly support a multidisciplinary 
approach with annual comprehensive screening in SSc specialized centres. In this 
disease evaluation, patient reported questionnaires covering the different ICF domains 
can contribute to the early identification of disease symptoms or other risk factors in 
functioning that may require specific treatment or guidance. 
In the Leiden University Medical Center, a yearly recurrent, two day- diagnostic and care 
program for SSc patients has been implemented for patients referred by non-academic 
as well as academic rheumatologists. The program consists of: a) an inventory of the 
patients problems and needs by means of questionnaires; b) clinical history taking and 
clinical evaluation by a specialized rheumatologist, pulmonologist, cardiologist, and 
health professionals (occupational therapist, physical therapist and/or social worker) 
according to the patients needs; c) pulmonary function tests, High Resolution CT 
thorax, ECG, transthoracal echography of the heart, cardio-pulmonary exercise testing 
(CPET), 24h rhythm registration and blood analysis; Diagnostic outcome parameters 
are discussed in a multidisciplinary meeting and result into a treatment advice for the 
referring rheumatologist . In the first 3 months time, 44 patients were referred (38). 
Treatment advice resulted in further referral to another specialist (n=2 respectively 
cardiac electrophysiology and endocrinology), analysis of suggestive pulmonary arterial 
hypertension (n=3), change of supportive medical therapy (n=3) or immunosuppressive 
therapy (n=4). Health professional advice resulted into further intensive treatment by 
a peripheral physical therapist (n=9), referral to a psychotherapist (n=1). The required 
period between the program and reporting the advice to the referring rheumatologist 
was 3,5 weeks. The program has continued in the past years; so far 350 individual 
patients were evaluated. 
Part	IV:	Non	pharmacological	care
Evidence for effectiveness of SSc-specific psychosocial and rehabilitation intervention 
programs is scarce and trials are hindered by relatively low numbers of potential 
participants. The Scleroderma Patient-centered Intervention Network (SPIN) is an 
international collaboration of patient organisations, clinicians and researchers aiming 
to develop a research infrastructure to test accessible, low-cost self-guided online 
interventions to reduce disability and improve HRQL for SSc patients (39). Interventions 
that are being developed concern (1) general SSc self-management, (2) support for 
better coping with emotional distress; (3) support for managing body image distress 
and (4) physical and occupational therapy for hands. 
In the randomized trial “MIDAS” (Multidisciplinaire Intensieve DAgbehandeling 
Sclerodermie) rehabilitation consisted of a multiple components. Therefore, it is unclear 
which components contributed most to the treatment effect on general outcomes as 
Health Assesment Questionnaire. The choice for the rehabilitation strategy employed 
in this study is based on the previously established effectiveness of multidisciplinary 
treatment in other inflammatory disease (40) and was supported by the department’s 
experience. In other rehabilitation studies, specific focus on hand function resulted in 
relatively more improvement of hand outcome measures (41). Moreover, improvement 
of some hand outcome measures was not sustained 12 weeks after completion of after 
our team care program, suggesting a decrease in exercise intensity at home. Evidence 
on the effectiveness of advised home exercises is scarce. Partly non-sustained results 
were seen in SSc patients 9 weeks after completion of a 9 week supervised program 
(42), whereas most improvement was demonstrated 2 and 4 months after a 2 week 
rehabilitation course including prescribed home exercises (43).  
Limited evidence is present on self management in Systemic Sclerosis (44). A mail-
delivered self-management program including a workbook (chapters containing 
learning activities, with action plans modeled after the arthritis self-management 
programs) and exercise DVD (demonstrated face, mouth, hand, arm, and leg exercise) 
resulted in improved hand function and self-efficacy, decreased depression, fatigue, and 
pain; with self-efficacy for pain demonstrating the only statistically significant change. 
The same authors subsequently developed an interactive internet-based version of the 
SSc self-management program (45); showing promising results. In rheumatoid arthritis 
patients an internet-mediated physical activity intervention was employed (46) with 
high satisfaction rates from patients. In SSc however, an important condition for 
participation in home based programs is relatively stable disease, sufficient patient’s 
knowledge and accessible coaching if necessary. Further study in the direction of this 
kind of rehabilitation strategies is warranted including comparison between in-patient 
and out-patients modalities. Home based treatment of (hand) function supported by 
SSc specialized health care providers may allow financial savings in health recourses as 
well as minimizing intrusion into patients’ everyday life. 
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Since benefits of physical exercise on general health have been established (47), 
exercise training may also contribute to well being in SSc patients. The safety of 
exercise training for SSc patients was an important finding of the MIDAS trial including 
aerobic exercise (1 hr twice a week). Safety was confirmed in a non controlled study 
by Pinto et al including eleven SSc patients completing a 12 week training program (1 
hr twice a week) (48) and a controlled study by Oliviera et al describing the results of 7 
SSc patients and healthy controls completing an 8 week training program (40 minutes 
twice a week). 
Efficacy of exercise programs can be established by improved aerobic capacity as well 
as muscle strength and function. Aerobic capacity is defined as the maximum amount 
of oxygen the body can use during intense exercise and is a function both of cardio-
respiratory performance and the maximum ability to remove and utilize oxygen from 
circulating blood. Aerobic capacity is expressed as maximum oxygen uptake (VO2max); 
cardiac output x 13.4 x hemoglobulin x (arterial oxygen saturation-venous oxygen 
saturation). The degree to which aerobic capacity can be improved by training varies 
widely largely due to genetics, “low responders” will see little or no benefit, “high 
responders” may double their capacity(49). The average response to training in healthy 
persons is estimated as a 17% increase in VO2max. In the MIDAS trial, study patients 
achieved a mean improvement of the six minute walk distance (6MWD) of 42.8 meter, 
but no improvement of peak oxygen uptake was seen. Since disease consequences 
in SSc include both cardiorespiratory performance and microvascular system, a 
negative effect of the disease on trainability may be present. After a 8 week training 
program however, increased peak Oxygen uptake in both SSc patients and controls was 
demonstrated by Oliviera et al (50) thus illustrating that improving aerobic capacity 
is feasible in SSc patients. In this study patients with pulmonary involvement were 
excluded, which is unfortunate because lung involvement is a common complication 
in SSc. Sub analysis for patients with interstitial lung disease (ILD) in MIDAS was not 
possible due to the relatively small number of patients. 
Recently, the American Thoracic Society and European Respiratory Society stated 
“Pulmonary rehabilitation is a comprehensive intervention based on a thorough 
patient assessment followed by patient tailored therapies that include, but are not 
limited to, exercise training, education, and behavior change, designed to improve the 
physical and psychological condition of people with chronic respiratory disease and to 
promote the long-term adherence to health-enhancing behaviors” (51). This review 
concerned various pulmonary illnesses, explicitly for ILD patients it was concluded that 
‘evidence suggests that pulmonary rehabilitation may result in meaningful short-term 
benefits’. In 57 patients with Interstitial Lung Disease due to various causes, 6MWD 
improved with a mean of 35 m (95% CI 6 to 64 m) after completion of a 8 week exercise 
training program as compared with weekly telephone support, but oxygen uptake did 
not improve (52). Currently, a multicentre randomized controlled trial including 116 
patients with ILD is conducted which hopefully will provide further information (53) 
on trainability. In 183 patients with various forms of pulmonary arterial hypertension 
a sustained improved 6MWD and peak oxygen consumption at 3 and 15 week after 
initiating a 3 week exercise training in a hospital with continued training at home (54). 
The results were impressive: the mean six-minute walk distance increased 96 meters 
in the exercise training group and decreased 15 meters in a control group, exceeding 
improvements described for all types of advanced therapy in PH. Adverse events, such 
as respiratory infection, syncope or pre-syncope, occurred in 13% of patients. The 
optimal exercise training program for PH remains currently unknown. Slow, incremental 
exercise protocols at low intensity and short duration are often used initially. 
In conclusion, further studies on exercise training in SSc patients, especially those with 
organ involvement may provide more guidance in the risk-benefit determination in 
general. For individual patients however, tailored exercise prescription preceded by 
exercise assessment to diagnose cardiovascular co morbidities is warranted. 
Non-pharmacological interventions for SSc patients require dedicated and preferably 
experienced SSc health professionals (HP). In the Netherlands, a few SSc specialized 
hospitals provide services and research projects from which patients living relatively 
nearby may benefit. 
Currently a network is being developed in collaboration with the Dutch society for 
SSc patients ‘NVLE-connect’ for HP all over the Netherlands, providing a platform 
for exchanging experience and educational purpose. The NVLE-connect network 
was preceded by the EUSHnet, a project funded by EULAR, which was launched in 
2012 in order to improve non-pharmacological care and reduce inequity through 
an international network of health professionals working in SSc. Both initiatives will 
hopefully contribute to a standard of non-pharmacological care for SSc patients.
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Systemische Sclerose (SSc) is een zeldzame aandoening van het bindweefsel met 
onbekende oorzaak en zeer variabele expressie. De ziekte wordt gekenmerkt door 
de trias inflammatie, vasculopathie en fibrosering (toename van bindweefsel) (1). 
De meest karakteristieke uiting van vasculopathie is het fenomeen van Raynaud: een 
aanvalsgewijze tri-, of di-fasische verkleuring van de vingertoppen van wit naar blauw 
en vervolgens rood. Fibrosering van de organen wordt gezien in o.a. de longen, het hart 
en het maagdarmstelsel. In de huid leidt de fibrose tot verstrakking (sclerodermie). De 
prevalentie van SSc in Nederland wordt geschat op 8.9 per 100.000 inwoners (2). 
De variabiliteit in het ziektebeloop wordt bepaald door verschillen in huidbetrokkenheid 
en orgaan manifestaties. Op basis van klinische kenmerken kan SSc worden verdeeld 
in twee belangrijke subtypes. Dit zijn: a) gelimiteerde cutane SSc (LcSSc) waarbij de 
fibrosering van de huid zich beperkt tot de distale delen van de ledematen en er zich 
een matige en geleidelijke langzame fibrose van de inwendige organen kan voordoen 
Figuur 1 voorbeeld van een modified Rodnan skin score
en b) diffuus cutane SSc (DcSSc) met snel voortschrijdende fibrosering van de huid van 
bovenarmen/benen en/of romp en een hoog risico op orgaancomplicaties in de eerste 
ziektejaren. Met een huidscore kan het onderscheid tussen beide vormen kan worden 
gemaakt en kan de uitgebreidheid van de huidverandering worden gedocumenteerd. 
De modified Rodnan skin score (mRSS) is de meest gebruikte score in klinisch onderzoek 
(3). Hierbij wordt het lichaam wordt verdeeld in 17 zones (zie figuur 1), waarin de 
huiddikte met een schaal van 0-3 wordt uitgedrukt. 
Het fenomeen van Raynaud komt bij 3 tot 5 % van de algemene populatie voor 
zonder complicaties (4). Het kan echter ook de eerste manifestatie van SSc zijn. In een 
prospectieve studie ontwikkelde zich na een gemiddelde follow-up duur van 4 jaar bij 
12.6% van de patiënten met een ‘primaire’ Raynaud een zekere Systemische Sclerose 
(5). Het onderscheid tussen een primaire Raynaud en SSc kan mede gemaakt worden 
met behulp van het nagelriem onderzoek en bepaling van antistoffen. Nagelriem 
microscopie is een techniek waarmee capillairen zichtbaar worden gemaakt; de 
combinatie van reuze capillairen, bloedingen en afname van capillair dichtheid zijn 
typische veranderingen die passen bij een SSc nagelriem patroon (6). SSc specifieke 
autoantistoffen (anti-Centromeer, anti-Scl-70, anti-RNA polymerase III) kunnen helpen 
om de diagnose te stellen, maar de afwezigheid ervan sluit SSc niet uit; tot 11% van 
de patiënten met SSc testen negatief op antinucleaire antilichamen. Autoantistoffen 
dragen bij aan het vaststellen van een prognose door de correlaties tussen SSc 
specifieke autoantistoffen en diverse orgaan complicaties (7). 
Het voornaamste kenmerk van vroege ziekte is verstrakking ofwel verdikking van de 
huid (sclerodermie), of (in een vroege fase) zwelling van de handen; de zogenaamde 
‘puffy’ handen/vingers (8). Daarbij kunnen de handen krachteloos zijn, door discrete 
tendinitis, artritis of myo/neuropathie. De krachteloosheid wordt in geval van een niet-
onderkende SSc vaak geduid als een carpaal tunnel syndroom (CTS). Bij patiënten met 
actieve SSc kunnen fibrineuze afzettingen in peesschedes resulteren in een wrijvend 
geluid bij bewegen, de zogenaamde friction rubs. Myositis (indien aanwezig) heeft 
vaak een matige Creatine Kinase (CK) verhoging, maar is een prognostisch ongunstige 
factor (9). De inflammatie en later fibrose kan leiden tot microstomie en tendinogene 
of articulaire contracturen. Het sicca syndroom is vaak zeer hinderlijk aanwezig. 
In 2013 zijn de ACR/Eular classificatie criteria voor Systemische Sclerose gepubliceerd 
(10). Volgens deze classificatie kan bij een score van ≥9 worden gesproken van een 
zekere SSc. Items die zijn opgenomen in deze classificatie zijn: huidverdikking van 
de vingers tot voorbij de Meta carpo phalangeale (MCP) gewrichten, puffy fingers of 
verdikte huid van alleen de vingers, littekens aan de vingertoppen door verminderde 
circulatie (pitting scars), zweertjes aan de vingers (digitale ulcera), teleangieectasieën, 
afwijkende nagelriem capillaroscopie, Raynaud fenomeen, pulmonale hypertensie en/
of interstitiële longziekte en SSc-specifieke auto-antistoffen. 
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De mortaliteit van SSc is aanzienlijk: in een Canadese studie (11) werd bij 158 patiënten 
tussen 1994 en 2004 een 5-jaars overleving van 90%, en 10-jaars overleving van 82% 
gevonden. Overleden personen hadden vaker cardiale betrokkenheid, interstitiële 
longziekte, gastro-intestinale aandoeningen en renale crisis. In Eustar studie (EULAR 
Scleroderma Trials and Research group) was bij 234 personen die overleden aan de 
gevolgen van SSc In de (EUSTAR) database interstitiële fibrose de meest voorkomende 
oorzaak van overlijden (12). Bij patiënten met ernstige interstitiële fibrose bleek het 
grootste verlies in longfunctie op te treden in de eerste vier jaar na aanvang van 
ziekte, terwijl symptomen hierbij ontbraken (13). Daarbij lijken auto-antistoffen en 
niet zozeer de uitgebreidheid van de huidfibrose bij te dragen aan het identificeren 
van patiënten die het risico lopen een ernstige interstiële long fibrose te ontwikkelen 
(14). Risico stratificatie is van belang, zodat bij actieve ziekte door immuun modulatoire 
behandeling schade kan worden verminderd of verdere schade voorkomen (15). Bij 
patiënten met SSc worden met name ‘niet specifieke interstitiële pneumonitis’ (NSIP) 
en ‘usual interstitiële pneumonitis’ (UIP) gezien (16). De andere belangrijke long 
manifestatie is Pulmonale Arteriële Hypertensie (PAH): primair een ziekte gekenmerkt 
door pulmonale vasculaire weerstand veroorzaakt door proliferatie en contractie 
van de gladde spiercellen van de pulmonale arterioles. PAH komt in circa 10% van de 
patiënten met SSc voor. 
Cardiale betrokkenheid bij SSc kan bestaan uit myocarditis en pericarditis, met name 
bij vroege en actieve ziekte, maar ook relaxatie- en pompfunctie stoornissen door 
fibrose en geleidingstoornis kunnen optreden (17). In een autopsie studie werd in 
het hart bij 70% van patiënten met SSc fibrose waargenomen, tegenover 37% in een 
controlegroep (18). Verandering in de micro-circulatie, verstoorde perfusie en ook 
ontstekingsactiviteit kunnen leiden tot fibrose met verminderde contractiliteit, met 
een risico op een geleidingstoornis tot gevolg (19). In de Eustar database (Europese 
database met 7073 SSc patiënten) werd in een cross-sectionele studie door middel 
van conventionele echocardiografie bij 5.4% een verminderde linker ventrikel (LV) 
ejectie fractie gevonden. Hogere leeftijd, mannelijk geslacht, aanwezigheid van 
digitale ulcera, myositis en longbetrokkenheid waren significant geassocieerd met 
cardiale problematiek (20). Het gebruik van calciumblockers was geassocieerd met 
minder LV dysfunctie, zodat een protectief effect gesuggereerd werd. De prognose van 
patiënten met cardiale betrokkenheid is somber als deze eenmaal klinisch manifest 
is (19), hetgeen de noodzaak voor het ontwikkelen valideren van meer sensitieve 
beeldvormende technieken duidelijk maakt.
Wat nierbetrokkenheid betreft is de scleroderma renale crise (SRC) de meest gevreesde 
complicatie. Patiënten met een ziekteduur van < 4 jaar, diffuse of snel progressieve huid 
betrokkenheid, anti-RNA polymerase III positiviteit en het gebruik van glucosteroïden > 
15 mg/dag worden als belangrijke risicofactoren gezien (21;22). In het gastro-intestinale 
systeem kunnen functiestoornissen optreden als gevolg van spieratrofie en fibrose, 
mogelijk voorafgegaan door neuropathie. Dit kan leiden tot pijn, dysfagie, reflux, vroege 
verzadiging, opgeblazen gevoel, braken, diarree, constipatie, fecale incontinentie en 
malabsorptie en hierdoor substantieel gewichtsverlies (23). Fibrosering en vasculaire 
veranderingen kunnen ook urogenitale klachten veroorzaken (24;25).
De medische behandeling bestaat uit ondersteunende maatregelen enerzijds 
(behandeling infectieuze complicaties, therapie bij ulcera, verlichting gastro-intestinale 
complicaties, voeding supplementen bij malabsorptie), en behandeling gericht op 
ontsteking en fibrose anderzijds (26). Vroege herkenning van complicaties cruciaal, 
omdat de therapie dient te worden afgestemd op de individuele patiënt, afhankelijk 
van de omvang en ernst van orgaanbetrokkenheid en het stadium van de ziekte, actief 
of inactief. Niet medicamenteuze behandeling kan bestaan uit fysieke rehabilitatie, 
educatieve programma’s, ondersteuning van zelfmanagement en psychologische 
ondersteuning. Hoewel er toenemende aandacht is voor niet-medicamenteuze 
behandeling, hebben beschikbare studies vaak een klein aantal deelnemende patiënten 
en soms een niet-gecontroleerde opzet (27).
Patiënten met SSc hebben te kampen met een onzeker ziektebeloop, wisselende impact 
op lichamelijk functioneren en beperkte behandel mogelijkheden. Bovendien worden 
ze vaak geconfronteerd met een veranderd uiterlijk; verandering van gelaatstrekken 
door huid verstrakking en verkleinde mondopening (microstomie), contracturen, 
teleangiectasiëen, pigment veranderingen en digitale ulcera. Er is toenemende aandacht 
voor de psychische belasting die dit met zich meebrengt. Een significant verminderde 
mentale kwaliteit van leven en milde tot matige depressie bij een aanzienlijk 
aantal patiënten met SSc werden aangetoond, evenals een laag zelfbeeld (28-30). 
Vanuit medisch oogpunt wordt de impact van een ziekte vaak uitgedrukt in een mate 
van fysieke beperking. De Internationale Classificatie van Functioneren (ICF) van de 
Wereldgezondheidsorganisatie (WHO) beschrijft het functioneren van mensen in 
bredere zin, inclusief de factoren die op het functioneren van invloed zijn (31). In dit 
schema staat de patiënt centraal en worden de volgende domeinen beschreven: a) 
ziektekenmerken (body functions en structures), b) activiteiten en maatschappelijke 
participatie, c) contextuele factoren als omgeving (o.a. klimaat, sociale status en 
beschikbare behandeling) en d) persoonlijke kenmerken van patiënt (bijvoorbeeld 
bewegingsangst). 
Een selectie van ICF domeinen of categorieën die als minimale norm dienen voor de 
rapportage over gezondheid en functioneren van patiënten wordt een ‘ICF core set’ 
genoemd. Voor SSc is deze core set in ontwikkeling (32). Een core set kan helpen te 
verduidelijken in hoeverre gevalideerde meet instrumenten ziekte beleving van een 
patiënt beschrijven. 
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De doelstelling van dit proefschrift was het verkrijgen van meer inzicht in de impact 
van SSc op de gezondheid van patiënten, met betrekking tot de ICF hoofdstukken 
Body functies en structuren, Activiteiten en Participatie en Contextuele factoren, zoals 
revalidatie. 
Hoofdstuk 2
Middels ‘speckle tracking strain analysis’ werd de linkerventrikelfunctie van 104 
patiënten met SSc vergeleken met 37 gezonde controle personen, en werd de relatie 
met conventionele echocardiografie-parameters, inspanning capaciteit en 24 uur 
ritme registratie geëvalueerd. Er was geen significant verschil in ventrikel volumes 
of linker ventrikel ejectie fractie (LVEF) tussen de patiënten met SSc en controle 
personen. Er werd echter wel een significant verschil gezien in de geschatte pulmonale 
arteriële systolische druk (PASP), diastolische functie parameters en longitudinale en 
circumferentiële strain, allen ten nadele van de patiënten met SSc. Bovendien werd bij 
multivariate analyse een onafhankelijke correlatie gezien van de afzonderlijke strain 
waardes en inspanningcapaciteit. Tenslotte werd bij de patiënten met een afwijkende 
ritmeregistratie een vertraagde globale, longitudinale en circumferentiële strain 
gevonden. Er werd geconcludeerd dat speckle tracking strain analysis een geschikte 
techniek is voor het vast stellen van subklinische linkerventrikeldysfunctie. 
Hoofdstuk 3
 
Tot voor kort was er meer bekend over de negatieve invloed van SSc op de seksuele 
functie bij mannen dan bij vrouwen. Deze cross-sectionele studie vergeleek de seksuele 
functie en zorgen over seksualiteit (seksuele distress) van 37 vrouwen met SSc met die 
van gezonde controle personen. Ook werd de correlatie van seksuele functie met ziekte 
karakteristieken bij vrouwen met SSc geëvalueerd. Hiervoor werden gevalideerde 
vragenlijsten als de Female Sexual Function Index (FSFI) en de Female Sexual Distress 
Scale (FSDS) gebruikt. Bij 70% van de patiënten werd verminderde seksuele functie 
gezien, bij 57% verhoogde seksuele distress. Seksuele dysfunctie, gedefinieerd als 
zowel verminderde seksuele functie als verhoogde seksuele distress, was aanwezig 
bij 47% van de patiënten. Bij patiënten met een verminderde seksuele functie werd 
meer relationele onvrede en langere duur van de ziekte waargenomen. Het gebruik 
van antidepressiva, meer depressieve symptomen, en een langere duur van de ziekte 
waren statistisch significant geassocieerd met meer seksuele distress. Multivariate 
analyses toonden aan dat relationele onvrede de enige variabele was die significant 
geassocieerd was met een lage seksuele functie bij patiënten met SSc. Depressie was 
de enige variabele die significant geassocieerd was met seksuele distress. Hetzelfde 
patroon van associaties werd gevonden in de gezonde controlegroep. 
Hoofdstuk 4
De Franse generieke vragenlijst ‘Mouth handicap in Systemic Sclerosis (MHISS) evalueert 
‘mond handicap’ bij patiënten met SSc; de beperkingen in mondfunctie, droogheid van 
de slijmvliezen en esthetische bezwaren door een veranderd uiterlijk. De MHISS werd 
vertaald, getest door 16 SSc patiënten en aangepast waar nodig. Vervolgens werden 
diverse aspecten van validiteit getoetst in een groep van 52 patiënten met SSc. De 
divergente validiteit toetst of het instrument in staat is om onderscheid te maken tussen 
‘bekende groepen’ met de verwachte verschillen in scores. Convergente validiteit 
bepaalt hoe sterk is het instrument gecorreleerd met andere meet instrumenten. 
Interne consistentie beschouwt de samenhang van de verschillende vragen binnen de 
vragenlijst, en de test-hertest betrouwbaarheid toetst de reproduceerbaarheid. 
Binnen de groep van 52 deelnemende patiënten bleken bij degenen met hoge MHISS 
scores significant meer algemene beperkingen (Health Assessment Questionnaire 
(HAQ), meer beperking van de maximale mondopening ( MMO), meer subjectieve 
xerostomie (droge mond) en meer objectieve xerostomie (droge ogen). Spearman 
correlaties met dezelfde parameters waren matig, de interne consistentie was 
voldoende, evenals de test - hertest betrouwbaarheid. Geconcludeerd werd dat de 
Nederlandse versie van de MHISS goede psychometrische eigenschappen toonde en 
nuttig is bij de beoordeling van de mondhandicap bij SSc patiënten.
Hoofdstuk 5
In hoofdstuk 5 werden de validiteit en responsiviteit van de Michigan Hand 
Questionnaire (MHQ) bij patiënten met SSc beoordeeld. De MHQ bevat 57 items 
en 6 domeinen: functie, activiteiten van het dagelijks leven, pijn, werk, esthetiek en 
tevredenheid. Hieruit kunnen 6 subschalen en een totaal score worden uitgerekend. 
De data werden verzameld bij de studie beschreven in hoofdstuk 8. 
Drieënvijftig patiënten (28 in de interventiegroep en 25 in de controlegroep) voltooiden 
de MHQ bij aanvang en na 12 weken. De overige uitkomstmaten waren: de HAQ (Health 
Assessment Questionnaire), Hand Mobiliteit in Sclerodermie (HAMIS), Sequential 
Occupational Dexterity Assessment (SODA), grijpkracht, pinch grip en modified Rodnan 
Huid Score (mRSS). De validiteit werd bepaald door het berekenen van Spearman 
correlatiecoëfficiënten tussen de baseline MHQ totale score, subschalen en andere 
uitkomstmaten. De responsiviteit werd alleen in de interventiegroep geëvalueerd aan 
de hand de Standardized Response Mean (SRM), Effect Size (ES), en Responsiviteit 
Ratio (RR). Een ‘treatment effect’ (verschil tussen de interventie en controlegroep) 
werd berekend door middel van een pooled ES. 
Significante correlaties werden gezien tussen de totaalscore van de MHQ en de HAQ (r 
= -0.62 ), HAMIS (r = -0.54 ), SODA (r = 0.47), SODA Pain (r = 0.32) en MRSS (r = 0.46). 
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De ES van de MHQ totale score in de interventiegroep was 0.49, het geen beter was 
dan die van alle andere uitkomstmaten. Soortgelijke resultaten werden verkregen voor 
de SRM en RR. De gepoolde ES van het verschil tussen interventie-en controlegroep 
voor de MHQ totale score was 0.86. Geconcludeerd werd dat de MHQ voldoende 
validiteit en responsiviteit toonde bij patiënten met een SSc, en daarmee een geschikt 
instrument lijkt om in deze patiënten groep de handfunctie te evalueren.
Hoofdstuk 6
Door middel van een systematische review van de literatuur werd de arbeidsparticipatie 
en factoren van invloed bij SSc patiënten beschreven. Twaalf klinische studies met 
kwantitatieve informatie over de arbeidssituatie van SSc patiënten en/ of factoren die 
samenhangen met arbeid ongeschiktheid (work disability, WD) werden geselecteerd. 
De methodologische kwaliteit werd beoordeeld aan de hand van drie aspecten 
(selection bias, information bias en statistical bias) en bleek laag in 11 van de 12 studies. 
Arbeidsparticipatie varieerde tussen 11% en 82% na een gemiddelde ziekteduur van 2.5 
tot 14 jaar. Er was matig bewijs voor een verband tussen meer functionele beperkingen, 
meer ziekte specifieke symptomen en slechtere kwaliteit van leven aan de ene kant 
en de aanwezigheid van WD anderzijds. Er was matig bewijs voor de afwezigheid van 
een associatie tussen WD en leeftijd, geslacht en SSc subtype. Inconsistent bewijs 
werd gezien voor een verband tussen WD en opleiding of ziekteduur. Geconcludeerd 
werd dat WD een belangrijke uitkomst is bij patiënten met SSc, die geassocieerd is 
met functionele beperkingen, ziektespecifieke symptomen en slechtere kwaliteit van 
leven. Dit benadrukt de noodzaak van onderzoek naar interventies ter voorkoming of 
vermindering van WD bij patiënten met SSc, vooral bij patiënten met een slechtere 
gezondheidstoestand.
Hoofdstuk 7
Deze cross-sectionele studie inventariseerde de zorg- en informatiebehoefte en 
tevredenheid over geboden zorg bij 77 patiënten met SSc. Hiertoe werd een vragenlijst 
gebruikt met 27 vragen die verdeeld werden in diverse domeinen: zorg voor lichamelijke 
klachten, psychische klachten, steun systeem, arbeid en dagelijkse activiteiten, overige 
gezondheidvragen en informatie behoefte. Ook werd naar de voorkeur van de patiënt 
met betrekking tot de wijze en organisatie van zorgverlening en informatieverstrekking 
gevraagd. Van 83% van de respondenten gaf 42 % aan één of meer onvervulde 
zorgvragen te hebben, waarbij de hoogste percentages van patiënten met onvervulde 
zorgvragen werden gezien in de fysieke (30%) en psychologische (20%) domeinen. De 
hoogste percentages van patiënten met informatie behoeften werden gevonden voor 
medische onderwerpen (20-28%). Meer onvervulde zorgbehoefte was geassocieerd 
met slechter psychisch functioneren, en een hogere informatiebehoefte met slechter 
fysiek functioneren en een diagnose diffuse SSc. Een jaarlijks, gestandaardiseerd, 
multidisciplinair diagnostisch programma werd als een geprefereerd als zorgmodel 
(59%) en de reumatoloog als een favoriete bron van informatievoorziening (75%).
Hoofdstuk 8
Een gerandomiseerde gecontroleerde studie evalueerde de veiligheid en effectiviteit 
van een multidisciplinair zorgprogramma voor patiënten met SSc, door deze te 
vergelijken met gebruikelijke poliklinische zorg. Dit zorgprogramma had als werktitel 
Multidisciplinaire Intensieve DAgbehandeling Sclerodermie (MIDAS). Het vond plaats 
op de Reumatologie Ambulante Zorg afdeling van het Leids Universitair Medisch 
Centrum, destijds ‘Sole Mio Ambulant’, met een frequentie van één dag per week en 
een totale duur van 12 weken. De dagbehandeling bestond verschillende onderdelen: A 
) groepsessies met oefeningen ter verbetering van de conditie, hand/mond oefeningen 
en educatie; B) individuele behandelingen door de reumatoloog, ergotherapeut, 
fysiotherapeut, maatschappelijk werker en reumatologie verpleegkundige, afhankelijk 
van de individuele behoeften van de patiënten; en C) individuele oefeningen bij een 
fysiotherapeut in de buurt ( 1 maal/week) en een home-based oefenprogramma 
(tenminste 6 dagen per week). Uitkomstmaten waren: de Hand Mobiliteit in 
Sclerodermie (HAMIS) test, handgrijpkracht, maximale mondopening (MMO), 
6-minuten loopafstand (6MWD), de maximale aërobe capaciteit (VO2max), Checklist 
Individual Strength 20 (CIS - 20), SSc Health Assessment Questionnaire (HAQ), en Short 
Form 36 (SF-36). Metingen vonden plaats op baseline en 12 en 24 weken. 
Achtentwintig patiënten werden door randomisatie toegewezen aan de interventie 
groep, 25 aan de controlegroep. Vijfentwintig patiënten (89%) in de interventiegroep 
voltooiden het programma. Na 12 weken was er een significante grotere verbetering 
van knijpkracht (2.2 versus -1.8, P < 0,001), MMO (1.4 versus -0.9 mm, p = 0.01), 
6MWD (42.8 versus 3.9, P = 0.02), en HAQ score (-0.18 versus 0.13, P = 0.02) in de 
interventiegroep ten opzichte van de controlegroep. De verschillen voor de andere 
uitkomstmaten toonden geen statistisch significant verschil. Na 24 weken bleef alleen 
het effect op de MMO aanwezig. Geconcludeerd kon worden dat in SSc patiënten een 
12-weken durend multidisciplinaire dagbehandeling effectiever was dan de reguliere 
ambulante zorg met betrekking tot diverse functionele uitkomstmaten.
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